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English version 
Development of multidimensional liquid chromatographic methods hyphenated 
to mass spectrometry, preparation and analysis of complex biological  
samples.  
 
Immunoadsorbers based on monolithic epoxy-activated CIM disks have been developed in 
order to target biomarkers of heart diseases. The developed immunoadsorbers permitted to 
selectively isolate myoglobin and NT-proBNP from human serum. Anti-NT-proBNP-CIM disks 
permitted a quantitative isolation of NT-proBNP at concentrations down to 750 amol/µL in 
serum (R2 = 0.998). 
Six different restricted access materials have been evaluated with respect to their ability to 
remove hemoglobin from hemolysates. Experiments at different pH revealed that the 
retention of hemoglobin can be drastically diminished at pH 10.7. Because of better chemical 
stability at high pH, the polymeric Biotrap 500 MS RAM column was optimized for the 
analysis of hemolysates. The setup permits to quantitatively extract antibiotics from whole 
blood hemolysates at biologically relevant concentrations (200 pg/µL), and without carry-over 
of hemoglobin. 
A new 2D-HPLC-ESI-MS/MS setup for proteome analysis was developed. It consisted of a 
peptide separation by RP-HPLC at pH 10.0, followed by IP-RP-HPLC at pH 2.1. This new 
setup was compared with a classical SCX x IP-RP-HPLC setup. Separation repeatability is 
similar with both setups. The orthogonality between methods of separation is higher in the 
SCX x IP-RP-HPLC approach than in the RP x IP-RP-HPLC scheme. However, the better 
peptide distribution and separation efficiency achieved with the RP x IP-RP-HPLC setup 
permitted to identify significantly more peptides than with the classical SCX x IP-RP-HPLC 
setup. Both approaches are complementary and a combination of both setups permits to 
identify more peptides than replicate injections performed with a single setup. 
 
 
 
 
 
Key-words: 
Affinity chromatography, biomarker, CIM, complementarity, Corynebacterium glutamicum, 
hemoglobin, hemolysate, hyphenation, mass spectrometry, micro-HPLC, monolithic column, 
multidimensional liquid chromatography, NT-proBNP, orthogonality, proteome analysis, 
RAM, repeatability, serum, trap-column 
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Version française 
Développement de méthodes chromatographiques liquides 
multidimensionnelles couplées à la spectrométrie de masse, préparation et 
analyse d’échantillons biologiques complexes. 
 
Des immunoadsorbeurs ont été développés à partir de disques CIM monolithiques pour 
l’analyse de biomarqueurs impliqués dans des maladies cardio-vasculaires. Les colonnes 
développées ont permis d’isoler sélectivement la myoglobine et le NT-proBNP du sérum 
humain. Les colonnes anti-NT-proBNP ont permis l’isolation quantitative du NT-proBNP (R2 
= 0,998) à des concentrations jusqu’à 750 amol/µL de sérum. 
Six matériaux à accès restreints ont été évalués en fonction de leur aptitude à exclure 
l’hémoglobine d’hémolysats sanguins. Des injections à différents pH ont montré que la 
rétention de l’hémoglobine est drastiquement restreinte à pH 10,7. En raison d’une bonne 
stabilité à pH basique, la colonne polymérique Biotrap 500 MS RAM a été retenue pour 
l’extraction d’antibiotiques d’hémolysats sanguins. Des extractions quantitatives d’analytes à 
faibles concentrations (200 pg/µL) ont été réalisées sans effet mémoire d’hémoglobine sur la 
colonne. 
Un nouveau système 2D-HPLC-ESI-MS/MS pour l’analyse protéomique a été développé. Le 
système est composé d’une séparation par RP-HPLC à pH 10,0, suivie d’une séparation par 
IP-RP-HPLC à pH 2,1. Ce nouveau système a été comparé à un système conventionnel 
SCX x IP-RP-HPLC. L’orthogonalité des méthodes de séparation est plus élevée dans 
l’approche SCX x IP-RP-HPLC que dans le schéma RP x IP-RP-HPLC. Cependant, en 
raison d’une meilleure distribution des peptides et d’une meilleure efficacité de séparation, le 
système RP x IP-RP-HPLC permet d’identifier significativement plus de peptides. Les deux 
approches sont complémentaires et une combinaison des deux systèmes permet d’identifier 
plus de peptides que des analyses répétées par un système unique. 
 
 
 
 
 
Mots-clefs: 
Analyse protéomique, biomarqueur, chromatographie d’affinité, chromatographie liquide 
multidimensionnelle, CIM, colonne monolithique, colonne d’enrichissement, 
complémentarité, Corynebacterium glutamicum, couplage, hémoglobine, hémolysat, micro-
HPLC, NT-proBNP, orthogonalité, RAM, répétabilité, sérum, spectrométrie de masse 
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Résumé substantiel 
 
Des immunoadsorbeurs ont été développés à partir de colonnes disques CIM monolithiques 
pour l’analyse de biomarqueurs impliqués dans des maladies cardio-vasculaires 
(myoglobine, NT-proBNP). Pour chacun des antigènes étudiés, des anticorps ont été greffés 
avec succès sur le disque polymérique. Les colonnes développées ont permis d’isoler 
sélectivement la myoglobine et le NT-proBNP du sérum humain. La myoglobine a été 
sélectivement isolée puis détectée dans des échantillons de sérum jusqu’à 250 fmol/µL. 
Cependant, la capacité des anticorps greffés n’est pas suffisante pour l’analyse 
d’échantillons cliniques. L’analyse frontale d’une colonne anti-NT-proBNP révèle l’aptitude de 
l’immunoadsorbeur à lier jusqu’à 250 pmol de NT-proBNP, ce qui est suffisant pour l’analyse 
d’échantillons cliniques. De plus, les colonnes anti-NT-proBNP ont une très bonne stabilité 
temporelle (> 18 mois) et leur préparation présente une très grande reproductibilité inter lots. 
Les colonnes anti-NT-proBNP ont permis l’isolation quantitative du NT-proBNP (R2 = 0,998) 
à des concentrations jusqu’à 750 amol/µL de sérum, ce qui correspond à des concentrations 
en NT-proBNP dans le sérum de patients gravement malades. Le couplage des 
immunoadsorbeurs à un spectromètre de masse a été réalisé pour des concentrations 
jusqu’à 7,8 fmol/µL en implémentant une colonne d’enrichissement de type PepmapTM C18. 
 
Six matériaux à accès restreints (RAM) ont été évalués en fonction de leur aptitude à exclure 
l’hémoglobine d’hémolysats sanguins. Globalement toutes les colonnes présentent les 
mêmes propriétés : à pH 2,1 une adsorption significative ainsi qu’un effet mémoire 
conséquent de l’hémoglobine dans des injections consécutives. La dérivatisation du 
matériau LiChrospher ADS avec des polymères neutres ou positivement chargés tels que 
l’amino-dextrane, la polyéthylèneimine et la polylysine ne permet pas de diminuer 
l’adsorption des protéines sur la colonne. Des injections à différents pH (2,1-10,7) ont 
montré que la rétention de l’hémoglobine est drastiquement restreinte à pH basique (10 
mmol/L éthanolamine, pH 10,7). En raison de sa bonne stabilité à pH basique, la colonne 
polymérique Biotrap 500 MS RAM a été retenue pour l’extraction d’antibiotiques 
d’hémolysats sanguins. Des échantillons réels dopés à la tétracycline ont été analysés avec 
le système SPE-HPLC-ESI-MS développé. La détection a été assurée par un spectromètre 
de masse quadrupôle linéaire fonctionnant en mode SIM. Des extractions quantitatives 
d’analytes à faibles concentrations (jusqu’à 200 pg/µL) ont été réalisées sans effet mémoire 
d’hémoglobine sur la colonne Biotrap 500 MS.  
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Un système chromatographique de type SCX x IP-RP-HPLC a été développé pour analyser 
des mélanges complexes de peptides. Des fractions ont été collectées après l’échangeur 
cationique et les peptides fractionnés ont été ensuite séparés par IP-RP-HPLC à pH 2,1 
dans la seconde dimension chromatographique. Le nombre de charges positives portées par 
les peptides apparaît être un paramètre crucial pour la rétention des peptides sur la colonne 
échangeuse d’ions. L’addition d’acétonitrile dans les éluants permet de supprimer les 
interactions secondaires entre les peptides et la phase stationnaire (interactions 
hydrophobes). Une bonne répétabilité en terme d’indentification des peptides est obtenue : 
54,0 % des peptides sont identifiés au minimum trois fois lors de quintuples injections. 
L’analyse des échantillons en triplicata apparaît comme un bon compromis entre la quantité 
de peptides identifiés et le temps d’analyse. Un nouveau système 2D-HPLC-ESI-MS/MS 
pour l’analyse protéomique a été développé. Le système est composé d’une séparation par 
RP-HPLC à pH 10,0, suivie d’une séparation par IP-RP-HPLC à pH 2,1. Bien que de la 
triéthylamine a été utilisée pour obtenir le pH basique, aucun appariement d’ions n’est 
observé et la rétention des peptides est gouvernée par les interactions solvophobes. Comme 
la seconde dimension chromatographique est identique dans les deux systèmes, il a été 
possible de comparer entre-elle la première dimension de chacun des systèmes (SCX vs. 
RP-HPLC à pH basique). Des répétabilités similaires ont été observées. L’orthogonalité des 
méthodes de séparation est plus élevée dans l’approche SCX x IP-RP-HPLC que dans le 
schéma RP x IP-RP-HPLC. Cependant, en raison d’une meilleure distribution des peptides 
et d’une meilleure efficacité de séparation, le système RP x IP-RP-HPLC permet d’identifier 
significativement plus de peptides. Les deux approches sont complémentaires et une 
combinaison des deux systèmes permet d’identifier plus de peptides que des analyses 
répétées par un unique système. Aucun des deux systèmes n’est discriminatoire à l’égard du 
pI ou de la masse des protéines. Le nombre d’enzymes identifiées révèle la capacité des 
systèmes 2D-HPLC-ESI-MS/MS développés à analyser des protéomes complets tels que 
celui de C. glutamicum. 
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Deutsche Version 
Entwicklung von mehrdimensionalen, flüssigkeitschromatographischen 
Methoden gekoppelt mit Massenspektrometrie, Vorbereitung und Analyse von 
komplexen biologischen Proben. 
 
Immunoadsorber, die auf monolithischen Epoxy-aktivierten CIM-Disks basieren, wurden 
entwickelt, um Biomarker für Herzkrankheiten nachweisen zu können. Die entwickelten 
Immunoadsorber erlaubten eine selektive Isolierung von Myoglobin und NT-proBNP aus 
menschlichen Serum. Anti-NT-proBNP-CIM-Disks ermöglichten die quantitative Isolierung 
von NT-proBNP mit Konzentrationen bis zu 750 amol/µL im Serum (R2 = 0,998). 
Sechs verschiedene „Restricted Access Materials“ wurden im Hinblick auf ihre Fähigkeit, 
bzgl. der Entfernung von Hämoglobin aus Hämolysaten untersucht. Experimente bei 
unterschiedlichen pH-Werten ergaben, dass die Retention von Hämoglobin bei einem pH-
Wert von 10,7 deutlich verkleinert werden kann. Aufgrund ihrer höheren chemischen 
Stabilität bei höheren pH-Werten wurde die polymere „Biotrap 500 MS RAM“ für die Analyse 
von Hämolysaten optimiert. Die Methode ermöglicht die quantitative Extraktion von 
Antibiotika aus Gesamtblut Hämolysaten mit biologisch relevanten Konzentrationen (200 
pg/µL), ohne die Verschleppung des Hämoglobins. 
Eine neue 2D-HPLC-ESI-MS/MS-Methode wurde für die Proteomanalyse entwickelt. Sie 
bestand aus einer Peptid-Trennung mittels RP-HPLC bei einem pH-Wert von 10,0 und 
anschließender IP-RP-HPLC bei einem pH-Wert von 2,1. Anschließend wurde diese neue 
Methode mit einer klassischen SCX x IP-RP-HPLC-Methode verglichen. Die Orthogonalität 
zwischen den beiden Trennmethoden bei der SCX x IP-RP-HPLC ist hierbei höher als bei 
der entsprechenden RP x IP-RP-HPLC-Methode. Allerdings erlaubt die bessere Verteilung 
der Peptide und die bessere Trenneffizienz der SCX x IP-RP-HPLC-Methode die 
Identifizierung einer höheren Anzahl an Peptiden. Beide Methoden sind komplementär, und 
eine Kombination beider Methoden erlaubt die Identifizierung einer größeren Anzahl an 
Peptiden als wiederholte Injektionen bei einer eindimensionalen Methode. 
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I. Goal of the thesis 
The outstanding development of new analytical techniques in the last thirty years has 
revolutionized our way to handle and analyze biological molecules and 
macromolecules. Thus, the introduction of fused silica capillaries [1] in the late 
seventies permitted the development and the miniaturization of numerous separation 
techniques such as capillary gas chromatography (GC), high-performance liquid 
chromatography (HPLC) and capillary electrophoresis (CE). In the late eighties, 
advances in mass spectrometry (MS) and more particularly soft ionization methods 
permitted to analyze high-molecular ions such as proteins and peptides. Electrospray 
ionization (ESI) developed by J. Fenn [2] and matrix-assisted laser 
desorption/ionization (MALDI) by F. Hillenkamp, M. Karas and K. Tanaka [3,4] are now 
the most common ionization modes for bio-molecular compounds. The 
miniaturization of HPLC columns (75 – 200 µm i.d.) and the decrease of mobile 
phase flow rates (0.2 – 3 µL/min) facilitated the hyphenation of liquid chromatography 
with mass spectrometry. Finally, peptide sequencing based on gas-phase 
fragmentation was achieved with tandem mass spectrometry (MS/MS). 
Fragmentation rules established by K. Biemann [5] and new algorithms or search 
engines such as Mascot [6,7] and Sequest [8] finalized a fully automatic interpretation 
of huge MS/MS data sets. 
Biological samples are extremely complex and no single dimensional analytical 
technique is able to handle them. The numerousness of the analytes is mostly 
responsible for such a high complexity. Thus, in case of biological fluids such as 
urine, serum or blood hemolysates, several thousands of components have already 
been reported. The high dynamic range (in terms of concentration) of the analytes 
also increases the difficulties of analysis. Dynamic ranges of 1-108 or of 1-1010 are 
common [9]. As a matter of fact, a sample simplification is required to get reliable and 
reproducible identifications. This can be achieved by combining several separation 
steps [10-13] (e.g. 2D-HPLC) with a specific and sensitive detection technique [14-16] 
(e.g. MS/MS or ELISA). 
The analysis of a biological sample can be required for various reasons. First, one 
aim of studies can lie in the detection and/or the quantitation of only a single or a 
handful of analytes. For instance, the analytes may be biomarkers in a diagnostics 
study. In case of heart infarct, only proteins specific to heart diseases may be 
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researched. In a therapeutic study, the analytes of interest may be antibiotics in 
blood or drug degradation products in urine. This first approach is characterized by 
fishing out few analytes of interest. On the other hand, some studies require the 
detection of as many as possible components present in the sample. Thus, the 
differential analysis of two cell states is performed by checking in two cell extracts the 
presence (or the absence) of all presumably expressed proteins. The development of 
this second approach also called holistic strategy (holistic, greek holos, “whole”) is 
only possible because of the latest technical advancements. Obviously, these two 
different analytical goals are antagonist and require different setups. 
In this context, the aim of the thesis was to develop HPLC-MS methods allowing 
meaningful analyses of biological samples. The methods should be established with 
model compounds but evaluated on real biological samples (serum, whole blood, 
protein cell extract). They should also be able to respond to common bioanalytical 
challenges (biomarker detection, drug targeting, proteome analysis) in classical and 
holistic strategies and should be easily transposable to similar samples.  
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II. Theoretical part 
Medical diagnostics and therapeutical studies are mostly performed on biological 
materials such as blood and its components, tissue and tissue fluids, excreta and 
secreta. To avoid dissolution steps and to assure a high compatibility of the 
investigated samples with the chromatographic setups, only native fluid materials 
(such as human whole blood and human serum) or protein cell extracts were 
investigated. These biological materials are described in the following chapter. 
Structures and properties of the most relevant components of these biological fluids, 
namely peptides and proteins, are also presented. Finally, a theoretical description of 
the separation and detection methods employed in this work is given. 
 
1 Biological samples 
1.1 Biological fluids 
Blood is the fluid consisting of plasma, blood cells, and platelets that is circulated by 
the heart through the vascular system, carrying oxygen and nutriments to and waste 
materials away from all body tissues. A healthy human adult has around 5 liters 
blood in his body, which represents around 7 % of its whole weight. Optically, 
oxygenated blood is bright red. This color is explained by the presence of 
oxygenated iron in the hemoglobin of red blood cells. Human hemoglobin is built up 
with four subunits, each subunit being a globular protein embedded with a heme 
group. The name hemoglobin, as a concatenation of heme and globin, reflects this 
particular structure. The heme itself consists of a protoporphyrin group and an iron 
atom, being responsible for the binding of oxygen. The structure of a heme is 
depicted in Fig. 1. The molecular weight of undissociated hemoglobin is about 68,000 
Da (four 17,000 Da subunits).  
The lysis of red blood cells leads to the release of hemoglobin into the surrounding 
fluid. The name hemolysate refers to a whole blood sample in which the red blood 
cells have been lysed. Thus, hemolysates differ from whole blood only by the free 
circulation of hemoglobin (and other species originally contained in red blood cells) in 
the liquid phase of the medium. 
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Fig. 1. Structure of a heme, consisting of a protoporphyrin group and an iron atom. 
 
Plasma can be defined as the liquid phase of blood and consists of the residual fluid 
obtained after blood clotting (approximately 55 % of blood volume). Plasma consists 
of water (91 %) and proteins (7 %) but also contains salts, glucids, lipids, vitamins, 
and hormones. The total protein concentration is usually evaluated to 60 to 85 g/L in 
healthy adult plasma [17]. Ten plasma proteins represent about 90 % of this value as 
depicted in Fig. 2. Albumin (up to 60 %) and immunoglobulins (about 35 %) are the 
major plasma proteins whereas fibrinogen (about 5 %) is responsible of blood 
coagulation. The removal of fibrinogen permits to obtain serum. Thus, serum differs 
from plasma only by the absence of fibrinogen. The clear yellowish color of serum is 
explained by the formation of bilirubin during the degradation process of hemoglobin. 
The physical and chemical properties of blood and its derivates are highly influenced 
by various salts dissolved at different concentrations. Sodium chloride represents by 
itself 75 % of the total salt amount. Buffer properties of bicarbonate are responsible 
for the slightly basic pH of blood (7.4). Potassium and calcium are not directly 
responsible for blood stability but permit to maintain vital functions such as nerve 
excitability and muscle contractions. 
Blood and blood derivates are very sensitive to coagulation and protein precipitation. 
To avoid such phenomena some sample handling procedures must be followed. For 
instance, freeze-thaw cycles should be avoided and samples should only be diluted 
in physiological buffers or salt solutions.  
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Fig. 2. The major proteins in human plasma, classified as a function of their 
concentration. 
 
1.2 Cells and protein cell extracts 
The cell (latin cellula, “small room”) is the structural and functional unit of all living 
organisms. A cell is an own entity able to take in nutrients, to convert these nutrients 
into energy, and finally to carry out specialized functions. Cells contain their own 
hereditary information and are consequently able to reproduce themselves. Some 
organisms, such as bacteria, consist of a single cell, whereas other organisms are 
made of multiple cells. For instance, the human body consists of 220 different types 
of cells and biological tissues. In the case of multicellular organisms, the different 
cells are differentiated and specialized for one particular task. Thus bone marrow 
cells produce blood cells, while muscle cells are responsible for the production of 
muscle tissue. 
Two kinds of cells can be distinguished: prokaryotic cells and eukaryotic cells. The 
major difference resides in the lack of a cell nucleus in prokaryotic cells, whereas 
eukaryotic cells contain a membrane-delineated compartment that houses the 
genetic information. Prokaryotic cells are mostly singletons, whereas eukaryotic cells 
are usually found in multi-cellular organisms. 
For analytic purposes, cells are often lysed. Cell lysis refers to the burst of a cell and 
to the resulting release of its content. Depending on the kind of cells, lyses are 
achieved in different manners. However, all mechanisms are leading to the disruption 
of the cellular membrane. Few of them are listed bellow and quickly described [18]: 
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 cells are placed in a hypotonic environment (e.g. deionized water). Water 
osmotically diffuses into the cells and the cells burst. This procedure can be 
enzymatically improved (e.g. with lysozyme) 
 by repetitive freeze-thaw cycles, cellular membranes are distorted until 
disruption 
 small cell layers are dessicated at 20-30 °C and finally ground in a mortar 
 by immerging cells in a cold and water miscible organic solvent, lipids of the 
cellular membranes are removed and the cells burst 
 with a vibration cell/mixer mill, cells are placed in a steel container with glass 
beads and violently agitated 
 under rapid variations of pressure produced by ultrasonic waves, cells are 
rapidly destroyed 
 cells are pressed under pressure until membrane disruption (French press) 
 
Protein cell extracts correspond to the proteins that are released during cell lysis. 
Depending on the protocol used to perform protein collection, protein cell extracts 
may contain only a part or the whole proteins originally present in the cells. For 
instance, membrane proteins, which are particularly difficult to be extracted, may not 
be present in protein cell extracts. 
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2 Structure and properties of proteins 
2.1 Amino acids, peptides and proteins 
Proteins are macromolecules constituted of an enchainment of building blocks called 
amino-acids. All amino acids are made up of one central carbon atom (α) with a 
tetrahedral configuration. The four groups bound to this α-carbon atom consist of an 
amine group, a carboxyl group, a hydrogen atom, and a so-called side chain. Amino 
acids differentiate themselves in the structure of the side chains. Because of 
differences in terms of chemical composition, length, and functional groups, the side 
chains are responsible for the various chemical properties of the amino acids. One 
distinguishes amino acids with aliphatic, aromatic, and heterocyclic side chains but 
also with hydroxyl-, sulfhydryl-, carboxyl-, and amido groups. Twenty amino acids are 
occurring in natural proteins. One-letter- and three-letter symbols have been 
introduced to refer to these proteogenic amino acids [19]. They are listed in Tab. 1. 
Except for glycine, the α-carbon atom is an asymmetric center. One can thus 
distinguish D- and L- isomers. Only L- isomers are present in the human body.  
Fig. 3. Amino-acid sequence of the pentapeptide AGSFK [20]. 
 
Two consecutive amino acids are bound together by coupling the α-carboxyl group of 
the first amino acid with the α-amino group of the second amino acid. The resulting 
amide bond is often referred as peptide bond. During the formation of the bond, 
water is removed, and what remains of each amino acid is called an amino-acid 
residue. A five amino-acid sequence is depicted in Fig. 3. The term oligopeptides is 
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employed to refer to amino-acid enchainments up to 20 residues; those with more 
are called polypeptides. Over 50 residues, the term protein is generally used. 
 
Tab. 1. Name, 3-letter symbol, 1-letter symbol and structure of the 20 proteinogenic 
amino acids. 
 
The peptide bond is characterized by high kinetic stability (resistance to hydrolysis) 
and also by double bond properties. This double bond character results in a planar 
arrangement and six atoms are present in the same plane. They consist of the α-
carbon atom and the α-carboxyl group of the first amino acid, and also of the α-
amino group and the α-carbon atoms of the second amino acid. On the opposite, the 
bonds between the α-carbon atoms and the amino- and carboxyl groups are single 
bonds, resulting in free rotation around their axes. These free rotations permit the 
folding of peptides and proteins in different manners. Generally four structure levels 
are differentiated: the primary-, secondary-, tertiary-, and quaternary structures. 
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The primary structure of a protein, also called sequence, corresponds to the order in 
which the different amino acids are assembled. The amino-acid sequence is by 
convention written from the amino terminus (N-terminus) to the carboxyl terminus (C-
terminus) [19]. 
The secondary structure corresponds to the arrangement in space of the amino-acid 
chain. The first elements of secondary structure, the alpha helix and the beta sheet 
were suggested in 1951 by Linus Pauling [21-23]. The alpha helix structures are 
stabilized by hydrogen bonds between amino- and carboxyl groups of the protein 
backbone. The side chains are directed to the outside and can interact with each 
other or with the medium. Angles between peptide bonds are 80°. The helix is made 
of around 3.7 amino-acid residues per spiral turn. By stretching an alpha helix a beta 
sheet can be obtained. In the latter, two anti-parallel chains are observed. All the 
atoms of the peptide bond are present in the same plane, but the α-carbon atoms are 
simultaneously located in two different planes. The periodicity is about 7 Å. 
Schematic representations of alpha-helix and beta-sheet structures are represented 
in Fig. 4. Beta-elbow structures are also found. They consist of four consecutive 
amino acids for which an hydrogen bond between the carboxyl group of the first 
amino acid and the amino group of the forth amino acid is formed. Random coils are 
also observed. These structures are non-periodic structures but the valence angles 
are still observed. 
The tertiary structure corresponds to the spatial arrangement of the different 
secondary structures. This three-dimensional structure is specific to each protein and 
is maintained with chemically different bonds. Disulfide bonds, established between 
two cysteine residues are particularly strong because of their covalent nature. The 
tertiary structure of a protein depends on the surrounding medium. Parameters such 
as solvent, ionic strength, viscosity and concentration have influence on the 
conformational structure of the protein. For instance, in aqueous medium non-polar 
amino acids are tending to avoid water, whereas polar amino acids are presented on 
the outside. The presence of prosthetic groups is also influencing the three-
dimensional structure of proteins. A prosthetic group is a molecule bond to a protein, 
but which is not constituted of amino acids (e.g. the heme group of hemoglobin). The 
complexity of proteins is also increased by post-translational modifications such as 
acetylation, phosphorylation, and glycosylation. 
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(b) (a)  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Schematic representation of (a) alpha-helix- and (b) beta-sheet structures. 
 
Several protein subunits with defined tertiary structures are able to interact together 
to form a multi-protein complex, which is usually called quaternary structure. 
Generally, non covalent bonds are maintaining such structures. 
Fibrous proteins and globular proteins are often distinguished. Fibrous proteins are 
often structural proteins (e. g. collagen and fibrin) with folded or spiral chains, 
whereas globular proteins hold their name from their spherical or elliptic structure. 
Fibrous proteins are generally non soluble in water. On the contrary, globular 
proteins (e.g. albumin) are in many cases water soluble. 
Because of their amino-acid constitution, peptides and proteins are amphoteric 
molecules. They possess both acidic and basic groups. Thus the charge of a protein 
depends not only on the number of acidic or basic groups present in the sequence, 
but also on the pH of the solution in which the protein is present. The pH at which a 
protein carries no net electrical charge is named isoelectric point (pI). 
The hydrophilicity/hydrophobicity of peptides is generally evaluated by computing the 
so-called grand average of hydropathy (GRAVY). The GRAVY value for a peptide or 
a protein is calculated as the sum of the hydropathy values of all the amino acids, 
divided by the number of residues in the sequence. The term hydropathy (strong 
feeling about water), and the hydropathy scale were first introduced in 1982 by J. 
Kyte and R. Doolittle [24]. The hydropathy scale is reproduced in Tab. 2. 
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Tab. 2. Hydropathy scale according to J. Kyte and R. Doolittle [24]. 
side-chain hydropathy index side-chain hydropathy index 
isoleucine 4.5 serine -0.8 
valine 4.2 tyrosine -1.3 
leucine 3.8 proline -1.6 
phenylalanine 2.8 histidine -3.2 
cysteine 2.5 glutamic acid -3.5 
methionine 1.9 glutamine -3.5 
alanine 1.8 aspartic acid -3.5 
glycine -0.4 asparagine -3.5 
threonine -0.7 lysine -3.9 
tryptophan -0.9 arginine -4.5 
 
2.2 Roles of proteins 
Proteins are playing important roles in life processes. For instance some proteins 
work as biocatalyzers (enzymes) to synthesize and construct cell elements. Proteins 
and particularly structural proteins are responsible together with nucleic acids for 
more than 2/3 of the anhydrous mass of a cell. 
They are present in membranes, tendons, muscles, and connective tissues. As 
regulation substances, proteins are essential during reaction processes and cell 
differentiation. Numerous peptides and proteins are involved in the control of genes 
and during neurobiological processes. In vertebrate species, immunoglobulins are 
assuring the body defense by identifying and neutralizing foreign objects such as 
bacteria or viruses. The antibodies, with their Y-shaped structure, are essential in 
therapeutic methods and diagnostics. Each antibody possesses a paratope specific 
for one particular epitope of an antigen. These lock-key matching properties permit 
antigen and antibody to specifically bind together. Other proteins are responsible for 
the transport and the storage of non soluble substances, metal atoms or oxygen. 
Some proteins may be disease agents and toxic for other organisms (toxins). 
Plasma proteins have numerous functions. All together they contribute to the colloid 
osmotic pressure of the blood. The most important proteins in human plasma are 
depicted in Fig. 2. Proteins present in human serum can be sorted in the following 
eight design/function groups [9]: 
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1. proteins secreted by solid tissues and which act in plasma. They are also 
called „classical plasma proteins“. They are bigger than the kidney filtration 
cut-off (~ 45 kDa) and more than 50,000 different molecular forms are present 
in plasma 
2. immunoglobulins. Because of their complexity, immunoglobulins form a unique 
class of proteins. Around 10 millions of different sequences are present in the 
blood of a human adult 
3. long-distance receptor ligands. In this group classical peptide- and protein 
hormones are classified (e.g. insulin and erythropoietin) 
4. local receptor ligands. They are generally small proteins responsible for 
interactions between neighbor cells. Concentrations of local receptor ligands in 
plasma are very low (some tens of pg/mL) 
5. temporary passengers. They correspond to non-hormone proteins which are 
transported in plasma from their secretion site to their primary function site 
6. tissue leakage products. The proteins are present in blood because of cell 
damage or death. Theoretically all proteins present in an organism can leak 
into plasma. In the case of human plasma up to 50,000 proteins may be 
present. In this group, the most important diagnostics markers are classified, 
e.g. troponin, Brain Natriuretic Peptide (BNP), and myoglobin used to 
diagnose cardiac disease 
7. aberrant secretions. These proteins are released from tumors or diseased 
tissues 
8. foreign proteins. They do not originate from the organism itself but from 
infectious organisms or parasites 
Human plasma possesses the largest and the most complex set of proteins 
(proteome) present in the human body. 
 
2.3 Proteome 
The term “proteome” was first coined by Mark Wilkins in 1995 [25]. A proteome refers 
to the total set of proteins expressed in a given cell (or tissue) at a given time (under 
well defined conditions). The proteome is larger than the genome, because one gene 
is responsible for the expression of more than one protein. Thus for human beings 
20,000 to 25,000 genes are leading to the possible expression of about 500,000 
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proteins [26]. Because of their various functions, proteins are present at different 
concentrations in cells or body fluids. Their dynamic range is extremely wide. 
Dynamic ranges of 1-108 or of 1-1010 are usual [9]. 
Fig. 5. Strategies for proteome analysis: top-down proteomics (left) and bottom-up 
proteomics (right). Reproduced from Huber [27]. 
 
The study of a proteome is termed "proteomics”. Because of the high complexity of 
proteomes, proteomics require the development of multi-dimensional analytical 
methods. Two strategies for proteome analysis have been explored. A scheme of 
these two strategies is depicted in Fig. 5. In the top-down approach, proteomes are 
mostly analyzed by two-dimensional gel electrophoresis (2D-GE). Proteins are first 
separated as a function of their isoelectric point followed by a size-dependent 
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separation step. The protein spots are usually extruded and submitted to tryptic 
digestion before analysis by mass spectrometry. In the bottom-up approach (or 
shotgun proteomics), proteins are digested immediately after their isolation. The 
resulting set of peptides is generally analyzed by multi-dimensional chromatography 
hyphenated to mass spectrometry. 
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3 High-performance liquid chromatography for the 
separation of biomolecules 
Combination of several chromatographic separations requires a good comprehension 
of the mechanisms occurring in each separation step. The large size and the 
ampholytic nature of peptides and proteins are among others [28] important 
parameters to be considered in terms of stationary phase or elution conditions. 
The major difference between the chromatographic separation of small organic and 
biomolecules is that peptides and proteins are able to simultaneously adsorb on 
different places of the stationary phase [29]. As a consequence, the complete 
desorption of a biomolecule only occurs when the elution strength of the eluents is 
high enough to take off all the adsorption points of the biomolecule on the stationary 
phase. These adsorption/desorption mechanisms are often described as an “on-off” 
model [30]. Multisite adsorption of biomolecules results in highly negative slopes in 
plots depicting the logarithm of the retention factor k as a function of the eluent 
strength (e.g. percentage of acetonitrile for reversed-phase chromatography). A 
comparison for nitrobenzene (123.1 Da) and lysozyme (16,951.5 Da) is depicted in 
Fig. 6.  
Fig. 6. Plots of the logarithmic retention factor vs. the concentration of acetonitrile in 
the reversed-phase chromatography of lysozyme (solid lines) and nitrobenzene 
(dashed lines) on a polystyrene stationary phase. Reproduced from Chen [31]. 
 
Multisite adsorption also results in the focusing of biomolecules at the column head. 
Consequently, it is possible to load large volumes of biomolecular samples without 
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band broadening. Because of their large size, biomolecules diffuse very slowly in 
porous stationary phases (Fig. 7a). They need more time than small organic 
molecules to enter and to exit the pores and this results in slow mass transfer. To 
avoid this phenomenon, it is possible to reduce the size of the particles of the 
stationary phase (Fig. 7b). However, this results in a lower permeability of the 
column.  
 
Fig. 7. Comparison of four different column packings [20]. 
(a) Spheric, porous, and large particles (high permeability, large interparticle voids, 
low efficiency); (b) spheric, porous, and small particles (low permeability, small 
interparticle voids, high efficiency); (c) spheric, non-porous, and small particles (low 
permeability, small interparticle voids, high efficiency, small loadability), (d) monolithic 
phase (high permeability, high efficiency). 
 
One can also use non-porous material (Fig. 7c) but at the cost of a decrease in terms 
of column loadability. Stationary phases particularly well designed for the separation 
of biomolecules are the so-called monoliths (Fig. 7d). Because of their structure, 
monolithic columns combine high permeability and high efficiency. A monolith (or a 
continuous bed volume) is a unitary porous structure formed by in situ polymerization 
[32-35]. Because of the monolithic structure, the whole mobile phase is pumped 
through the pore channels [36]. Thus the mass transfer of the analytes is supported by 
convective flow in the macropore channels [37] (> 50 nm) and the diffusion dependent 
mass transfer occurs only in the micro- and in the mesopores (< 2 nm, and 2 - 50 nm, 
respectively). Monolithic columns also present a high permeability and consequently 
permit rapid separations of biomolecules at high flow rates [38-42]. 
To better understand the requirements of each separation step, the principles of the 
chromatographic methods [43-46] employed in our work are summarized in Tab. 3 and 
described in the next sections. 
 
 
(a) (b) (c) (d)
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Tab. 3. Chromatographic separation methods combined in this work. 
 
method of separation acronym principle of separation 
non-interactive methods 
size-exclusion chromatography SEC differences in molecule size 
interactive methods 
ion-exchange chromatography IEC electrostatic interactions 
reversed-phase chromatography RPC solvophobic interactions 
ion-pair reversed-phase 
chromatography IP-RPC 
electrostatic and solvophobic 
interactions 
affinity chromatography AC biospecific interactions 
 
 
3.1 Reversed-phase and ion-pair reversed-phase HPLC 
In reversed-phase high-performance liquid-chromatography (RP-HPLC) the analytes 
are separated in a polar medium (e.g. water). Retention occurs due to solvophobic 
interactions between the analytes and a hydrophobic stationary phase. Solid phases 
used in RP-HPLC are mostly alkylated silica materials (e.g. octadecyl silica) or 
hydrophobic organic polymers (e.g. PS-DVB). The elution of the retained analytes 
takes place through the addition of an organic solvent (e.g. acetonitrile or methanol) 
in the elution mixture. This thermodynamically facilitates the desorption of the 
analytes from the stationary phase. Polar acids such as phosphoric acid, hydrochloric 
acid, and formic acid are usually added to the mobile phase in order to denaturate 
the proteins. Peak symmetries are thus improved by avoiding secondary interactions 
between biomolecules and residual silanol groups of silica-based stationary phases. 
Under such conditions, the retention of the analytes is mostly due to solvophobic 
interactions [47]. A schematic representation of such interactions is depicted in Fig. 8. 
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Fig. 8. Schematic representation of a solvophobic effect. 
The introduction of an apolar analyte in a polar mobile phase is energetically 
unfavorable. The generation of a cavity implicates the destruction of numerous 
hydrogen bonds, which is energetically not counterbalanced by the solvatation of the 
analyte in the solvent (a) and (b). The adsorption of an apolar analyte on the apolar 
stationary phase requires the destruction of less hydrogen bonds and is 
consequently energetically more favorable (c). Adsorption consequently occurs on 
the stationary phase (d). 
 
In ion-pair reversed-phase high-performance liquid chromatography, relatively 
hydrophobic acids (e.g. trifluoroacetic acid, heptafluorobutyric acid) or bases 
(triethylammonium acetate) are added to the eluents. Consequently, biomolecules 
are not only separated as a function of their hydrophoby but also as of their charge. 
Different models have been proposed (ion-pair model, dynamic ion-exchange model) 
but nowadays the non-stoechiometric model is generally accepted. The hydrophobic 
groups of the deprotonated acids or bases (amphiphiles) are adsorbed on the non 
polar stationary phase and an electrical surface potential is generated [48]. The 
concentration of the ion-pair reagent is generally not high enough to completely cover 
the stationary phase. Biomolecules are then retained on the stationary phase 
because of electrostatic and solvophobic interactions [49-52]. The principle of ion-pair 
reversed-phase chromatography is schematically depicted in Fig. 9a. 
 
Reversed-phase and ion-pair reversed-phase chromatography are very well 
designed to separate peptides and proteins with high efficiency and high peak 
capacity. This is mostly due to the absence of conformation isomers in the media 
during the separation process. The chromatographic conditions (e.g. 0.05 % TFA) 
are indeed harsh enough to denaturate most of the proteins. This separation process 
can consequently not be used for the fractionation of protein mixtures performed in 
order to collect biologically active proteins. The separation of nine peptides with ion-
(a) (b) (c) (d)
polar mobile
phase
apolarstationary
phase
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pair reversed-phase high-performance liquid chromatography is depicted in Fig. 9b. 
Fig. 9. (a) Schematic representation of electrostatic and solvophobic interactions in 
ion-pair reversed-phase chromatography. (b) IP-RP-HPLC-MS analysis of a 9-
peptide mixture [20]. 
Column, PS-DVB, 60 x 0.20 mm i.d.; mobile phase, (A) H2O + 0.05 % TFA, (B) ACN 
+ 0.05 % TFA; gradient, 0-50 % B in 15 min; flow rate, 2.5 µL/min; 50 °C; detection, 
ESI-MS; sample, solution containing 1=bradykinin fragment 1-5, 2=[Arg8]-
vasopressin, 3=methionine enkephalin, 4=leucine enkephalin, 5=oxytocin, 
6=bradykinin, 7=LHRH, 8=bombesin, 9=substance P; injection, 1 ng of each peptide. 
 
The eluents (e.g. water, methanol, and acetonitrile) and the modifiers (e.g. TFA, and 
TEAA) used in RP-HPLC and IP-RP-HPLC are volatile. This volatility permits to 
hyphenate the chromatographic separation step with mass spectrometric detection 
by using interfaces such as electrospray ionization [53;54] or matrix-assisted laser 
desorption ionization [55;56]. The advantages of a mass spectrometric detection are 
detailed in section 4.2 of this chapter. 
 
3.2 Ion-exchange HPLC 
In ion-exchange high-performance liquid-chromatography (IEX-HPLC) the analytes 
submitted to separation are positively or negatively charged. One speaks of cation-
exchange HPLC or anion-exchange HPLC, respectively. The positive (resp. 
negative) analytes electrostatically interact with negative (resp. positive) functional 
groups grafted on the stationary phase. For peptides and proteins, the interactions 
with the stationary phase may occur with amino-acid residues inside the peptide 
backbone but also with the carboxyl group at the C-terminus and the amine group at 
the N-terminus of the sequence. Amino-acid residues electrostatically interacting in 
IEX-HPLC are the acidic amino acids (aspartic acid, and glutamic acid) and the basic 
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amino acids (arginine, lysine, and histidine). A schematic representation of the 
electrostatic interactions taking place in ion-exchange chromatography is depicted in 
Fig. 10. 
 
Fig. 10. Electrostatic interactions between an anion-exchange stationary phase and 
the octapeptide WVNADGYK [20]. 
 
Because of their amphoteric properties, proteins can be separated by anion-
exchange and cation-exchange HPLC. At pH > pI, proteins have a negative net 
charge and can be separated by anion-exchange HPLC. On the contrary, at pH < pI, 
proteins have a positive net charge and they can be separated by cation-exchange 
HPLC. The choice between cation-exchange and anion-exchange HPLC is 
determined by the pI value of the proteins and the pH value at which the separation 
should be performed [57]. To get reproducible retention of proteins on the stationary 
phases, the difference │pH – pI│ should be higher than one pH unit. Protein 
separations using (a) anion-exchange and (b) cation-exchange HPLC are depicted in 
Fig. 11. 
The elution of the analytes is performed by increasing the ionic strength of the mobile 
phase. This is mostly achieved by performing a salt gradient (e.g. sodium chloride) 
during the course of elution. Consequently, the eluents and as a matter of fact IEX-
HPLC are generally non compatible with hyphenation to mass spectrometry. Organic 
solvents (e.g. acetonitrile) are sometimes added to the aqueous eluents to lower 
secondary hydrophobic interactions between analytes and stationary phase [58]. 
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Fig. 11. Separation of proteins with anion-exchange and cation-exchange HPLC [20]. 
(a) Column, 250 x 4.0 mm i.d. ProPac SAX-10, 10 µm; mobile phase, 10-min 
gradient of 0-0.50 mol/L NaCl in 20 mmol/L Tris-HCl, pH 8.0; flow rate, 1.0 mL/min; 
temperature, ambient; detection, UV at 220 nm; sample, 10 µL of a solution 
containing 1=conalbumin (130 µg/mL), 2=transferrin (200 µg/mL), 3=ovalbumin (500 
µg/mL), 4=trypsin inhibitor (170 µg/mL); (b) column, 250 x 4.0 mm i.d. ProPac SCX-
10, 10 µm; mobile phase, 10-min gradient of 0.50 mol/L NaCl in 50 mmol/L Na2HPO4, 
pH 6.0; flow rate, 1.0 mL/min; temperature, ambient; detection, UV at 220 nm; 
sample, 10 µL of a solution containing 1=trypsinogen (400 µg/mL), 2=α-
chymotrypsinogen A (70 µg/mL), 3=ribonuclease A (300 µg/mL), 4=cytochrome C (70 
µg/mL), 5=lysozyme (100 µg/mL). 
 
During a separation performed with ion-exchange HPLC, the three-dimensional 
structures of biomolecules are usually preserved. Proteins are not denaturated as 
long as the pH of the eluent does not attain harsh values. Under these conditions, 
biomolecules collected after IEX-HPLC are still biologically active. On the other hand, 
the three-dimensional structures of the proteins and the resulting different 
conformations are mostly responsible for broad chromatographic peaks. For this 
reason, the efficiency and the peak capacity in ion-exchange HPLC are significantly 
smaller than in reversed-phase- and ion-pair reversed-phase HPLC. 
 
3.3 Affinity chromatography 
Affinity chromatography is based on highly-specific biological interactions between 
two species such as antigen and antibody, glycoprotein and lectin, or enzyme and 
co-enzyme. One of the partners is covalently bound to the stationary phase, whereas 
the other (the analyte) is present in the sample. The biospecific interaction between 
the two partners is used to selectively bind the analyte to the column. The elution is 
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performed either with competitive adsorption or with conformational modification. The 
latter can be achieved by variation of the pH or of the ionic strength. A schematic 
representation of affinity chromatography is depicted in Fig. 12. 
Fig. 12. Principle of affinity chromatography [59]. 
 
Affinity chromatography is the separation method with the highest selectivity, 
enabling the isolation of a single biomolecule (e.g. protein) from very complex 
samples (e.g. serum) [60;61]. This high selectivity is due to a very specific affinity 
interaction between both interacting molecules. Electrostatic interactions but also 
hydrogen bonding, hydrophobic interactions and tight steric fit of the interacting 
molecules are involved. 
 
3.4 Size-exclusion chromatography 
In size-exclusion chromatography, analytes are separated as a function of their size 
(hydrodynamic volume). The stationary phase consists of a porous material with 
defined pore sizes. Molecules over a critical size are too voluminous to enter into the 
pores and are eluting in the solvent front. Molecules under the exclusion limit not only 
move between the particles of the stationary phase but also penetrate into the pores. 
Thus big analytes elute at the beginning, whereas small analytes elute at the end of 
the chromatographic process, as illustrated in Fig. 13. The mobile phase acts as a 
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solvent and has no influence on the separation. Any adsorptive interactions between 
the surface of the chromatographic support and the analytes have to be avoided in 
order not to bias the size dependence of elution. 
 
Fig. 13. Principle of size-exclusion chromatography [27]. 
 
3.5 Restricted access materials 
Restricted access materials (RAM, term introduced in 1991 [62]) have been developed 
in order to perform on-line sample preparation and to get rid of the handling of 
untreated biological samples. Restricted access materials permit the direct injection 
of complex biological fluids (e.g. serum) into a HPLC system. On a RAM column, 
small proteins or organic molecules are extracted whereas the majority of proteins 
are flowing through the column. This result is achieved by the combination of 
different chromatographic modes. Various stationary phases are nowadays available 
and different mechanisms have been developed [63-65]. Generally, a combination of 
size-exclusion chromatography and reversed-phase HPLC is employed. The outside 
surface of the stationary phase is constituted of unreactive, hydrophilic groups, 
whereas the inner surface of the stationary phase is grafted with hydrophobic 
material. Large biomolecules can not access the inner surface of the 
chromatographic support and are consequently not retained. On the contrary, small 
biomolecules or small organic molecules penetrate into the pores, where they are 
retained [66-68]. A schematic representation of a restricted access material is depicted 
in Fig. 14.  
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Fig. 14. Schematic representation of the restricted access medium LiChrospher 
ADS. Large proteins can not access the inner surface of the chromatographic 
support. Analytes can penetrate into the pores, where they are retained [65]. 
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4 Methods of detection 
In the next section, a brief description of the different methods of detection utilized in 
this work is given. First, immunodetection methods are described. They are generally 
highly specific and have very low limits of detection. However, they require a good 
knowledge of the analyte and the production of new antibodies for each new 
investigated analyte. On the other side, mass spectrometric detection is more 
generic. The hyphenation of mass spectrometry with chromatography is also 
relatively easy. Mass spectrometry is nowadays the detection method of choice in 
analytics and bioanalytics. 
 
4.1 Immunodetection methods 
Enzyme-linked immunosorbent assays (ELISA) were first described in the seventies 
[15;16]. These biological assays permit to specifically detect and quantify biomolecules 
present at low concentrations in complex samples. Generally, antibodies specific for 
an antigen are bound to the surface of test tubes or in wells of a microtiter plate (Fig. 
15a). The complex sample is then introduced and the antibodies specifically catch 
and bind the antigen of interest (Fig. 15b). 
Fig. 15. Schematic representation of a sandwich ELISA. 
(a) Plate coating with catching antibodies; (b) sample loading and capture of antigen; 
(c) addition of detecting antibodies and binding to antigen; (d) substrate addition and 
conversion in a detectable form. 
 
Since the other constituents of the sample are not retained by the antibodies, it is 
possible to wash them out with an appropriate buffer. This mechanism is similar to 
the one utilized in affinity chromatography. Detection and quantitation are then 
performed by means of antibodies specific to another epitope than the one already 
occupied by the catching antibodies. The detecting antibodies are themselves 
Y
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covalently bound to an enzyme. A sandwich structure (catching antibody – antigen – 
detecting antibody - enzyme) is obtained (Fig. 15c). Finally, a substrate is added in 
the medium and is converted to a detectable (chromogenic or fluorescent) form by 
the enzyme (Fig. 15d). 
The main practical advantages of this technique are the ease of handling, the 
possibility to work with fully automated systems, and the rapidity of the detection 
(micro-ELISA reader) [69]. Moreover, very low limits of detection are achieved [70]. 
However, the development of two types of antibodies specific to different epitopes of 
the antigen are time consuming and expensive. 
Numerous variations of ELISA have been developed. Among them, ECLIA 
(electrochemiluminescence immunoassay) is also based on a sandwich principle. 
However, the catching antibodies are immobilized on magnetic beads through the 
formation of a biotin-streptavidin complex. The detecting antibodies are covalently 
bound to a tris(2,2’-bipyridyl)ruthenium(II)-complex, which luminesced by electric 
energy [71]. 
 
4.2 Mass spectrometry 
Mass spectrometry presents numerous advantages. First, this is a very sensitive 
method of detection. Signals have already been detected for analytes down to the 
zeptomol level [72]. Mass spectrometry also gives under special conditions (e.g. 
tandem mass spectrometry) structural information on the analyte. Finally, with the 
introduction in the late eighties of two revolutionary ionization techniques, namely 
electrospray ionization [2] and matrix-assisted laser desorption/ionization [3;4], it has 
become possible to hyphenate mass spectrometry with high-performance liquid 
chromatography for the analysis of large biomolecules. 
 
4.2.1 Principle of electrospray ionization 
The term electrospray refers to the dispersion of a liquid in numerous small charged 
droplets with the help of an electric field. Thus, electrospray-ionization of an analyte 
is achieved by two processes: 
- the formation of electrically charged droplets from the in-coming sample solution 
- the transfer of the ions from the droplets to the gas phase under the influence of a 
strong electric field. 
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In practice, the sample solution is continuously pumped trough a capillary tube into 
the ESI source at flow rates typically ranging from a few nL/min to several µL/min. 
The application of a high-voltage potential (2-6 kV) between the end of the capillary 
tube and the counter-electrode (end plate) results in the electrolysis of the liquid and 
induces a charge accumulation at the liquid surface located at the tip of the capillary 
(Fig. 16a). The charges repulse themselves and a decrease of the surface tension of 
the sample solution occurs. A so-called Taylor cone is formed and a thin liquid 
filament protrudes. The liquid filament finally breaks when the Rayleigh limit (the 
charge repulsion equals the surface tension) is exceeded. 
Fig. 16. Schematic representation of the ESI process at macroscopic (up) and 
microscopic (down) scale [59]. 
 
The droplets shrink with the evaporation of the solvents (Fig. 16b) and finally ions 
find themselves in the gas phase (Fig. 16c). The real mechanism is not yet 
completely understood. According to the so-called charge residue model [73] the 
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droplets shrink until only one single ion is present in the droplet. Whereas according 
to the ion evaporation model, the ions are released from the droplets with Coulomb 
explosions [74]. 
The hyphenation of ESI-MS to HPLC requires a compatibility of the eluent used 
during the separation step with the ionization process. For separations performed 
with reversed-phase HPLC or ion-pair reversed-phase HPLC the concentration of 
organic solvent determines the retention of the analytes on the column and can 
consequently not be arbitrarily changed. For this reason an organic solvent is 
sometimes added to the mobile phase after the column and before the electrosray 
source. This liquid is either introduced parallel to the capillary tube with a concentric 
arrangement [75;76] or introduced with a T-piece [77]. 
In pneumatically assisted ESI, the liquid entering in the ESI interface is surrounded 
by a third concentric tube permitting the introduction of a so-called spraying gas in 
order to support and stabilize the spray. 
 
Electrospray ionization is especially well adapted to ionize large molecules (e.g. 
proteins, peptides, and nucleic acids) [78-80]. ESI permits to bring the analytes in the 
gas phase without inducing fragmentation. Another advantage of ESI is that during 
the ionization process, multi-charged ions are produced. Thus also big molecules, 
having a mass far above the detection range of the mass analyzer, can be detected. 
The value measured in the analyzer is indeed not the mass of the analytes but the 
m/z value with m the mass of the ion and z the charge of the ion. Consequently, an 
analyte with a mass of around 100,000 Da and possessing 100 charges is detected 
at around m/z 1,000. For this reason, molecules up to several millions Da can be 
analyzed with mass spectrometry despite limitations of quadrupole- and ion-trap 
analyzers. 
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4.2.2 Quadrupole mass analyzer 
Quadrupole mass analyzers consist of four parallel metal rods arranged 
symmetrically. Ideally, the fours rods should have the shape of a hyperbola in cross 
section but cylindrical rods practically approximate a hyperbolic-field. Diagonally 
opposite rods are electrically connected together. Both a direct current (DC) and an 
oscillating radio frequency (RF) signal are applied across the rods, adjacent rods 
having opposite charge (Fig. 17a). 
 
Fig. 17. (a) Quadrupole with hyperbolic rods and applied potential; (b) stability areas 
as a function of UDC and VRF for ions with different masses [81;82]. 
 
The potential 0Φ  between two adjacent rods can be described by 
( )tfVU RFDC π2cos0 ⋅−=Φ  with f  being the frequency of the RF potential. By 
applying this potential 0Φ  to each pair of rods, a quadrupolar electric field results. 
Each point ( )zyx ,,  in the electrical field is exposed to the potential 
( ) 2
0
22
0, r
yx
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−⋅Φ=Φ  with 0r  being the half of the distance between two opposite rods. 
Thus, ( )yx,Φ  does not depend on z  and the ions entering the analyzer are only 
submitted to accelerations following the x - and y -directions. The trajectory of an ion 
is then described by the so-called Mathieu equations [83;84], and it is possible to define 
in a ( )RFDC VU ,  plot, stability regions for which the coordinates ( )yx,  of an ion remain 
smaller than 0r  (Fig. 17b). Ions present in such a region have stable trajectories in 
the quadrupole and will successfully traverse the quadrupole to reach the detector. 
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All other ions have unstable trajectories and will collide with the rods at some point. 
By maintaining a constant RFDC VU ratio, a straight operating line of the analyzer is 
obtained as depicted in Fig. 17b. By scanning along this operating line, a successive 
detection of different masses occurs. The higher the slope, the better the resolution. 
By applying 0=DCU , all the ions with a m/z higher than the one defined by RFV  are 
stable ( )0ryandx < . Under these conditions the ions are systematically brought back 
to the center of the rods, even if they were deflected by a collision. This focusing 
effect is important to increase the transmission of ions after collisions. 
Quadrupole mass analyzers present a high ion transmission from the interface to the 
detector. They are also easy to use and the calibration is long-term stable. 
 
4.2.3 Quadrupole ion trap mass analyzer 
The principle of quadrupole ion trap mass analyzers was already described by W. 
Paul and H.S. Steinwedel in 1960 [85]. However, the first commercial analyzer was 
released only 20 years later because of technical reasons [86]. In an ion trap analyzer, 
the ions are captured (trapped) in an electric field. In this electric field, the ions move 
on stable trajectories. By varying the electric field the ions can be selectively ejected 
from the ion trap to the detector as a function of their m/z. Contrary to a quadrupole, 
where only ions with a specific m/z are able to pass through the analyzer, the whole 
ions are captured in the ion-trap analyzer and are only afterwards selectively ejected 
to the detector as a function of their m/z. A schematic representation of an 
electrospray-ion trap mass spectrometer is depicted in Fig. 18. 
The quadrupole ion trap consists of a ring electrode and two hyperbolic end-cap 
electrodes. The ions can enter and exit the ion trap through two small holes in the 
middle of each end-cap electrode. The ions produced in the ion source are focused 
and transported to the ion trap by means of skimmers and octapole lenses. In order 
to slow down the incoming ions, a helium pressure of ~ 3 x 10-3 bar is maintained in 
the ion trap. Thus the kinetic energy of the ions is reduced by collisions of the ions 
with helium atoms, and the ions are trapped. The application of a variable voltage on 
the ring electrode and on the end-cap electrodes results in a quadrupole electric field 
in the trap. The ions are then stabilized and move on trajectories defined by the 
Mathieu equations [87]. 
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Fig. 18. Schematic representation of an electrospray-ion trap mass spectrometer. 
 
During a measurement cycle, the ions are accumulated in the ion trap for a short 
period of time, mostly between 0.1 and 100 ms. Subsequently, the entrance of the 
ion trap is closed for in-coming ions by changing electric potentials. Thus once the 
ion trap is filled, no other ion can penetrate. This permits first to avoid a too high 
charge concentration in the ion trap and a resulting decrease of the mass accuracy. 
This also prevents any interference between two consecutive measurements. 
The sequential ejection of the ions happens by the application of a mass selective 
resonance frequency to the end-cap electrodes. The oscillation amplitudes of the 
ions increase, and finally a destabilization of the ion trajectories occurs and the ions 
are ejected. The out-going ions are finally detected with a multiplier, which converts 
and amplifies the signal into an electric current. 
One of the advantages of the ion trap is the possibility to perform tandem mass 
spectrometry experiments (MS/MS). This permits the production of fragment ions by 
means of collision-induced dissociations. In this modus, ions with an m/z of interest 
(called precursor ions) are isolated in the ion trap, whereas the other ions are ejected 
by the application of resonance frequencies. The kinetic energy of the precursor ions 
is then increased up to a value at which the ions collide with the helium atoms also 
present in the trap. During these collisions, enough potential energy is transferred to 
the ions to induce fragmentation. The fragments (product ions) are then sequentially 
ejected from the trap and detected. An alternative is to isolate in the trap a product 
ion and to fragment it by performing new collision-induced dissociations. This 
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process is theoretically n times repeatable (MSn) but is practically limited because of 
a signal decrease by each MS cycle. A schematic representation of the different 
steps to perform an MS/MS analysis is depicted in Fig. 19. 
Fig. 19. Schematic representation of an MS/MS cycle with a quadrupole ion trap 
mass spectrometer. 
 
The advantages of an ion trap are the high scan speed (10 to 20 times quicker than a 
quadrupole mass spectrometer) and the possibility to perform up to 10 successive 
MS/MS cycles. As a result, ion traps are the analyzers of choice for hyphenation with 
chromatographic systems, which require high data acquisition rates but also product 
ion mass spectra for structure elucidation and identification of the analytes. 
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4.3 Identification of peptides and proteins with mass 
spectrometry and algorithmic computation [88]  
Two different approaches are nowadays used to identify peptides and proteins with 
mass spectrometry detection. Both the Peptide Mass Fingerprinting (PMF) and the 
Peptide Fragment Fingerprinting (PFF) approaches are based on the comparison of 
measured mass spectra with theoretical peak lists saved in a data bank. Generally, 
the complex protein mixture one wants to analyze is previously enzymatically 
digested with a specific enzyme (e.g. trypsin) and the resulting complex peptide 
mixture is separated by two-dimensional high-performance liquid chromatography 
before introduction in the mass spectrometer. 
In the Peptide Mass Fingerprinting (PMF) approach, a peptide is identified by 
measuring its m/z and by comparing it to a list of m/z calculated from a list of 
peptides generated from in silico digestion of the proteins in a database. Protein 
identification occurs when one or more peptides matching a part of the protein 
sequence are identified. In this approach, the identification of a peptide is only based 
on a single m/z measurement. To get high-confidence results, it is of importance to 
get very accurate m/z values (3-5 ppm mass deviation) and to use high-resolution 
mass analyzers such as time-of-flight (TOF) or Fourier Transform Ion Cyclotron 
Resonance (FT-ICR) being able to differentiate lysine (m/z 128.095) from glutamine 
(m/z 128.059). Anyways, to get the best mass accuracy it is recommended to 
perform internal mass recalibration. This procedure is, however, time consuming for 
the operator and seldom automated. 
In the Peptide Fragment Fingerprinting (PFF) approach, the complex protein mixture 
to be analyzed is digested and separated as in the previously described PMF 
approach. The difference appears in the mass spectrometric detection. After MALDI 
or ESI ionization, peptides are fragmented in the gas phase. The fragments obtained 
in the gas phase are finally separated, detected, and compared to sets of theoretical 
fragments. Theoretical fragments are obtained from in silico fragmentation of 
peptides, according to fragmentation rules and to the type of instrument used for the 
fragmentation [89-92]. In this approach, a peptide is identified by the mass of the intact 
precursor peptide ion, but also by the m/z of each fragment observed in the 
spectrum. For this reason it is possible to get unambiguous peptide and protein 
identification without high accuracy mass instruments (e.g. quadrupole ion trap). 
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At low collision energy (< 200 eV), fragmentations generally occur at three different 
locations of the peptide backbone: just before, just after, or exactly at the location of 
the peptide bonds. If the charge remains on the N-terminus of the sequence, so-
called an, bn, and cn ions are obtained, whereas xn, yn, and zn ions are formed when 
the charge is carried on the C-terminus of the sequence. The common nomenclature 
for sequence ions in peptide mass spectra is depicted in Fig. 20. Some other 
fragmentations are sometimes observed. They usually correspond to elimination of 
water, ammonia, and carbon monoxide along the peptide backbone but eliminations 
from the side chains can also happen. 
 
Fig. 20. Collision induced fragmentations along the peptide backbone [93]. 
 
Numerous algorithms have been developed for fully automated interpretation of huge 
amounts of MS and MS/MS data. Some of them are listed in Tab. 4. For PFF, two 
search engines are leading on the market: Sequest from Jimmy Eng and John Yates 
[8], and Mascot from Matrix Science [6;7]. Generally the operator only needs to enter 
search parameters (e.g. protease used for the digestion, chemical modification, 
investigated organism, mass tolerance) and to load the mass spectra as peak lists 
(e.g. ASCII format) into the search engine. After computation the operator gets a list 
of identified peptides/proteins. In the case of Mascot, the confidence of the 
identifications is evaluated by the so-called MOWSE (molecular weight search) 
scoring algorithm. A MOWSE score is computed for each peptide/protein. The 
MOWSE score is defined as ( )Plog10 ⋅−  with P  the probability to assign a random 
hit as a positive hit. For instance, a MOWSE score 200 signifies that the probability to 
have a random hit is 10-20. 
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Tab. 4. List of on-line available search engines for protein identification with PMF [94]. 
 
Because the MOWSE score is only an approximation, the level of false positives is 
usually independently tested by performing a search in a reverse database [95]. In a 
reverse database, each polypeptide sequence of the forward database is written in 
reverse from last residue to first. Consequently, the reverse database has the same 
size, the same number of entries, and the same amino-acid distribution than the 
forward database. The hits obtained by performing a search in the reverse database 
are truly random hits. Assuming to have the same number of random hits by 
performing a search in the forward version of the database, one can evaluate the 
confidence of your peptide/protein identifications by computing the ratio:  
databaseforwardtheinobtainedhitsofnumber
databasereversetheinobtainedhitsofnumber  
The obtained value should approximately correspond to the confidence threshold 
chosen for the Mascot search (generally 95 %). 
 
 
search engine web site
Aldente http://www.expasy.org/tools/aldente/
Mascot http://www.matrixscience.com
Protein prospector http://prospector.ucsf.edu/
Profound http://prowl.rockefeller.edu/prowl-cgi/profound.exe
PeptideSearch http://www.narrador.embl-heidelberg.de
DARWIN http://www.cbrg.ethz.ch/darwin
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III. Development of monolithic immuno-
adsorbers for the isolation of biomarkers from 
human serum 
1 Introduction 
1.1 Aim of the work 
High-performance affinity chromatography (HPAC) is one of the most sensitive and 
selective methods for the isolation of single compounds from highly complex 
biological samples [61, 96]. Already described in 1953 by Leonard Lerman [97], affinity 
chromatography permits nowadays the specific extraction of proteins from samples 
as complex as serum.  
However, to cover a large range of analytes the high specificity of HPAC implicates 
the use of a very high number of affinity columns having different selectivities. 
Consequently, affinity chromatography is not very useful for large-scale proteomic 
and peptidomic analysis. Nevertheless, affinity chromatography finds two prominent 
applications in proteomics.  
The first application consists in the depletion of the high-abundant proteins from 
human serum. Antibodies against albumin, transferrin, and immunoglobulins are 
immobilized on a stationary phase. Then, the sample (e.g. serum) is injected into the 
affinity column. The flowthrough containing the compounds of interest is collected for 
further analyses, whereas major serum proteins are retained on the column. After 
elution of high-abundant proteins and regeneration of the column, a new sample can 
be injected. Commercially available columns allow the elimination of > 99 % of the 
targeted proteins for up to 200 injections without showing any decrease in 
performance [98,99]. 
Affinity chromatography finds a second major application for the quantitative analysis 
of biomarkers. In the past decade, the analysis of whole proteomes has triggered the 
search for biomarkers of disease. Because simultaneous quantitation of all the 
proteins present in samples as complex as human serum is not possible, quantitation 
should be only based on few proteins specific to one biological or diagnosis question. 
Biomarkers are typically very low concentrated: ng/mL concentration range for 
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common tumor markers, and pg/mL concentration range for heart disease markers 
[100]. With the actual status of technique, there is no simple way that mass-
spectrometry based approaches can routinely quantify such biomarkers without 
reducing the complexity of the sample [101]. Because only few biomarkers are 
introduced yearly into the market [100], a lot of time and money can be invested for the 
investigation and the analysis of each biomarker. In such conditions, affinity-based 
approaches can be developed for each biomarker and affinity chromatography plays 
a major role. Antibodies specific to the biomarker of interest are immobilized on a 
stationary phase. The sample (e.g. serum) is injected into the affinity column and all 
proteins are flowing through, except the biomarker specifically retained on the 
column. After elution, the biomarkers are collected for further analyses.  
Monolithic supports are materials comprising a continuous bed volume. Because of 
their structure, monolithic columns combine high permeability and high efficiency. 
Almost no diffusion resistance is observed during mass transfer (see chapter II, 
section 3). Consequently, antigens present in a sample/mobile phase can quickly 
interact with antibodies immobilized on such supports [102, 103]. Monolithic supports are 
thus the materials of choice to immobilize antibodies for affinity chromatography. 
Convective Interaction Media (CIM) monoliths are now available as flat disks [104]. 
Several monolithic disks bound with different antibodies/ligands can be stacked into a 
single cartridge, permitting the easy development of immunoadsorbers for conjoint 
liquid chromatography [105].  
In this context, the aim of our work in cooperation with Roche Diagnostics (Penzberg, 
Germany) was to develop monolithic CIM immunoadsorbers, permitting to target 
biomarkers of heart disease at relevant concentrations. Our work was focused on two 
biomarkers: myoglobin and NT-proBNP.  
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1.2 Investigated biomarkers 
1.2.1 Myoglobin as biomarker of heart infarct 
Myoglobin [106] is a cytoplasmic protein which involved in the transport of oxygen. 
Myoglobin also permits oxygen storage in primary aerobic working muscles such as 
heart. Human myoglobin (Mw 17,041.9 / 17,052.5 Da) is made of a single polypeptide 
chain of 153 amino acids:  
GLSDGEWQLV LNVWGKVEAD IPGHGQEVLI RLFKGHPETL EKFDKFKHLK 
SEDEMKASED LKKHGATVLT ALGGILKKKG HHEAEIKPLA QSHATKHKIP 
VKYLEFISEC IIQVLQSKHP GDFGADAQGA MNKALELFRK DMASNYKELG 
FQG 
 
The tertiary structure of the protein is mostly α-helical; eight α-helical portions are 
separated by unarranged structures (see Fig. 21). The dimensions of the protein 
measured in solution are: 4.5 x 3.5 x 2.5 nm. The property of myoglobin to bind 
oxygen molecules is due to the presence of a heme group. This non-covalent group 
made of a porphyrin ring is able to complex iron and is responsible for the red color 
of myoglobin. Two histidine residues inside the natural protein play a decisive role for 
the binding of oxygen to the heme group.  
Fig. 21. Three-dimensional representation of human myoglobin. 
 
When a muscle (e.g. heart muscle) is injured, myoglobin is released into serum [107]. 
Such a case occurs during myocardial infarction. Therefore, myoglobin is an 
important factor in the diagnosis of acute myocardial infarction [108], early reinfarction 
[109], and successful reperfusion following lysis therapy [110]. Two hours after 
infarction, the plasma myoglobin concentration rises, and after 6-9 hours a 
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concentration peak is reached (200 – 1,000 ng/mL plasma). After 12-24 hours the 
myoglobin concentration recovers a value of 3 -65 ng/mL [111, 112]. A method for the 
absolute quantitation of myoglobin in human serum has already been established 
[59;88;113;114] but myoglobin was not isolated with immunoadsorber. In the present work, 
the isolation of human hemoglobin from serum with immunoaffinity has been 
investigated. 
 
1.2.2 NT-proBNP as biomarker of heart insufficiency 
Brain Natriuretic Peptide (BNP) is a vasoreactive peptide hormone implicated in 
coronary heart disease, arterial hypertension, valvular disease, and primary 
myocardial disease. N-terminal prohormone Brain Natriuretic Peptide (NT-proBNP) 
and BNP are obtained after cleavage into two parts of the prohormone Brain 
Natriuretic Peptide (proBNP) by the protease furin (see Fig. 22). BNP is biologically 
active but very unstable in plasma. NT-proBNP is much more stable (a few days in 
blood). To circumvent this problem of stability, the concentration of BNP is generally 
evaluated by determining the concentration of NT-proBNP. In the present work, NT-
proBNP has been retained as biomarker model [115]. The concentration of NT-proBNP 
in plasma is about 30 pg/mL for healthy people. In case of left ventricular diastolic 
and/or systolic dysfunctions, concentrations higher than 1,000 pg/mL are achieved 
[116, 117]. Thus, plasma NT-proBNP is recognized as a sensitive and specific marker 
for diagnosis of left ventricular dysfunction [118].  
Two types of NT-proBNP were provided by Roche Diagnostics: recombinant 
histidine-tagged NT-proBNP expressed in Escherichia coli and synthetic NT-proBNP. 
Their sequences and properties are the following:  
Histidine-tagged NT-proBNP (1-66): Mw 8521.2 / 8526.3 Da, pI 7.24 
MRGSHHHHHH GSHPLGSPGS ASDLETSGLQ EQRNHLQGKL SELQVEQTSL 
EPLQESPRPT GVWKSREVAT EGIRGHR 
 
Synthetic NT-proBNP (1-76): Mw 8434.4 / 8439.4 Da, pI > 9.0 
HPLGSPGSAS DLETSGLQEQ RNHLQGKLSE LQVEQTSLEP LQESPRPTGV 
WKSREVATEG IRGHRKXVLY TLRAPR, with X = norleucine 
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Fig. 22. Schematic drawing of proBNP showing enzymatic cleavage into biologically 
active BNP and NT-proBNP. Reproduced from Hall [119].  
 
2 Materials and methods 
2.1 Chemicals and samples 
Deionized water (18.2 MΩ cm) was prepared with a Purelab Ultra Genetic system 
(Elga, Griesheim, Germany). Acetonitrile (E Chromasolv) was purchased from 
Sigma-Aldrich (Steinheim, Germany). Analytical reagent grade sodiumdihydrogen-
phosphate-1-hydrate, suprapur acetic acid (100 %), and sodium hydroxyde (> 99 %) 
were obtained from Merck KGaA (Darmstadt, Germany). Sodium chloride was 
supplied by Grüssing GmbH (Filsum, Germany). Guanidine hydrochloride (≥ 99.0 %), 
ortho-phosphoric acid (> 85 %), heptafluorobutyric acid (≥ 99.0 %), and trifluoroacetic 
acid (≥ 99.5 %) were purchased from Fluka (Buchs, Switzerland). Analytical reagent 
grade hydrochloric acid was purchased from Fisher Scientific (Schwerte, Germany). 
Ubiquitin from bovine erythrocytes was supplied by Sigma (Schnelldorf, Germany) 
Human myoglobin and myoglobin depleted serum were obtained from the Institute for 
Reference Materials and Measurements of the European Union (Geel, Belgium). 
Recombinant streptavidin, His-tagged NT-proBNP, synthetic NT-proBNP, anti-
myoglobin antibodies, and anti-NT-proBNP polyclonal antibodies were supplied by 
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Roche Diagnostics (Penzberg, Germany).  
Anti-NT-proBNP antibodies were polyclonal antibodies specific against amino acids 
[1-21] from NT-proBNP. The antibodies were extracted from the serum of sheep 
immunized with NT-proBNP. Procedures for the preparation and the biotinylation of 
the antibodies have already been published elsewhere [117]. A 1.67 mg/mL 
streptavidin solution was prepared by dissolving 5 mg of a streptavidin lyophilizate in 
3.0 mL of a 0.5 mol/L, pH 8.0 sodium phosphate solution.  
Epoxy-activated CIM disks with 6.0 mm diameter, 2.0 mm thickness and column 
volume of 56 µL were kindly obtained from Aleš Štrancar (BIA Separations d.o.o., 
Ljubljana, Slovenia). The basis material of the CIM disks was poly(glycidyl 
methacrylate-co-ethylene glycol dimethacrylate). The polymer material has a volume 
of 33.6 µL and a mass of 23 mg per disk. The polymer material is chemically stable 
at pH 1-14 and buffer concentrations 0-8 mol/L. Consequently, very harsh conditions 
(e.g. 100 mmol/L hydrochloric acid medium) can be employed to release the 
biomarkers from the antibodies. 
Fractions were evaporated with a vacuum concentrator (model 5301) supplied by 
Eppendorf AG (Hamburg, Germany). 
 
2.2 Analytical setups 
2.2.1 Isolation of biomarkers with CIM disks 
The following setup, particularly well designed for flow rates of 30-150 µL/min, was 
used to run monolithic CIM disks. It consisted of a low-pressure Rheos 2000 HPLC 
system (Flux Instruments, Basel, Switzerland), a degasser from Knauer GmbH 
(Berlin, Germany), and a Rheodyne injection system (Rohnert Park, CA, USA) with a 
1,000 µL external loop. UV detection was monitored at 214 nm with a 45 nL Z-
shaped capillary detection cell (Ultimate, LC Packings, Amsterdam, the Netherlands). 
Fractions collected after the separation performed on monolithic CIM disks were then 
analyzed either with HPLC-ESI-MS or with immunoassays.  
 
2.2.2 High-performance liquid chromatography-mass spectrometry 
The separation setup used to analyze fractions collected or biomarkers trapped after 
CIM disks consisted of a capillary/nano system from LCPackings (Amsterdam, The 
Netherlands), equipped with an Ultimate low-pressure gradient micro-pump (model 
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Ultimate), a Switchos micro-column 10-port switching unit with loading pump (model 
Switchos), and a micro-injector (model Famos). Trap columns (PS-DVB monolith 5 x 
0.2 mm i.d., and PepmapTM C18 5 x 0.3 mm i.d., 5 µm) were obtained from 
LCPackings (Amsterdam, the Netherlands). Analytical column (60 x 0.1 mm i.d.) was 
a poly-styrene/divinylbenzene (PS-DVB) monolith prepared according to the 
published procedure [120].  
Fig. 23. Instrumental setup for off-line, two-dimensional biomarker detection by 
HPAC x IP-RP-HPLC-ESI-MS. 
(a) Pumping system for affinity enrichment; (b) affinity CIM disk; (c) UV detector for 
monitoring the first dimension; (d) 10 x 0.20 mm i.d. monolithic trap column trap 
column; (e) pumping system for IP-RP separation; (f) autosampler; (g) 10-port 
switching valve; (h) 60 x 0.10 mm i.d. monolithic separation column; (i) pump for 
loading and washing; (j) UV detector for monitoring the second dimension; (k) 
electrospray-ion trap mass spectrometer. 
Fractions were collected after the UV detector (c) and injected into the second 
dimension with the autosampler (f), or NT-proBNP was trapped on a column (d) 
finally mounted on a 10-port switching valve (g). 
e-
(a)
(b)
(c)
(d)
(e)
(f)
(d)
(g)
(i)
(h) (j)
1st dimension: HPAC
2nd dimension:
ion-pair reversed-phase
HPLC-ESI-MS, 
pH 2.1
(k)
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Eluents were degassed with helium. The trap column permitted to inject high sample 
volumes (e.g. 10 µL) without peak broadening. It also permitted the analysis of 
samples containing traces of sodium chloride without failing the source of the mass 
spectrometer. An ion-trap mass spectrometer (model esquire HCT) from Bruker 
Daltonics (Bremen, Germany) with a modified ESI-ion source (spray capillary: fused 
silica capillary, 0.090 mm o.d., 0.020 mm i.d.) was utilized as detector.  
The instrument was operated in MS mode. MS spectra were recorded in positive ion 
mode with an electrospray voltage of 3,500 V. The heated capillary temperature was 
set to 300°C. The following mass spectrometric parameters were applied: ultra scan 
50 – 3,000 m/z; scan speed, 26,000 m/z per s; full scan, 500 – 1,500 m/z; ion 
polarity, positive; trap drive, 93.2; octapole RF amplitude, 88.5 Vpp; lens 2, -36.1 V; 
capillary exit, 253.8 V; nebulizer gas, 20 psi; dry gas, 4 L/min; end-plate high-voltage 
offset, -500 V; ICC target, 70,000; maximum accumulation time, 200 ms. 
A schematic representation of the setup is depicted in Fig. 23. 
 
2.2.3 Detection and quantitation of NT-proBNP with immunoassays 
Fractions collected after affinity-CIM disks were analyzed with immunoassays 
performed with an Elecsys 2010 instrument (Roche Diagnostics, Penzberg, 
Germany). Detection and quantitation are based on an electrochemiluminescence 
immunoassay (ECLIA) [71]. Biotinylated polyclonal antibodies against epitope (1-21) 
are bound through a straptavidin-biotin complex to magnetic beads. These antibodies 
are used to catch NT-proBNP. Polyclonal antibodies against epitope (39-51) are 
covalently bound to a tris(2,2’-bipyridyl)ruthenium(II)-complex and are employed for 
detection. The reaction mixture is aspirated into a measuring cell, where the 
microparticles are magnetically captured onto the surface of an electrode. The 
application of a voltage to the electrode induces a chemiluminescent emission, which 
is measured by a photomultiplier. The results are determined via a calibration curve. 
NT-proBNP concentrations can be measured between 0.6 amol/µL (5 fg/µL) and 
4,130 amol/µL (35,000 fg/µL). If the concentration of NT-proBNP is out of range, the 
sample is diluted with human NT-proBNP depleted serum [117, 121]. 
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2.3 Preparation of affinity CIM disks 
Two different schemes were followed for the preparation of affinity CIM disks. 
Antibodies specific to biomarkers were either directly bound to the monolithic support 
or immobilized via the formation of a streptavidin-biotin complex [105;122]. 
 
2.3.1 Preparation of anti-myoglobin- and anti-NT-proBNP CIM disks 
via direct immobilization 
An epoxy-CIM disk was mounted into the column housing and washed for 15 min at 
a flow rate of 70 µL/min with bidistilled water to eliminate the storage liquid, ethanol-
water (20/80). Then, the epoxy-CIM disk was equilibrated with 0.50 mol/L sodium 
phosphate, pH 8.0, for 25 min at a flow rate of 70 µL/min. Antibody solutions (400 µL 
of 5.0 mg/mL anti-myoglobin antibody in 150 mmol/L sodium chloride solution or 
3,000 µL 3.34 mg/mL in 166 mmol/L potassium phosphate, pH 8.5, for anti-NT-
proBNP) were pumped through the epoxy-CIM disk at a flow rate of 15 µL/min. The 
effluent was collected in a glass tube positioned at the column outlet. Then, the 
affinity-CIM disk was removed from the housing, immersed in 3 mL of the collected 
antibody solution and stored at room temperature overnight. A schematic 
representation of the immobilization of the antibodies on the stationary phase is 
depicted in Fig. 24. The opening of the epoxy-ring is achieved by a nucleophilic 
attack of an amine group of the antibodies. 
 
Fig. 24. Preparation of monolithic immunoadsorbers: direct immobilization of 
antibodies on an epoxy-activated CIM disk. 
 
The anti myoglobin- or anti-NT-proBNP-CIM disk was washed from non-bound 
antibody molecules with 1,500 µL of 0.5 mol/L sodium phosphate, pH 8.0 (70 
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µL/min). Housing and connecting tubes were also washed with sodium phosphate, 
pH 8.0 and purged with air. After antibody immobilization, the anti-NT-proBNP- and 
anti-myoglobin-CIM disks were washed with 1,500 µL of 0.50 mol/L sodium 
phosphate, pH 8.0 at a flow rate of 70 µL/min. To block residual epoxy groups, 5.0 
mL of 1.0 mol/L ethanolamine were pumped through the column at a flow rate of 70 
µL/min. The CIM disk was immersed in 1.0 mol/L ethanolamine solution overnight at 
room temperature. Subsequently, the disk was washed with 2.5 mL of 0.50 mol/L 
sodium phosphate, pH 8.0, 1.0 mol/L NaCl at 70 µL/min, followed by 4.0 mL of 0.5 
mol/L sodium phosphate, pH 8.0, at 70 µL/min, and finally with 2.5 mL 30 mmol/L 
sodium chloride at 70 µL/min.  
 
2.3.2 Preparation of affinity CIM disks via streptavidin-biotin 
anchorage 
The epoxy-CIM disk was mounted into the housing and washed for 15 min at a flow 
rate of 70 µL/min with bidistilled water to eliminate traces the storage liquid, ethanol-
water (20/80). The epoxy-CIM disk was equilibrated for 25 min at a flow rate of 70 
µL/min with 0.50 mol/L sodium phosphate, pH 8.0. Then, 3 mL of a 1.67 mg/mL 
streptavidin solution were pumped through the epoxy-CIM disk at a flow rate of 15 
µL/min. The effluent was collected in a glass tube positioned at the column outlet. 
Then the CIM disk was removed from the housing, immersed in 3 mL of the collected 
streptavidin solution, and stored at room temperature overnight. 
The streptavidin-CIM disk was washed from non-bound streptavidin molecules with 
1,500 µL of 0.50 mol/L sodium phosphate, pH 8.0 (70 µL/min). Housing and 
connecting tubes were also washed with sodium phosphate, pH 8.0 and purged with 
air. A biotinyl-anti-NT-proBNP antibody solution consisting of 0.50 mg antibodies 
present in 500 µL 50 mmol/L potassium phosphate, 150 mmol/L sodium chloride, pH 
7.0 was prepared. The absorbance of the antibody solution was measured in 
quintuplicate at 280 nm using a UV-Vis spectrophotometer (Model DU 7400, 
Beckman, Fullerton, CA). The solution was then infused over the streptavidin-CIM 
disk at 10 µL/min. The solution eluting at the outlet of the column was collected and 
its absorbance was measured in quintuplicate. This procedure was repeated three 
times. The total absorbance was reduced by about 80 % (see Fig. 26), meaning that 
80 % of the antibodies may have reacted with streptavidin. In total, approximately 
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0.40 mg of antibody were fixed on the disk. It corresponds to 17.4 mg/g polymer 
material. These values are in accordance with values published elsewhere [103,123]. A 
schematic representation of the immobilization of the antibodies on the stationary 
phase is depicted in Fig. 25. The epoxy-ring opening is achieved by a nucleophilic 
attack of an amine group of streptavidin. 
 
Fig. 25. Preparation of monolithic immunoadsorbers: immobilization of antibodies on 
an epoxy-activated CIM disk via streptavidin-biotin complex. 
 
 
Fig. 26. Absorbance decrease of the biotinyl-anti-NT-proBNP antibody solution after 
infusion over the streptavidin CIM-disk. Detection with UV at 280 nm. 
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After antibody immobilization, the biotinyl-anti-NT-proBNP-streptavidin-CIM disk was 
washed with 1,500 µL of 0.50 mol/L sodium phosphate, pH 8.0 at a flow rate of 70 
µL/min. To block residual epoxy groups, 5.0 mL of 1.0 mol/L ethanolamine were 
pumped through the column at a flow rate of 70 µL/min. The CIM disk was immersed 
in the 1.0 mol/L ethanolamine solution overnight at room temperature. Subsequently, 
the disk was washed with 2.5 mL of 0.50 mol/L sodium phosphate, pH 8.0, 1.0 mol/L 
NaCl at 70 µL/min, followed by 4.0 mL of 0.50 mol/L sodium phosphate, pH 8.0, at 70 
µL/min, and finally with 2.5 mL 30 mmol/L sodium chloride at 70 µL/min.  
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3 Isolation of myoglobin from human serum by 
affinity chromatography 
3.1 Isolation of myoglobin at high concentration 
In 30 µL of myoglobin depleted serum, 75 pmol human myoglobin were spiked. The 
concentration of human myoglobin in serum was consequently 2.5 pmol/µL. This 
value was far above biologically relevant values (0.5 to 60 fmol/µL), but allowed 
trouble-free detections of myoglobin with MS even in large fraction volumes. 
The sample was diluted up to 150 µL with 150 mmol/L NaCl and injected over the 
anti-myoglobin-CIM disk at 30 µL/min. After 85 min, the pump was switched to deliver 
5 % CH3COOH at 120 µL/min and 120-µL fractions were collected every minute. 
Finally the column was re-equilibrated for further injections by pumping 150 mmol/L 
NaCl at 30 µL/min. The chromatogram is depicted with dashed lines in Fig. 27.  
Fig. 27. Elution profile of a serum sample spiked with 2.5 pmol/µL myoglobin. 85 min 
loading on mini CIM disk IV: mobile phase, 150 mmol/L NaCl; flow rate, 30 µL/min; 
room temperature; sample, 75 pmol human myoglobin spiked in 30 µL human serum 
and diluted to 150 µL with 150 mmol/L sodium chloride. 30 min elution: mobile phase, 
5 % CH3COOH; flow rate, 120 µL/min; room temperature 
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Elution is performed with acetic acid which explains the increase in intensity 
observed during the whole elution window.  
Ten µL of the collected fractions were then injected without further pre-treatment into 
the RP-HPLC-ESI-MS system described in section 2.2.2 and equipped with a 10 x 
0.2 mm PS-DVB trap- and a 60 x 0.2 mm PS-DVB analytical column. A 
representative reconstructed total ion current chromatogram and a mass spectrum 
corresponding to myoglobin are depicted in Fig. 28 and in Fig. 29. 
Fig. 28. Reconstructed total ion current chromatogram of a fraction collected after 
mini CIM disk IV corresponding to the elution of human myoglobin with 
H2O/CH3COOH 95:5 (v/v). 3-min trapping: column, PS-DVB, 10 x 0.2 mm i.d.; mobile 
phase, 0.10 % HFBA in H2O, isocratic elution; flow rate, 10.0 µL/min; room 
temperature; sample, 10 µL of fraction 92-93’ collected after the anti-myoglobin-CIM 
disk. RP-HPLC-ESI-MS analysis: column, PS-DVB, 60 x 0.2 mm i.d.; mobile phase, 
(A) 0.050 % TFA in H2O, (B) 0.050 % TFA in ACN; linear gradient, 0-60 % B in 9.0 
min; flow rate, 2.5 µL/min; temperature, 55°C. 
 
Peak areas corresponding to intact human myoglobin were calculated from extracted 
ion chromatograms of m/z 1004.0, 948.3, 898.4, 853.6, 813.0, and 776.1 with m/z 
widths of ± 0.5. These m/z correspond to intact myoglobin 17 to 22 times protonated, 
respectively. Before integration, peaks were smoothed using a Gauss algorithm and 
a smoothing width of 1.5 s. The resulting elution curve is depicted with solid lines in 
Fig. 27. A very sharp elution is observed, proving that myoglobin molecules were 
retained on the anti-myoglobin-CIM disk. In order to evaluate the recovery of human 
myoglobin after the monolithic immunoadsorber, a reference solution of myoglobin 
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(312 fmol/µL in 5 % CH3COOH) was injected in the RP-HPLC-ESI-MS setup. By 
comparing the peak areas computed for the fractions collected after the anti-
myoglobin-CIM disk and the peak area computed for the reference, it was possible to 
calculate the myoglobin recovery after the monolithic immunoadsorber. A myoglobin 
yield of 32 % was computed. Such a recovery is acceptable but may not be sufficient 
for the analysis of low-concentrated samples. Two reasons may explain this value. 
First, the capacity of the immunoadsorber to bind myoglobin may be not sufficient 
enough for the high amount of myoglobin injected. The other reason is that the 
antibodies may be not well suited for affinity chromatography (e.g. inappropriate 
binding constants). 
Fig. 29. Mass spectrum of human myoglobin observed at 7.0 min. Conditions as in 
Fig. 28. The different charge states of myoglobin are indicated. 
 
3.2 Isolation of myoglobin at low concentration 
In order to check if the anti-myoglobin-CIM disk can be utilized for real samples, a 
similar experiment as before was performed with a myoglobin concentration of 250 
fmol/µL in serum. Thus, 75 pmol myoglobin were spiked into 300 µL myoglobin- 
depleted serum. The sample was diluted up to 600 µL with 150 mmol/L NaCl and 
injected over the anti-myoglobin-CIM disk at 50 µL/min. After 70 min, the pump was 
switched to deliver 5 % CH3COOH at 120 µL/min and eight 120-µL fractions 
corresponding to the elution of myoglobin were collected.  
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Fig. 30. Extracted ion chromatogram of a fraction collected after mini CIM disk IV 
corresponding to the elution of human myoglobin with H2O/CH3COOH 95:5 (v/v). 4-
min trapping: column, PS-DVB, 10 x 0.2 mm i.d.; mobile phase, 0.10 % HFBA in 
H2O, isocratic elution; flow rate, 10.0 µL/min; room temperature; sample, 10 µL of 
fraction 74-75’ collected after the anti-myoglobin-CIM disk. RP-HPLC-ESI-MS 
analysis: column, PS-DVB, 60 x 0.1 mm i.d.; mobile phase, (A) 0.050 % TFA in H2O, 
(B) 0.050 % TFA in ACN; linear gradient, 0-60 % B in 9.0 min; flow rate, 0.8 µL/min; 
room temperature. 
 
Fig. 31. Mass spectrum of human myoglobin observed at 10.0 min. Conditions as in 
Fig. 30. The different charge states of myoglobin are indicated. 
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Ten µL of the collected fractions were then injected without further pre-treatment into 
the RP-HPLC-ESI-MS system. Myoglobin was detected in the fractions. However, as 
it can be observed in the extracted ion chromatogram (m/z 1219.0, 1137.8, 1066.8, 
1004.1, 948.3, 898.4, 853.6, 813.0, 776.1, 742.4, and 711.5 with m/z widths of ± 0.3 
and Gaussian smoothing width of 1.5 s) depicted in Fig. 30, the signal attributed to 
myoglobin is near the limit of detection of the mass spectrometer. The corresponding 
mass spectrum is depicted in Fig. 31. 
 
3.3  Conclusions 
Anti-myoglobin antibodies were successfully bound to an epoxy-activated monolithic 
CIM disk. The antibodies still presented affinity to myoglobin once bound to the 
stationary phase. Myoglobin was selectively isolated from human serum with the 
developed anti-myoglobin-CIM disk. At high concentration (2.5 pmol/µL), a recovery 
of about 32 % was achieved. Myoglobin was successfully isolated and detected from 
serum samples at concentrations down to 250 fmol/µL. However, the binding 
strength of the immunoadsorber is not sufficient for the analysis of real samples. 
Because the antibodies themselves (and not the amount of antibodies bound on the 
stationary phase) appeared to be responsible for this low binding capacity, it was 
decided to focus our work on another biomarker: NT-proBNP. 
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4 Isolation of NT-proBNP from human serum by 
affinity chromatography 
4.1 Evaluation of the loadability of anti-NT-proBNP-CIM 
disk 
The loadability of anti-NT-proBNP CIM disk was evaluated by frontal analysis [124]. 
The amount of NT-proBNP bondable on the disk was evaluated from breakthrough 
curves as follows. Anti-NT-proBNP-CIM disk was washed with 30 mmol/L sodium 
chloride at 10 µL/min using a syringe pump. The column effluent was monitored 
using a UV detector with a 45 nL Z-shaped capillary detection cell. For the 
determination of the column hold-up volume, 5.0 % acetic acid was infused and the 
strong increase in UV absorption at 214 nm was taken as the column hold-up time 
(5.25 min). After washing of the column with 500 µL 30 mmol/L sodium chloride at 70 
µL/min, direct infusion of 50 ng/µL (5.84 pmol/µL) NT-proBNP solution was 
performed at 10 µL/min and the UV signal was observed at 214 nm. The obtained 
elution profile is depicted in Fig. 32. The inflection point was determined at 9.50 min. 
The amount of his-tagged NT-proBNP bound on the column was then evaluated to 
(9.50 - 5.25) x 10 x 5.84 ≈ 250 pmol.  
Fig. 32. Breakthrough curve of his-tagged NT-proBNP infused on anti-NT-proBNP-
CIM disk. Sample, 50 ng/µL (5.84 pmol/µL) his-tagged NT-proBNP in 30 mmol/L 
NaCl; direct infusion; flow rate, 10 µL/min; room temperature; UV detection, 214 nm.  
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unspecific interactions with the stationary phase, a 5.84 pmol/µL solution of ubiquitin 
was infused under the same conditions. The inflection point was determined at 5.75 
min (see Fig. 33). This value is very similar to the hold-up time of the system (5.25 
min). The small difference (only ~ 10 % of the time difference observed by infusing 
NT-proBNP) is attributed to the imprecision of the method. 
 
Fig. 33. Breakthrough curve of ubiquitin infused on anti-NT-proBNP-CIM disk. 
Sample, 5.84 pmol/µL ubiquitin in 30 mmol/L NaCl; direct infusion; flow rate, 10 
µL/min; room temperature; UV detection, 214 nm. 
 
 
4.2 Isolation with CIM disk of NT-proBNP from human 
serum at 125 fmol/µL 
In 300 µL serum, 37.5 pmol synthetic NT-proBNP were spiked. The concentration of 
synthetic NT-proBNP in serum was consequently 125 fmol/µL. The sample was 
diluted to a final volume of 600 µL with 150 mmol/L NaCl and was injected over the 
anti-NT-proBNP-CIM disk. The loading and washing step was performed with 150 
mmol/L NaCl at 50 µL/min for 102 min. Elution was performed with pumping of 100 
mmol/L HCl at 120 µL/min. During the whole chromatographic process, 300-µL 
fractions (corresponding to 6.0 min or 2.5 min) were collected. The chromatogram is 
depicted in Fig. 34.  
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Fig. 34. (up) UV chromatogram of synthetic NT-proBNP spiked in serum and injected 
over anti-NT-proBNP-CIM disk and (down) elution profile. 102-min loading step: 
mobile phase, 150 mmol/L NaCl; flow rate, 50 µL/min; room temperature; sample, 
37.5 pmol synthetic NT-proBNP spiked in 300 µL serum and diluted to 600 µL in 150 
mmol/L NaCl; fractions, 17 x 6.0 min. Elution: mobile phase, 100 mmol/L HCl; flow 
rate, 120 µL/min; room temperature; fractions, 20 x 2.5 min. Concentration of NT-
proBNP in the collected fractions was determined with ECLIA. 
 
The analysis of the fractions with ECLIA revealed a very clear elution profile. Most of 
the synthetic NT-proBNP (92 % of the 37.5 pmol injected) were detected in the 7 first 
fractions of the elution step. Very low concentrations of NT-proBNP were detected in 
the flow-through and washing steps. The results are summarized in Tab. 5 and 
depicted in Fig. 34. These results show the ability of anti-NT-proBNP-CIM disk to 
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isolate NT-proBNP from serum samples. 
 
Tab. 5. Concentration of synthetic NT-proBNP in 300-µL fractions collected after anti-
NT-proBNP-CIM disk. The concentrations were determined with ECLIA. The loading 
and washing step is corresponding to fractions # 1-16, and the elution starts with 
fraction # 17. 
 
Fraction number NT-proBNP [pg/mL] Fraction number
NT-proBNP 
[pg/mL] 
  1     1,198 20          32 
  2     2,537 21          31 
  3     1,075 22 301,960 
  4        327 23   18,652 
  5        187 24        598 
  6          63 25          37 
  7          41 26     1,050 
  8          38 27     1,100 
  9          34 28        717 
10          33 29        105 
11          33 30          28 
12          34 31          30 
13          27 32          31 
14          32 33          29 
15          31 34          29 
16          32 35          34 
17          32 36          33 
18          32 37          29 
19          30 38          30 
 
 
4.3 Isolation with CIM disk of NT-proBNP from human 
serum at 7.8 fmol/µL 
In order to check the capacity of the anti-NT-proBNP-CIM disk to isolate NT-proBNP 
at lower concentrations, 2.35 pmol of synthetic NT-proBNP were spiked in 300 µL 
serum (synthetic NT-proBNP concentration of 7.8 fmol/µL in serum). Then the 
sample was diluted to a final volume of 600 µL with 150 mmol/L NaCl. The solution 
was injected over the anti-NT-proBNP-CIM disk. The loading and washing step was 
performed with 150 mmol/L NaCl at 50 µL/min for 102 min. Elution was performed by 
pumping 100 mmol/L HCl at 120 µL/min. The corresponding chromatogram is 
depicted in Fig. 35. 
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Fig. 35. (up) UV chromatogram of synthetic NT-proBNP spiked in serum and injected 
over anti-NT-proBNP-CIM disk and (down) elution profile. 102-min loading step: 
mobile phase, 150 mmol/L NaCl; flow rate, 50 µL/min; room temperature; sample, 
2.35 pmol synthetic NT-proBNP spiked in 300 µL serum and diluted to 600 µL in 150 
mmol/L NaCl; fractions, 17 x 6.0 min. Elution: mobile phase, 100 mmol/L HCl; flow 
rate, 120 µL/min; room temperature; fractions, 19 x 2.5 min. Concentration of NT-
proBNP in the collected fractions was determined with ECLIA. 
 
During the separation, fractions were collected and analyzed with ECLIA as in 
section 4.2. The analysis of the fractions revealed a very clear elution profile. Most of 
the synthetic NT-proBNP (85 % of the 2.3 pmol injected) were detected in the first 5 
fractions of the elution step. Very low concentrations of NT-proBNP were detected in 
the flow-through and washing steps (see Tab. 6 and Fig. 35). 
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Tab. 6. Concentration of synthetic NT-proBNP in 300-µL fractions collected after anti-
NT-proBNP-CIM disk. The concentrations were determined with ECLIA. The loading 
and washing step is corresponding to fractions # 1-16, and the elution starts with 
fraction # 17. 
 
Fraction number NT-proBNP [pg/mL] 
Fraction 
number 
NT-proBNP 
[pg/mL] 
1        488 20        688 
2        561 21        140 
3        300 22          61 
4        119 23          46 
5          82 24          26 
6          36 25          14 
7          15 26          13 
8          12 27          11 
9          12 28          11 
10          10 29            9 
11          13 30          13 
12          11 31          10 
13          11 32          11 
14          10 33          13 
15          11 34          11 
16            9 35          14 
17            9 36          12 
18         13,419 37          10 
19         40,540   
 
 
4.4 Stability and bath-to-batch reproducibility of anti-NT-
proBNP-CIM disks 
Anti-NT-proBNP-CIM disk showed very good properties in terms of elution profile and 
sample recovery. However, the implementation of the CIM disk in a routine analysis 
setup requires a stability of the immunoadsorber and also a good batch-to-batch 
reproducibility. This was checked by injecting 2.35 pmol synthetic NT-proBNP spiked 
in 300 µL serum (7.8 fmol/µL in serum) on anti-NT-proBNP-CIM disks from different 
batches. The samples were diluted to a final volume of 600 µL with 150 mmol/L NaCl 
and loaded with 150 mmol/L NaCl at 50 µL/min for 102 min. The elution was 
performed by pumping 100 mmol/L HCl at 120 µL/min. Fractions were collected and 
analyzed with ECLIA as previously described. 
Three anti-NT-proBNP-CIM disks from three different batches were evaluated. Two 
disks were tested after preparation and another after 18 months. The results are 
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depicted in Fig. 36. For all three affinity disks very similar elution profiles were 
obtained. A slight band broadening worsening is observed for the immunoadsorber 
after 18 months (more than 35 loading/elution cycles) but the elution profile is still 
well defined. The reproducibility from batch to batch appears excellent. Therefore 
anti-NT-proBNP-CIM disks are well-suited for high through-put analyses of NT-
proBNP in human serum. 
 
Fig. 36. Elution profile of synthetic NT-proBNP with three anti-NT-proBNP-CIM disks 
from three different batches. Conditions as in Fig. 35. 
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4.5 Calibration curve with anti-NT-proBNP-CIM disk 
Serum concentrations of NT-proBNP in patients suffering from systolic and diastolic 
dysfunctions are in the high amol/µL order of concentration. To test the ability of CIM 
disk immunoadsorbers to quantitatively extract NT-proBNP from real samples, serum 
aliquots were spiked with NT-proBNP at concentrations down to 750 amol/µL, and 
were injected over an anti-NT-proBNP-CIM disk. NT-proBNP recoveries were 
evaluated by ECLIA analyses of collected fractions. 
After equilibration of the affinity CIM disk with 150 mmol/L NaCl, a blank run 
consisting of an injection of 300 µL of human serum diluted to 600 µL with 150 
mmol/L NaCl was performed. The loading and washing steps were performed with 
150 mmol/L NaCl at 50 µL/min for 102 min. The “elution” was performed by pumping 
100 mmol/L HCl at 120 µL/min. 300-µL fractions were collected as in section 4.2 and 
analyzed with ECLIA. 
The results of the ECLIA measurements for the blank injection are depicted in Fig. 
37. One observes that the immunoadsorber is not completely free from synthetic NT-
proBNP from previous injections. NT-proBNP naturally present in serum may also 
contribute to this signal. However, the amount of NT-proBNP detected in the elution 
peak was of about 10 fmol to be compared with 225 fmol (~ 4%) injected in the 
system for the first calibration point. It was concluded that the column can be utilized 
without further washing cycles for the injection of the standards. 
Fig. 37. Blank elution profile of serum with an anti-NT-proBNP-CIM disk. Sample, 
300 µL serum diluted to 600 µL in 150 mmol/L NaCl. Other conditions as in Fig. 35. 
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Under the same conditions, 300 µL from synthetic NT-proBNP serum solutions 
(synthetic NT-proBNP concentrations: 750 amol/µL, 1,000 amol/µL, 2,000 amol/µL, 
and 4,000 amol/µL) were injected over the immunoadsorber. The collected fractions 
were also analyzed with ECLIA. The elution profiles were similar for the four tested 
concentrations. They are depicted inFig. 38. Synthetic NT-proBNP is mostly retained 
on the column during the loading and washing step. In all cases, a sharp elution 
occurs immediately after the switch to 100 mmol/L HCl. At 4,000 amol/µL, a slight 
flowing-through is observed in the five first fractions. In all cases, the amount of 
synthetic NT-proBNP eluting in fractions # 17 to # 22 corresponds to more than 70 % 
of the total amount of NT-proBNP detected during the chromatographic run. It 
appears that even at low concentrations, anti-NT-proBNP-CIM disks are very well 
designed for the enrichment of NT-proBNP from serum. 
 
Fig. 38. Elution profiles of synthetic NT-proBNP spiked in serum and injected over 
anti-NT-proBNP-CIM disk. Samples, 300 µL human serum spiked with synthetic NT-
proBNP at (a) 750 amol/µL, (b) 1,000 amol/µL, (c) 2,000 amol/µL, and (d) 4,000 
amol/µL. Conditions as in Fig. 35. 
 
A calibration curve, corresponding to the amount of synthetic NT-proBNP detected in 
the elution peak (fractions # 17 to # 22) as a function of the concentration of synthetic 
NT-proBNP in human serum was computed and is plotted in Fig. 39.  
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concentrations for diagnostics purposes. More generally, these results prove the 
ability of immunoadsorbers based on monolithic supports to quantitatively extract 
proteins of interest from biological complex matrixes. 
Fig. 39. Synthetic NT-proBNP recovered in elution peak (fractions # 17 to # 22) after 
anti-NT-proBNP-CIM disk as a function of synthetic NT-proBNP spiked in human 
serum. A very good linear correlation is observed. 
 
4.6 Hyphenation of anti-NT-proBNP-CIM disk with mass 
spectrometry 
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4.6.1 Hyphenation with PS-DVB monolithic trap column 
Synthetic NT-proBNP was spiked into serum to a concentration of 125 fmol/µL. 300 
µL spiked serum were diluted up to 600 µL with 150 mmol/L NaCl and injected over 
anti-NT-proBNP-CIM disk. The sample was loaded for 60 min with 150 mmol/L NaCl 
at a flow rate of 50 µL/min. The washing step was performed with 150 mmol/L NaCl 
at 500 µL/min. Then, the elution was performed by hyphenating a monolithic PS-DVB 
5 x 0.2 mm column to anti-NT-proBNP-CIM disk and by pumping 100 mmol/L HCl at 
15 µL/min for 90 min. It was not possible to set a higher flow rate, because of the 
resulting high back pressure (130 bar) incompatible with CIM disk certifications (50 
bar). The monolithic column was then decoupled from anti-NT-proBNP-CIM disk and 
mounted as a trap column in the RP-HPLC-ESI-MS setup (see 2.2.2). Synthetic NT-
proBNP was eluted in back-flush from the trap column and finally separated from 
residual serum proteins with a monolithic PS-DVB 60 x 0.1 mm column with an 
acetonitrile gradient. Synthetic NT-proBNP was observed in the extracted ion 
chromatogram (Fig. 40) and in mass spectrum (Fig. 41). 
Fig. 40. Reconstructed total ion current chromatogram of synthetic NT-proBNP. 
Sample, 37.5 pmol synthetic NT-proBNP spiked in 300 µL serum and diluted to 600 
µL with 150 mmol/L NaCl, injected over anti-NT-proBNP-CIM disk, eluted with 100 
mmol/L HCl PS-DVB, 5 x 0.2 mm i.d. column. The column was decoupled from anti-
NT-proBNP-CIM disk and implemented as a trap column for RP-HPLC-ESI-MS. 
Mobile phase, 0.10 % HFBA in H2O, isocratic elution; flow rate, 10.0 µL/min; room 
temperature. RP-HPLC-ESI-MS analysis: column, PS-DVB, 60 x 0.1 mm i.d.; mobile 
phase, (A) 0.050 % TFA in H2O, (B) 0.050 % TFA in ACN; linear gradient, 0-80 % B 
in 20.0 min; flow rate, 0.8 µL/min; 55°C. 
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Fig. 41. Mass spectrum of synthetic NT-proBNP. Sample, 125 fmol/µL synthetic NT-
proBNP in serum; trap column, PS-DVB, 5 x 0.2 mm i.d.; eluents, gradient, flow rate, 
and temperature as in Fig. 40. 
 
The same experiment was performed with serum samples spiked with synthetic NT-
proBNP at lower concentrations. However, NT-proBNP was no longer detected. 
 
4.6.2 Hyphenation with PepmapTM C18 trap column 
Hyphenation of anti-NT-proBNP-CIM disk was also investigated with a 5 x 0.3 mm 
PepMapTM C18 trap column. The higher permeability of the PepmapTM column in 
comparison with the PS-DVB column, permitted to perform elution from anti-NT-
proBNP-CIM disk at flow rates up to 50 µL/min without leakage from CIM disk 
housing (110 bar). Synthetic NT-proBNP serum solutions were prepared and injected 
into the HPLC system as depicted in Fig. 23. The samples were loaded and washed 
with 150 mmol/L NaCl at 50 µL/min. After 105 min, a PepmapTM C18 trap column 
was hyphenated to anti-NT-proBNP-CIM disk and 100 mmol/L HCl was pumped at 
50 µL/min for 30 min. The trap column was then dismantled from CIM disk and 
implemented as a trap column in the RP-HPLC-ESI-MS system previously described. 
Synthetic NT-proBNP was eluted in back-flush with an acetonitrile gradient and finally 
detected with ESI-MS. 
Synthetic NT-proBNP concentrations down to 7.8 fmol/µL in serum were detected 
(see Fig. 42 and Fig. 43). 
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Fig. 42. Reconstructed total ion current chromatogram of synthetic NT-proBNP. 
Sample, 2.35 pmol synthetic NT-proBNP spiked in 300 µL serum and diluted to 600 
µL with 150 mmol/L NaCl, injected over anti-NT-proBNP-CIM disk, eluted with 100 
mmol/L HCl PepmapTM C18, 5 x 0.3 mm i.d. column. The column was decoupled 
from CIM disk and implemented as a trap column for RP-HPLC-ESI-MS. Mobile 
phase, 0.10 % HFBA in H2O, isocratic elution; flow rate, 10.0 µL/min; room 
temperature. RP-HPLC-ESI-MS analysis: mobile phase, (A) 0.050 % TFA in H2O, (B) 
0.050 % TFA in ACN; linear gradient, 0-50 % B in 15.0 min; flow rate, 0.8 µL/min; 
room temperature. 
 
Fig. 43. Mass spectrum of synthetic NT-proBNP. Sample, 7.8 fmol/µL synthetic NT-
proBNP in serum injected over anti-NT-proBNP-CIM disk and trapped PepmapTM 
C18, 5 x 0.3 mm i.d. column. eluents, gradient, flow rate, and temperature as in Fig. 
42. 
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4.6.3 Discussion 
As shown in Fig. 42 and in Fig. 43, it was possible to detect synthetic NT-proBNP at 
concentrations down to 7.8 fmol/µL in human serum with trapping on PepmapTM, and 
ESI-MS detection. This corresponds to a gain sensitivity of 16 in comparison with the 
sensitivity observed with the monolithic PS-DVB 5 x 0.2 mm trap column (see 4.6.1). 
The reason of this gain is probably due to the better analyte transfer from anti-NT-
proBNP-CIM disk to the PepmapTM C18 trap column (50 µL/min, no leakage) than 
from anti-NT-proBNP-CIM disk to the monolithic PS-DVB trap (10-15 µL/min, critical 
pressure). The hydrophobicity of the stationary phase may play a minor role. The 
PepmapTM C18 trap column seems to be the trap column of choice for analyte 
transfer from CIM disks because of the low produced back pressure. 
However, strong synthetic NT-proBNP carry-over was observed with the PepmapTM 
C18 trap column (data not shown), which is not wished for sample quantitation. As no 
carry-over was observed with PS-DVB trap columns, a PS-DVB based stationary 
phase with low back pressure should be the best trap column. 
 
Sample recovery with trapping and RP-HPLC-ESI-MS appears to be smaller than the 
recovery observed with ECLIA detection (85 %, see 4.3) at similar concentrations. 
Injection of 300 µL of synthetic NT-proBNP at 7.8 fmol/µL in serum with 85 % 
recovery correspond to approximately 2.0 pmol synthetic NT-proBNP eluting from 
CIM disk during the elution process. This value is far above the detection limit of the 
mass spectrometer (some fmol), and a very intensive signal should be obtained with 
ESI-MS detection. Different phenomena can be involved in the low recovery of 
synthetic NT-proBNP from serum samples with trapping and analysis with RP-HPLC-
ESI-MS. The following factors can be mentioned: 
 insufficient analyte transfer from anti-NT-proBNP-CIM disk to PepmapTM C18 
trap column 
 insufficient loadability of PepmapTM; especially with serum samples (bleeding 
of the antibodies, incomplete depletion of high-abundant proteins; serum 
albumin, ferroxidase, and thrombin have already been detected) 
 incomplete elution of NT-proBNP from the PepmapTM trap column; strong 
carry-overs were already observed 
 degradation of NT-proBNP; degradation products of NT-proBNP were already 
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detected in neutral and acidic solutions; degradations only occur at N- and C- 
termini and have consequently no impact on ECLIA detection (epitopes for 
catching and detecting antibodies in the middle of the protein sequence) 
 ion-suppression in the ESI source (co-elution of proteins, impurities) 
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5 Conclusions 
Immunoadsorbers based on monolithic epoxy-activated CIM disks have been 
developed in order to target biomarkers implicated in heart diseases (myoglobin, and 
NT-proBNP). In both cases, antibodies were successfully bound to the polymeric disk 
material. The developed immunoadsorbers permitted to selectively isolate myoglobin 
and NT-proBNP from human serum. Myoglobin was successfully isolated and 
detected from serum samples at concentrations down to 250 fmol/µL. However, the 
binding capacity of the antibodies was not sufficient for the analysis of clinical 
samples. Frontal analysis of anti-NT-proBNP-CIM disk revealed the ability of the 
immunoadsorber to bind up to 250 pmol NT-proBNP. This capacity is highly sufficient 
for the analysis of clinical samples (some pmol). Anti-NT-proBNP-CIM disks show a 
very good stability over 18 months, and an excellent batch-to-batch reproducibility 
has been observed. Anti-NT-proBNP-CIM disks permitted a quantitative isolation of 
NT-proBNP at concentrations down to 750 amol/µL in serum (R2 = 0.998). This 
concentration corresponds to NT-proBNP concentrations in serum of highly ill 
patients. Hyphenation of CIM immunoadsorbers with mass spectrometry has been 
achieved for concentrations down to 7.8 fmol/µL. 
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IV. Development of an on-line SPE-HPLC-ESI-
MS method for the analysis of drugs in whole 
blood hemolysates 
1 Introduction 
For medical diagnostic and therapeutic purposes, determination of drug 
concentrations in biological fluids is essential. Drugs are generally monitored in blood 
and its components but also in biological fluids such as saliva, urine, synovial fluid, 
and cerebrospinal fluid. These fluids are difficult to be analyzed due to their 
complexity. The complexity is not only due to the numerousness of the analytes but 
also to their high dynamic range (in terms of concentration) [9]. For the analysis of 
whole blood time consuming sample preparation is required. Drugs of interests are 
indeed usually bound to erythrocytes and lysis of the erythrocytes is required. 
Generally, protein precipitation with ZnSO4/MeOH is performed and followed by 
centrifugation. Only after these steps of preparation the sample can be injected into a 
HPLC chain. Such sample preparations are labor-intensive and can not be 
automated at low costs. They are generally considered as the time-limiting step in the 
analytical process and are undesirable for routine procedures (especially for 
analyses with more than 100 samples a day). In order to circumvent these problems, 
Roche Diagnostics (Penzberg, Germany) has developed a hemolysis reagent 
permitting to obtain homogeneous hemolysates. After addition of the reagent to 
whole blood, a clear hemolysate is obtained in few minutes and the sample can be 
injected without further treatment into a HPLC-MS setup.  
In order to address small molecules of interest (e.g. immunosuppressive compounds 
such as rapamycin), high-abundant proteins such as hemoglobin (120-170 mg/mL) 
and albumin (60 mg/mL) have to be eliminated from the hemolysate. This can be 
achieved by performing on-line solid phase extraction (SPE) [125-127] before separation 
and detection with HPLC-ESI-MS. Some experiments have already permitted to 
detect 40 µg/mL rapamycin in hemolysate by Roche Diagnostics. However, high 
carry-over, especially of hemoglobin, has been observed in the following injections. 
Such a carry-over is not compatible with high-throughput quantitative analysis. 
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In this context, the aim of our work in cooperation with Roche Diagnostics was to 
develop an on-line SPE-HPLC-ESI-MS method, permitting to target drugs at relevant 
concentrations. The specifications of the setup were the following: 
1. injection of whole blood hemolysate over an “appropriately” designed material 
2. elimination of hemoglobin and proteins 
3. quantitative analysis of targets (small drugs) 
4. no carry-over of hemoglobin in a consecutive blank injection 
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2 Materials and methods 
2.1 Chemicals and instruments 
Deionized water (18.2 MΩ cm) was prepared with a Purelab Ultra Genetic system 
(Elga, Griesheim, Germany). Acetonitrile (E Chromasolv), human hemoglobin 
(H7379-5G), and N,N’-disuccinimidylcarbonate were purchased from Sigma-Aldrich 
(Steinheim, Germany). Trifluoroacetic acid (≥ 99.5 %), DMSO, 4-(dimethylamino)-
pyridin, imidazole (≥ 99.5 %), ammonium acetate (> 99 %), ethanolamine (≥ 99.0 %), 
and potassium thiocyanate (≥ 98 %) were purchased from Fluka (Buchs, 
Switzerland). Analytical reagent grade sodiumdihydrogen-phosphate-1-hydrate, 1-
methyl-octyl-pyrrolidinium chloride, and Tris-HCl were supplied by Merck KGaA 
(Darmstadt, Germany). Aminodextran (MW 40,000 Da), 5-methyltetrahydrofolic acid 
(CAS # 68792-52-9; Sigma M0132), and whole blood samples were obtained from 
Roche Diagnostics (Penzberg, Germany). Poly-D-lysine hydrobromide (MW 30,000 – 
70,000 Da), carbonic anhydrase from bovine erythrocytes, β-lactoglobulin A and B, 
human insulin, ubiquitin from bovine erythrocytes, tetracycline hydrochloride (CAS # 
64-75-5), human hemoglobin (H7379-5G, batch # 095K7540), and human serum 
(H1388-20mL, batch # 026K0467) were supplied by Sigma (Schnelldorf, Germany). 
Ovalbumin, and L-ascorbic acid were purchased from Serva Electrophoresis 
(Heidelberg, Germany). 1,4-Dioxane was purchased from Riedel de Haen (Seelze, 
Germany). 
Polyethyleneimine 25 kDa and polyethyleneimine 60 kDa were obtained from the 
workgroup of Prof. Wenz (Department of Organic Macromolecular Chemistry, 
Saarland University, Saarbrücken, Germany). Polyethyleneimine 25 kDa is available 
by BASF (Ludwigshafen am Rhein, Germany) under the name Lupasol G 500 as a 
40 weight percent aqueous solution (Nprim.:Nsec.:Ntert. = 1:1.1:0.7). Polyethyleneimine 
60 kDa is available by Acros (Geel, Belgium) as a 60 weight percent aqueous 
solution (Nprim.:Nsec.:Ntert. = 1:2:1). 
Solution pH was measured with a pH SenTix 61 electrode and a pH-meter pH 537 
supplied by WTW (Weilheim, Germany). 
Vivaclear mini 0.5 clarifying filter membranes (0.8 µm PES) were obtained from 
Vivascience AG (Goettingen, Germany). 
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2.2 Preparation of blood hemolysates 
Four % lysis reagent was prepared by mixing 0.7 g 1-methyl-octyl-pyrrolidinium to 0.3 
g potassium thiocyanate in 25 mL H2O. Blood hemolysates were obtained at neutral 
conditions by mixing under gentle agitation whole blood and lysis reagent (300 µL 
whole blood, 2.7 mL 150 mmol/L NaCl, and 3 mL 4 % lysis reagent). After a few 
minutes the blood sample became clear and ready for injection to the HPLC-MS 
system. 
 
2.3 Columns 
ChromSpher Biomatrix was purchased from Varian, Inc. (Middelburg, The 
Netherlands). LiChrospher ADS was obtained from Merck KGaA (Darmstadt, 
Germany). Capcell Pak was supplied by Shiseido Co (Tokyo, Japan) and Bioptic AV-
2 was purchased from GL Sciences (Torrance, CA, USA). Biotrap 500 MS was 
obtained from ChromTech Ltd (Cogleton, United Kingdom) and SPS C18 was 
purchased from Regis Technologies, Inc (Morton Grove, IL, USA). 
 
2.3.1 Modification of LiChrospher ADS material 
LiChrospher ADS bulk material was activated with N,N’-disuccinimidyl-carbonate. 1 g 
bulk material was weighted in a 50 mL reaction tube and 10 mL water free dioxane 
was added. 2 mL N,N’-disuccinimidyl-carbonate diluted in DMSO (0.6 mol/L) and 2 
mL 4-dimethylaminopyridin in DMSO (0.6 mol/L) were added. The mixture was left 
for reaction at room temperature under agitation for 6 hours. Finally the mixture was 
centrifugated (10 min at 5,000 g). The supernatant was removed, and the particles 
were resuspended in 10 mL of a DMSO-dioxane solution (1:2.5) and agitated for 10 
min. The procedure was repeated twice. After a last centrifugation, the succinimidyl-
carbonated particles were desiccated overnight (16 hours) at 4°C (vacuum desiccator 
with sicapent). 
The activated particles were then coupled with aminodextran T40. 10 mL of a cold 
aminodextran T40 solution (10 mg/mL in 0.1 mol/L sodium phosphate buffer, pH 7.5) 
was added to the previously activated and desiccated particles. The mixture was 
agitated overnight (16 hours) at 4°C. After centrifugation, the particles were washed 
in phosphate buffer for 10 min under agitation. The procedure was repeated twice. 
The modified particles were finally stored in 10 mL 20 mmol/L Tris-HCl buffer, pH 7.0. 
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2.3.2 Packing of columns 
Modified or unmodified particles were packed in stainless steel 30 x 2.0 mm column 
housings supplied by Bischoff Chromatography (Leonberg, Germany). The particles 
were suspended and pushed at 3 mL/min with Tris buffer. After 20 mL, the packing 
solution was switched to acetonitrile/water 80:20 (v/v). The columns were closed at 
each extremity with two 2 µm stainless steel filters. 
 
2.4 Analytical setups 
2.4.1 One-dimensional HPLC setup 
The different RAM columns were implemented in a HPLC system from Dionex 
(Idstein, Germany). Solvent delivery was performed by a P680 HPLC pump. Sample 
injection was performed by an ASI-100 Automated Sample Injector. Signals were 
monitored by a UVD340U diode array detector. The analytical setup is depicted in 
Fig. 44. 
Fig. 44. One-dimensional analytical HPLC setup used to test RAM columns. 
 
2.4.2 Two-dimensional HPLC setup 
The 2D-HPLC-MS setup was assembled as follows. The loading pump was a P680 
HPLC pump from Dionex (Idstein, Germany) and the injection system consisted of a 
Rheodyne 6-port-valve (7725) mounted with a 1 mL external loop (Rohnert Park, CA, 
USA). Hemoglobin monitoring was performed with a diode array detector UVD340U 
(Dionex) implemented after the RAM column. The switching unit consisted of a 
auto-sampler
gradient pump
detector
RAM
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Rheodyne 6-port-valve (7000). The elution was performed over a Prontosil 300-5-
C18-H 5 µm (125 x 2.0 mm) analytical column from Bischoff Chromatography 
(Leonberg, Germany). Eluent delivery was assured with a Rheos 2000 pump from 
Flux Instruments (Basel, Switzerland). MS detection of the analytes was performed 
with a Thermo Finnigan Surveyor MSQ supplied by Dionex (Germering, Germany). A 
scheme of the analytical setup is depicted in Fig. 45. 
Fig. 45. Two-dimensional experimental setup used to extract analytes from 
hemolysates. Hemoglobin is monitored after RAM with UV-Vis detection. Analytes 
are detected after the analytical column with mass spectrometry. 
e-
UV detector
gradient pump
auto sampler
loading pump
quadrupoleESI
analytical
column
6-port
valve
RAM
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3  Choice of the stationary phase 
The so-called Restricted Access Materials are stationary phases of choice to analyze 
small analytes in complex biological matrixes with on-line SPE-HPLC. 
Macromolecules are excluded and can only interact with the outer surface of the 
material, whereas small analytes of interest access the inner surface of the pores 
and are retained. Different exclusion mechanisms have been developed and 
numerous media are now available on the market. Classifications of RAM have 
already been proposed [63;65]. They are generally based on the type of mechanism 
involved to exclude the macromolecules. A schematic classification is depicted in Fig. 
46. 
Fig. 46. Classification of restricted access materials (RAM) [65]. 
 
The exclusion is achieved either by a physical or by a chemical exclusion barrier. 
Physical exclusion barriers consist of small pore diameters (60 – 120 Å), whereas 
chemical exclusions are achieved by anchoring a polymer-network at the surface of 
the material. In both cases, macromolecules do not have the possibility to penetrate 
into the pores. Uniform or dual surface topochemistries are employed. In order to 
check if some stationary phases are better designed to exclude hemoglobin from 
whole blood hemolysate, six commercially available columns were chosen and tested 
under the same conditions. The name and characteristics of the columns are 
summarized in Tab. 7. Each type of exclusion mechanism (chemical vs. physical 
exclusion barrier and uniform vs. dual surface topochemistry) was represented. 
exclusion
barrier
surface
topochemistry commercial productsinside outside
uniform
dual
uniform
dual
physical
chemical
chemical
ChromSpher 5 Biomatrix 
(Chrompack)
ISRP GFFII (Regis Technologies)
LiChrospher ADS (Merck KGaA)
Hisep (Supelco)
Capcell Pak MF (Shiseido)
Bioptic AV-2 (GL Sciences) 
BioTrap 500 MS (ChromTech) 
SPS (Regis Technologies)
physical
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Tab. 7. Characteristics of the different tested RAM columns. 
 
Hemoglobin samples were prepared by dissolving human hemoglobin to a 
concentration of 150 mg/mL in 0.05 % aqueous trifluoroacetic acid (TFA). 10 µL of 
the hemoglobin solution were injected and eluted for 15 min isocratically with 0.05 % 
TFA, followed by a gradient of 0 - 100 % acetonitrile/0.05 % TFA in 30 min. The 
column effluent was monitored at 396 nm (the maximum of absorption of 
hemoglobin). Finally the columns were washed and regenerated by 100 % 
acetonitrile/0.05 % TFA for 2 min and 0.05 % aqueous TFA for 13 min. Blank 
injections consisting of 10 µL 0.05 % aqueous TFA were performed after each 
hemoglobin injection in order to check the carry-over of hemoglobin. For each HPLC 
run, the peaks corresponding to hemoglobin flowing-through and hemoglobin 
retained on the column were integrated. Integration values are only approximated 
values because of the saturation of the detector over 1,000 mAU. Ratios between 
hemoglobin retained and hemoglobin flowing through were also computed. Carry-
overs were also determined for each column by performing two consecutive blank 
injections. 
 
ChromSpher 
Biomatrix 
Varian 
LiChrospher 
ADS Merck 
Capcell Pak
Shiseido 
Bioptic AV-2 
GL 
Sciences  
Biotrap 500 
MS 
Chromtech 
SPS C18 
Regis 
stationary 
phase 
porous silica porous silica
porous 
silica 
porous silica
hydrophobic 
polymer 
porous silica
particle size 
[µm] 
5 25 5 5 n.a. 5 
pore size [Å] 120 60 80 n.a. n.a. 100 
length [mm] 50 25 50 50 13 50 
diameter [mm] 4.6 4.0 4.6 4.6 4.0 2.1 
pH stability 2.0-8.0 2.0-7.5 2.0-7.5 2.0-7.5 2.0-11.0 2.5-7.5 
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3.1 Hemoglobin exclusion with physical barrier and 
uniform surface topochemistry: ChromSpher Biomatrix 
The first column to be evaluated was ChromSpher Biomatrix from Varian. The 
physical exclusion of macromolecules is achieved by pore sizes of 120 Å. In-pore 
surface and external surface chemistries are similar. They consist of a combination of 
diol- and hydrophobic groups. Because of the arrangements of the diol- and the 
hydrophobic groups, only small analytes can access to hydrophobic surfaces, 
whereas macromolecules can only interact with diol groups. A schematic 
representation of ChromSpher Biomatrix material is depicted in Fig. 47. 
 
Fig. 47. Schematic representation of the topochemistry of ChromSpher Biomatrix [65]. 
 
Chromatograms corresponding to an injection of hemoglobin and to the first 
consecutive blank injection are depicted in Fig. 48 and in Fig. 49. One observes that 
hemoglobin is not only flowing through the column, but is also retained on the 
stationary phase. This signifies that hemoglobin is not completely excluded. The 
elution of hemoglobin occurred in a broad peak at about 20 % acetonitrile in the 
eluent. Carry-over is observed in a consecutive blank injection at a similar acetonitrile 
proportion. 
diol groups
hydrophobic groups
analytes
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Fig. 48. Retention of hemoglobin on ChromSpher Biomatrix Varian. Sample, 150 
mg/mL hemoglobin diluted in 0.05 % aqueous TFA; 10 µL injection; mobile phase, 
(A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then 
linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.5 
mL/min; room temperature; detection at 396 nm. 
 
Fig. 49. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, ChromSpher Biomatrix Varian; sample, 10 µL 0.05 % aqueous TFA; mobile 
phase, (A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % 
A, then linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.5 
mL/min; room temperature; detection at 396 nm. 
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3.2 Hemoglobin exclusion with physical barrier and dual 
surface topochemistry: LiChrospher ADS 
The physical exclusion of macromolecules is achieved by pore sizes of 60 Å in the 
LiChrospher ADS material. The acronym ADS signifies alkyl-diol-silica and 
summarizes the two different groups present at the surface of the material. The inner 
surface of the pores is coated with C18 chains, whereas diol groups are present on 
the external surface of the particles (see Fig. 14 and Fig. 50). Contrary to small 
analytes, macromolecules can not penetrate into the pores and can not be retained 
by interactions with C18 chains. 
Chromatograms corresponding to an injection of hemoglobin and to the first 
consecutive blank injection are depicted in Fig. 51 and in Fig. 52. As also observed 
with the ChromSpher Biomatrix column, hemoglobin is not only flowing through the 
column but is also retained on the stationary phase. Hemoglobin elutes in a broad 
peak at about 40 % acetonitrile in the eluent. Carry-over of hemoglobin is observed in 
a consecutive blank injection at a similar acetonitrile proportion. 
Fig. 50. Schematic representation of the topochemistry of LiChrospher ADS [65]. 
 
 
 
diol groups
C18 groups
analytes
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Fig. 51. Retention of hemoglobin on LiChrospher ADS Merck; sample, 150 mg/mL 
hemoglobin diluted in 0.05 % aqueous TFA; 10 µL injection; mobile phase, (A) 0.05 
% TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then linear 
gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.0 mL/min; room 
temperature; detection at 396 nm. 
 
Fig. 52. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, LiChrospher ADS Merck; sample, 10 µL 0.05 % aqueous TFA; mobile 
phase, (A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % 
A, then linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.0 
mL/min; room temperature; detection at 396 nm. 
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3.3 Hemoglobin exclusion with chemical barrier and 
uniform surface topochemistry: Capcell Pak 
In Capcell Pak materials, the silica support is covered with a uniform thin film of 
silicone polymer (capsule-type packing material). Chemical exclusion of 
macromolecules is achieved by polyoxyethylene chains grafted at the surface of the 
silicone layer. These long chains shield hydrophobic groups, which are only 
accessible to small analytes. Macromolecules can not really interact with the 
hydrophobic groups and flow through the column. A schematic representation of 
Capcell Pak is depicted in Fig. 53. 
Fig. 53. Schematic representation of the topochemistry of Capcell Pak [65]. 
 
Chromatograms corresponding to an injection of hemoglobin and to the first 
consecutive blank injection are depicted in Fig. 54 and in Fig. 55. As also observed 
with the columns with physical exclusion barrier, hemoglobin is flowing through the 
column but is also retained on the stationary phase. However, the amount of 
hemoglobin retained on the column appears to be much higher in the case of the 
Capcell Pak column (A#2 ≈ 30 x A#1) as compared to the previously tested columns 
(A#2 ≈ 3-5 x A#1). Hemoglobin is eluted from the stationary phase in a broad peak at 
about 40 % acetonitrile in the eluent. Hemoglobin carry-over is also observed in a 
consecutive blank injection. 
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Fig. 54. Retention of hemoglobin on Capcell Pak Shiseido; sample, 150 mg/mL 
hemoglobin diluted in 0.05 % aqueous TFA; 10 µL injection; mobile phase, (A) 0.05 
% TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then linear 
gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.0 mL/min; room 
temperature; detection at 396 nm. 
 
Fig. 55. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, Capcell Pak Shiseido; sample, 10 µL 0.05 % aqueous TFA; mobile phase, 
(A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then 
linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.0 
mL/min; room temperature; detection at 396 nm. 
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hydrophobic groups
analytes
polyoxoethylene, avidin,
or glycoprotein
3.4 Hemoglobin exclusion with chemical barrier and dual 
surface topochemistry: Bioptic AV-2, SPS, and Biotrap 
500 MS 
The three last materials evaluated in terms of human hemoglobin exclusion and 
carry-over are excluding macromolecules by combining a chemical barrier and 
different chemistries inside and outside the pores. For Bioptic AV-2, denaturated 
avidin molecules are grafted at the outer surface of the stationary phase. For SPS, 
polyoxoethylene chains are utilized (as for the Capcell Pak column). In case of 
Biotrap 500 MS, α1-acid glycoprotein molecules are bound at the outer surface of the 
particles. For all three materials, hydrophobic groups such as C18 chains (SPS) are 
present at the inner surface of the pores. A generic representation of the three 
columns is depicted in Fig. 56. 
 
 
 
 
 
 
 
 
Fig. 56. Schematic representation of Bioptic AV-2, SPS, and Biotrap 500 MS [65]. 
 
In all three cases, hemoglobin was observed in the flow-through but hemoglobin was 
also retained on the column. Elution of hemoglobin occurred at 20 %, 45 % and 30 % 
acetonitrile in the eluents for Bioptic AV-2, SPS, and Biotrap 500 MS materials, 
respectively. With all three columns, carry-over of hemoglobin was observed in 
consecutive blank injections. Chromatograms of hemoglobin and blank injection are 
depicted in Fig. 57 and in Fig. 58 for Bioptic AV-2, in Fig. 59 and in Fig. 60 for SPS, 
and in Fig. 61 and in Fig. 62 for Biotrap 500 MS, respectively. 
No significant difference was observed between the three materials with chemical 
exclusion and dual topochemistry. However, stronger retention of hemoglobin was 
observed with the SPS C18 material. The elution peak was also very broad (more 
than 10 min). The carry-over appeared more pronounced with the SPS C18 column. 
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Fig. 57. Retention of hemoglobin on Bioptic AV-2 GL Sciences Inc.; sample, 150 
mg/mL hemoglobin diluted in 0.05 % aqueous TFA; 10 µL injection; mobile phase, 
(A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then 
linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.0 
mL/min; room temperature; detection at 396 nm. 
 
Fig. 58. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, Bioptic AV-2 GL Sciences Inc.; sample, 10 µL 0.05 % aqueous TFA; mobile 
phase, (A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % 
A, then linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.0 
mL/min; room temperature; detection at 396 nm. 
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Fig. 59. Retention of hemoglobin on SPS C18 Regis; sample, 150 mg/mL 
hemoglobin diluted in 0.05 % aqueous TFA; 10 µL injection; mobile phase, (A) 0.05 
% TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then linear 
gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 0.5 mL/min; room 
temperature; detection at 396 nm. 
 
 
Fig. 60. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, SPS C18 Regis.; sample, 10 µL 0.05 % aqueous TFA; mobile phase, (A) 
0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then 
linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 0.5 
mL/min; room temperature; detection at 396 nm. 
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Fig. 61. Retention of of hemoglobin on Biotrap 500 MS Chromtech; sample, 150 
mg/mL hemoglobin diluted in 0.05 % aqueous TFA; 10 µL injection; mobile phase, 
(A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then 
linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.5 
mL/min; room temperature; detection at 396 nm. 
 
 
Fig. 62. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, Biotrap 500 MS.; sample, 10 µL 0.05 % aqueous TFA; mobile phase, (A) 
0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 15.0 min isocratic at 100 % A, then 
linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.5 
mL/min; room temperature; detection at 396 nm. 
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3.5 Conclusions and next steps 
Whatever the principle of macromolecule exclusion, the elution profiles for all six 
columns looked quite similar. Part of the hemoglobin eluted in the flow-through, while 
the rest reproducibly eluted as a relatively broad peak at 20-40 % acetonitrile 
concentrations. In all cases, most of the hemoglobin was retained on the column 
(peak # 2) as compared to elution in the flow-through (peak # 1). The following 
injections of pure water/0.05 % TFA showed relatively small peaks for hemoglobin in 
the flow-through, but significant peaks of retained hemoglobin. Carry-overs are in the 
same order of magnitude for the six columns. However, the exclusion of hemoglobin 
appears to be most efficient with ChromSpher Biomatrix and with LiChrospher ADS 
material (area peak # 2 / area peak # 1), and very ineffective for Capcell Pak. The 
comparison of the six columns in terms of hemoglobin carry-over and hemoglobin 
retention is summarized in Tab. 8. 
 
Tab. 8. Hemoglobin carry-over [%] at pH 2.1 in peak # 2 for six different RAM 
columns. Injections # 0 correspond to injections of 10 µL of 150 mg/mL hemoglobin 
and are considered as a reference for each column. Injections # 1 and # 2 are blank 
injections directly following injections # 0. 
 peak area of retained hemoglobin [%] 
 
ChromSpher 
Biomatrix 
Varian 
LiChrospher
ADS Merck 
Capcell 
Pak 
Shiseido 
Bioptic AV-2 
GL 
Sciences  
SPS C18 
Regis 
Biotrap 500 
MS 
Chromtech 
injection # 0 100 100 100 100 100 100 
injection # 1 0.52 0.20 0.35 0.10 0.20 0.11 
injection # 2 0.32 0.05 0.03 0.03 0.12 0.05 
area peak # 2 
/area peak # 1 
injection # 0 
3 5 30 6 7 8 
 
The areas of the peaks corresponding to retained hemoglobin (peak # 2) were also 
plotted in a histogram. As observed in Fig. 63, the higher retention was observed with 
SPS C18. It is not possible to directly compare the results of Capcell Pak and 
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ChromSpher Biomatrix with the results of the other restricted access materials 
because freshly prepared hemoglobin solutions were employed. 
 
Fig. 63. Hemoglobin retention on six different restricted access media. A different 
150 mg/mL hemoglobin solution was used to test Capcell Pak and ChromSpher 
Biomatrix. 
 
To explain the retention of hemoglobin on the stationary phase, two phenomena are 
taken into consideration. The first reason is that the pores are too large, permitting 
hemoglobin to enter and adsorb on the C18 groups or even interact with silanol 
groups. The second reason is that some unspecific interaction such as silanol/ion-
exchange interaction may take place on the outer surface of the material. 
An approach to diminish the amount of macromolecules binding on the inner surface 
of the pores is to sterically hinder the entrance into the pores. The most adapted 
material to our challenge seemed to be LiChrospher ADS from Merck. The reason is 
that this restricted access medium has the smallest pores of all materials available on 
the market with pore dimensions of 60 ± 10 Å (6 ± 1 nm). Moreover, diol groups on 
the outer surface are suitable for further functionalization. A modification of the 
LiChrospher ADS material and the influence on the retention of hemoglobin is 
investigated in the next section. 
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4 Modification of LiChrospher ADS with amino-
dextran 
Retention of hemoglobin may take place in the pores of the LiChrospher ADS 
material, where C18 chains are grafted to the silica based stationary phase. It 
signifies that the entrance of the pores (6 – 8 nm) may be too huge and permit at 
least partial penetration of hemoglobin molecules (MW 16,000 – 18,000 Da). The 
grafting of large and voluminous compounds (e. g. aminodextran) on the outer 
surface of the stationary phase should reduce the entrance space of the pores and 
diminish the amount of macromolecules accessing the hydrophobic chains inside the 
pores. A reaction scheme depicting the derivatization of LiChrospher ADS particles 
with aminodextran is represented in Fig. 64. 
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Fig. 64. Derivatization of LiChrospher ADS with aminodextran. 
 
An in-house 30 x 2.0 mm column was packed with unmodified LiChrospher ADS 
material and mounted in the one-dimensional HPLC system (see 2.4.1). 10 µL of five 
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0.5 mg/mL protein solutions were successively injected. The proteins (insulin, 
ubiquitin, β-lactoglobulin A+B, ovalbumin, hemoglobin) were covering a large range 
of masses: from 5,800 to 45,000 Da. The proteins were eluted for 5 min isocratically 
with 0.05 % aqueous TFA, followed by a gradient of 0-100 % acetonitrile/0.05 % TFA 
in 10 min. An in-house 30 x 2.0 mm column packed with modified LiChrospher ADS 
material with aminodextran was also subjected to the same chromatographic runs. 
For each chromatographic run, peak areas corresponding to proteins retained on the 
column were computed. Values are only approximated because of difficulties of 
integration due to very large fronting and tailing. The different results are summarized 
in Tab. 9. 
 
Tab. 9. Retention of proteins on a 30 x 2.0 mm in-house packed LiChrospher ADS 
column and on an in-house modified LiChrospher ADS material packed in a 30 x 2.0 
mm column a. 
protein MW (Da) 
protein amount 
[mAU.min] retained 
on LiChrospher ADS 
protein amount 
[mAU.min] retained on 
modified LiChrospher 
ADS 
insulin ~ 5,800 10.2 1.2 
ubiquitin ~ 8,600 4.7 not detected 
β-lactoglobulin A+B ~ 18,400 1.7 not detected 
ovalbumin ~ 43,000 not detected not detected 
hemoglobin ~ 64,500   subunits: 16,000 14.1 16.3 
a Samples, 0.5 mg/mL protein diluted in 0.05 % aqueous TFA; 10 µL injection; mobile 
phase, (A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 5.0 min isocratic at 100 % A, 
then linear gradient, 0-100 % B in 10.0 min, and 2.0 min at 100 % B; flow rate, 1.5 
mL/min; room temperature; detection at 214 nm, 396 nm for hemoglobin. 
 
For small proteins, which can penetrate at least part into a fraction of the pores to be 
retained on the C18 surface, RAM material modification shows a significant reduction 
of protein retention. Insulin adsorption is thus 10 fold smaller on the modified as 
compared to the unmodified material. Ubiquitin and lactoglobulins are no longer 
retained. 
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Ovalbumin, not retained on the unmodified material, is also not detected on the 
modified phase. However, hemoglobin adsorption is equivalent on both materials. 
Thus, it appears that the modification of Lichrospher ADS material with aminodextran 
is effective to suppress pore penetration of small proteins, but the modification does 
not seem to influence the retention of large proteins. It suggests, that adsorption of 
small proteins (e.g. insulin) occurs in the pores and is reduced by steric obstruction, 
whereas retention of large proteins is due to nonspecific adsorption at the outer 
surface of the restricted access material. 
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5 Modification of LiChrospher ADS with poly-D-
lysine and polyethyleneimine 
Nonspecific interactions between macromolecules and the outer surface of the 
restricted access material seem to explain the retention of large proteins. In order to 
check this hypothesis, LiChrospher ADS was derivatized with chemical structures 
(amines) presenting positively charged groups under acidic conditions (e.g. pH 2.1). 
Because hemoglobin also carries positive charges at low pH (pI 6.8), electrostatic 
interactions should permit to reject hemoglobin from the stationary phase and avoid 
non-specific retention. 
LiChrospher ADS bulk material was derivatized with polyethyleneimine 25 (MW 
25,000 Da), polyethyleneimine 60 (MW 60,000 Da), and poly-D-lysine. Then, columns 
were packed and successively mounted in the one-dimensional HPLC setup (see 
2.4.1). 10 µL of the 0.5 mg/mL protein solutions previously mentioned were 
successively injected over each column. The proteins were eluted for 5 min 
isocratically with 0.05 % TFA, followed by a gradient of 0-100 % acetonitrile/0.05 % 
TFA in 5 min. Unmodified LiChrospher ADS material was also tested to get reference 
values. 
Tab. 10. Retention of proteins on a 30 x 2.0 mm in-house packed LiChrospher ADS 
column and on in-house modified LiChrospher ADS materials packed in 30 x 2.0 mm 
columns a. 
a Samples, 0.5 mg/mL protein diluted in 0.05 % aqueous TFA; 10 µL injection; mobile 
phase, (A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 5.0 min isocratic at 100 % A, 
then linear gradient, 0-100 % B in 5.0 min, and 2.0 min at 100 % B; flow rate, 1.5 
mL/min; room temperature; detection at 214 nm, 396 nm for hemoglobin. 
 
  peak area of retained protein peak [mAU
.min] 
 MW (Da) pI unmodified
amino 
dextran 
poly-
ethylene-
imine 25 
poly-
ethylene-
imine 60 
polylysine 
30-70 
insulin ~ 5,800 5.5 2.3 2.3 38.1 14.2 12.6 
ubiquitin ~ 8,600 6.6 0.1 0.1 6.8 1.6 4.4 
hemoglobin ~ 16,000 6.8 2.5 1.4 2.3 1.5 4.8 
ovalbumin ~ 45,000 5.2 0.6 0.8 2.5 1.0 17.5 
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For each chromatographic run, peak areas corresponding to proteins retained on the 
column were computed. The different results are summarized in Tab. 10. No 
significant differences were observed between the unmodified LiChrospher ADS 
material and the material derivatized with aminodextran. For insulin and ubiquitin 
these results are in contradiction with the values presented in the previous section 
(see section 4). However, in the present case, a very steep gradient was utilized for 
elution (0 – 100 % acetonitrile in 5 min) and the integration of the peaks was much 
easier because of much more discernable peaks. To sum up, modification of 
LiChrospher ADS material with aminodextran has no real impact on the amount of 
retained proteins. 
Fig. 65. Influence of the derivatization of LiChrospher ADS material on the retention 
of insulin. Columns, 30 x 2.0 mm in-house packed columns with underivatized 
LiChrospher material, material derivatized with aminodextran, polyethyleneimine 25, 
and polyethyleneimine 60. Sample, 0.5 mg/mL insulin diluted in 0.05 % aqueous 
TFA; 10 µL injection; mobile phase, (A) 0.05 % TFA in H2O, (B) 0.05 % TFA in ACN; 
5.0 min isocratic at 100 % A, then linear gradient, 0-100 % B in 5.0 min, and 2.0 min 
at 100 % B; flow rate, 1.5 mL/min; room temperature; detection at 214 nm. 
 
Derivatization of LiChrospher ADS with polyethyleneimine 25 and 60 results in 
increased adsorptions of small proteins (e.g. insulin and ubiquitin). No significant 
influence is observed for larger proteins. No correlation was observed between pI of 
proteins and increases in adsorption. Higher amounts of adsorbed proteins were 
observed with modifications performed with polyethyleneimine 25 than with 
polyethyleneimine 60. Derivatization of LiChrospher ADS with poly-D-lysine results in 
increased adsorption for all four proteins. However, no correlation was observed 
between size of proteins and increase in adsorption. Chromatograms obtained for 
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insulin with unmodified LiChrospher ADS material, and material derivatized with 
aminodextran, and polyethyleneimines are depicted in Fig. 65. The chemical 
composition of modified and unmodified LiChrospher ADS materials was checked 
with elemental analyses (Model Vario EL, Elementar Analysensysteme GmbH, 
Hanau, Germany). The results are summarized in Tab. 11. Significant differences are 
observed for materials derivatized with polyethyleneimines. An increase of the N 
concentration of about 0.3 % is observed, proving the successful derivatization of the 
LiChrospher ADS material with polyethyleneimine 25 and polyethyleneimine 60. 
 
Tab. 11. Elemental analyses of LiChrospher ADS materials. 
 
As a conclusion, modifications of LiChrospher ADS with positively charged polymers 
do not diminish but increase the adsorption of positively charged proteins 
(chromatographic runs performed at pH 2.1). Thus, electrostatic interactions do not 
seem to play a major role in the exclusion/retention of proteins on the LiChrospher 
ADS material. Hydrophobic interactions between proteins and hydrophobic regions of 
the polymers grafted on the stationary phase may explain these results. 
Derivatization of LiChrospher ADS either with aminodextran (neutral at pH 2.1), or 
with polyethyleneimines and poly-D-lysine (positively charged at pH 2.1) did not 
permit to significantly reduce the adsorption of hemoglobin on the stationary phase. 
N [%] C [%] H [%]
unmodified material 0.02 20.65 3.16
activated material 0.02 22.46 4.75
material modified with aminodextran 0.04 22.50 3.67
material modified with polyethyleneimine 25 0.32 21.72 3.67
material modified with polyethyleneimine 60 0.29 21.72 3.68
material modified with polylysine 0.06 21.55 3.60
aminodextran 0.23 40.23 7.45
polyethyleneimine 25 14.89 24.10 8.10
polyethyleneimine 60 16.10 27.88 8.94
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6  Evaluation of LiChrospher ADS at different pH 
To better understand the adsorption of hemoglobin on LiChrospher ADS particles, 
solutions of hemoglobin were injected at various pH. For each pH value, amounts of 
hemoglobin flowing through (peak # 1) and retained on the column (peak # 2) were 
computed. Carry-over was also evaluated by performing blank injections consecutive 
to injections of hemoglobin. 
Ten µL of a 150 mg/mL hemoglobin solution were injected over an unmodified 
LiChrospher ADS column mounted in the one-dimensional HPLC setup. Elution was 
performed with a linear gradient (0-100 % B in 30 min) and followed by a wash step 
(2 min at 100 % B). The separation was performed at pH 6.6 (H2O/ACN + 5 mmol/L 
ammonium acetate), pH 8.3 (H2O/ACN + 5 mmol/L imidazole), and pH 10.7 
(H2O/ACN + 10 mmol/L ethanolamine). Detection was performed at 396 nm. 
At pH 6.6, hemoglobin is present in the flow-through (100 %), elutes at around 15 % 
B (24 %), and is also present in the wash peak (4 %). However, this separation is not 
always reproducible and the quantitation of the retained hemoglobin is rather difficult 
because of the large width and the flatness of the peaks. Accurate quantitation of 
hemoglobin in the flow-through is also difficult because of the high-intensity of the 
signal. Hemoglobin in the wash peak presents a carry-over and was previously not 
observed at pH 2.1 with TFA (see Fig. 51). A chromatogram of hemoglobin 
separated at pH 6.6 is depicted in Fig. 66. 
At pH 8.3, hemoglobin is present in the flow-through (100 %) and also elutes at 
around 30 % B (35 %) in a broad peak but is not present in the wash step. A 
chromatogram is depicted in Fig. 67. Carry-over in the flow-through and at 35 % B is 
observed in a blank injection following the injection of hemoglobin at pH 8.3 (see Fig. 
68) but no longer in a second blank injection. 
Finally, LiChrospher ADS was tested at pH 10.7, although pH 10.7 is far above the 
stability of silica-based stationary phases. Hemoglobin was present in the flow-
through (100 %) and also at 20 % B (20 %). Practically no memory effect was 
observed in a following blank injection. The corresponding chromatograms are 
depicted in Fig. 69 and in Fig. 70. 
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Fig. 66. Chromatogram of hemoglobin at pH 6.6. Column, LiChrospher ADS Merck; 
sample, 150 mg/mL hemoglobin diluted in 5 mmol/L ammonium acetate; 10 µL 
injection; mobile phase, (A) 5 mmol/L ammonium acetate in H2O, (B) 5 mmol/L 
ammonium acetate in ACN; 15.0 min isocratic at 100 % A, then linear gradient, 0-100 
% B in 30.0 min, and 2.0 min at 100 % B; flow rate, 1.5 mL/min; room temperature; 
detection at 396 nm. 
 
Fig. 67. Chromatogram of hemoglobin at pH 8.3. Column, LiChrospher ADS Merck; 
sample, 150 mg/mL hemoglobin diluted in 5 mmol/L imidazole; 10 µL injection; 
mobile phase, (A) 5 mmol/L imidazole in H2O, (B) 5 mmol/L imidazole in ACN; 15.0 
min isocratic at 100 % A, then linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 
100 % B; flow rate, 1.5 mL/min; room temperature; detection at 396 nm. 
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Fig. 68. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, LiChrospher ADS Merck; sample, 5 mmol/L imidazole; 10 µL injection; 
mobile phase, (A) 5 mmol/L imidazole in H2O, (B) 5 mmol/L imidazole in ACN; 15.0 
min isocratic at 100 % A, then linear gradient, 0-100 % B in 30.0 min, and 2.0 min at 
100 % B; flow rate, 1.5 mL/min; room temperature; detection at 396 nm. 
 
Fig. 69. Chromatogram of hemoglobin at pH 10.7. Column, LiChrospher ADS Merck; 
sample, 150 mg/mL hemoglobin diluted in 10 mmol/L ethanolamine; 10 µL injection; 
mobile phase, (A) 10 mmol/L ethanolamine in H2O, (B) 10 mmol/L ethanolamine in 
ACN; 15.0 min isocratic at 100 % A, then linear gradient, 0-100 % B in 30.0 min, and 
2.0 min at 100 % B; flow rate, 1.5 mL/min; room temperature; detection at 396 nm. 
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Fig. 70. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, LiChrospher ADS Merck; sample, 10 mmol/L ethanolamine; 10 µL injection; 
mobile phase, (A) 10 mmol/L ethanolamine in H2O, (B) 10 mmol/L ethanolamine in 
ACN; 15.0 min isocratic at 100 % A, then linear gradient, 0-100 % B in 30.0 min, and 
2.0 min at 100 % B; flow rate, 1.5 mL/min; room temperature; detection at 396 nm. 
 
Despite difficulties of quantitation because of very large and flat peaks, the tests 
performed at four different pH show that the higher the pH, the lower the retention 
and the carry-over of hemoglobin. The results are summarized in Tab. 12. 
 
Tab. 12. Hemoglobin exclusion and carry-over on a LiChrospher ADS column used 
at different pH. 
pH ratio A#2 / A#1 
hemoglobin in 
flow-through 
hemoglobin 
retained on the 
column 
hemoglobin in 
wash peak 
carry-over 
2.1 5.0 X X - X 
6.6 0.2 X X X X 
8.3 0.3 X X - 
disappear after 1 
injection 
10.7 0.2 X X - not detected 
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Practically no carry-over was observed at pH 10.7. This pH value appears to be 
optimal to avoid adsorption of hemoglobin and memory effects. However, silica-
based columns are not stable at this pH and routine analyses can not be envisaged 
at such a high pH. For this reason, LiChrospher ADS can not be routinely operated 
under such basic conditions. However, among the set of the six restricted access 
media previously tested, one of them (Biotrap 500 MS from Chromtech) is a polymer-
based material (certified stable up to pH 11) and will be tested at high pH in further 
experiments. 
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7  Evaluation of Biotrap 500 MS at pH 10.7 
7.1 Retention of hemoglobin on Biotrap 500 MS at pH 10.7 
Hemoglobin retention and carry-over were evaluated with Biotrap 500 MS at pH 10.7 
(H2O/ACN + 10 mmol/L ethanolamine). The same analytical setup as before was 
used (see 2.4.1). The gradient was 0-100 % acetonitrile in 15 min followed by a wash 
step consisting of 2 min at 100 % acetonitrile. 
By injection of 10 µL of a 150 mg/mL hemoglobin solution, most of the hemoglobin is 
flowing through the column (~ 80 %). The retained molecules (~ 20 %) are eluted 
with about 20 % acetonitrile. The corresponding chromatogram is depicted in Fig. 71. 
In a blank injection following the injection of hemoglobin practically no carry-over is 
observed as depicted in Fig. 72. 
High pH values seem to be really a key point for the break-through of hemoglobin in 
the flow-through volume of RAM columns as observed with LiChrospher ADS from 
Merck or with Biotrap 500 MS from Chromtech. 
 
Fig. 71. Retention of hemoglobin on Biotrap 500 MS Chromtech; sample, 150 mg/mL 
hemoglobin diluted in 10 mmol/L ethanolamine; 10 µL injection; mobile phase, (A) 10 
mmol/L ethanolamine in H2O, (B) 10 mmol/L ethanolamine in ACN; 15.0 min isocratic 
at 100 % A, then linear gradient, 0-100 % B in 15.0 min, and 2.0 min at 100 % B; flow 
rate, 1.5 mL/min; room temperature; detection at 396 nm. 
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Fig. 72. Hemoglobin carry-over: first blank injection after hemoglobin sample. 
Column, Biotrap 500 MS Chromtech; sample, 10 mmol/L ethanolamine; 10 µL 
injection; mobile phase, (A) 10 mmol/L ethanolamine in H2O, (B) 10 mmol/L 
ethanolamine in ACN; 15.0 min isocratic at 100 % A, then linear gradient, 0-100 % B 
in 15.0 min, and 2.0 min at 100 % B; flow rate, 1.5 mL/min; room temperature; 
detection at 396 nm. 
 
7.2 Extraction of analytes with Biotrap 500 MS at pH 10.7 
Two analytes (one neutral and one charged) were chosen as model compounds to 
characterize the extraction capability of Biotrap 500 MS at pH 10.7 (10 mmol/L 
ethanolamine). The first analyte was tetracycline hydrochloride. This antibiotic, the 
structure of which is depicted in Fig. 73, is water soluble and neutral at high pH. Its 
molecular formula is C22H24N2O8.HCl and its molecular weight is 480.90 g/mol. Mass 
spectrometric detection can be performed by monitoring m/z 445. The quantitation of 
tetracycline in biological fluids is generally achieved by HPLC-MS/MS, after protein 
precipitation [128]. Tetracycline and derivates are widely used in swine production [129]. 
Concentrations are generally in the ng/µL range [130-132].  
Fig. 73. Structure of tetracycline hydrochloride. 
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The second analyte was 5-methyltetrahydrofolic acid. Its structure is depicted in Fig. 
74. Its molecular formula is C20H23N7Na2O6.HCl and its molecular weight is 503.42 
g/mol. Mass spectrometric detection can be performed by monitoring m/z 460. At 
high pH (and particularly during the extraction step with 10 mmol/L ethanolamine), 
the molecule is present as a doubly negatively charged compound. 5-
methyltetrahydrofolic acid is very sensitive to oxidation but can be stabilized by 
spiking ascorbic acid [133]. The concentration of 5-methyltetrahydrofolate is ranging 
from 2 to 20 ng/mL in serum and from 100 to 200 ng/mL in erythrocytes. Quantitation 
is generally performed by solid phase extraction followed by LC-MS/MS or 
microbiologic assay [134;135]. 
 
Fig. 74. Structure of 5-methyltetrahydrofolic acid disodium salt. 
 
A synthetic whole blood solution was prepared by spiking human hemoglobin at 175 
mg/mL in human serum. Before use and to avoid HPLC system plugging, the solution 
was filtrated over a Vivaclear mini 0.5 clarifying filter membrane.  
Sixty ng tetracycline were spiked in 300 µL of the synthetic blood solution. Thus the 
concentration of tetracycline was 200 pg/µL. The sample was diluted to 900 µL with 
addition of 600 µL of 10 mmol/L ethanolamine. The sample was injected over Biotrap 
500 MS and washed for 5 min with 10 mmol/L ethanolamine at 3.2 mL/min. Then the 
switching valve was turned and elution occurred at 300 µL/min over the C18 column. 
Eluent A was 0.05 % aqueous TFA and eluent B was 0.05 % TFA in ACN. The linear 
gradients were 0 to 50 % B in 7.5 min, followed by 50 to 100 % B in 2.5 min and 
isocratic conditions at 100 % B for 2 min. Meanwhile the connections of the injection 
system were washed by performing a linear gradient of acetonitrile (0 to 100 % in 4 
min). Detection was performed in Single Ion Monitoring mode on m/z 445.2 ± 1.0. 
The corresponding chromatogram is depicted in Fig. 75. 
This experiment shows that it is possible to extract neutral analytes such as 4-
tetracycline from “synthetic blood hemolysates” with Biotrap 500 MS under high pH 
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conditions, compatible with low hemoglobin carry-over. Tetracycline at 
concentrations down to 200 pg/µL in “synthetic blood hemolysate” was detected in 
these preliminary experiments with a linear quadrupole mass analyzer. This value 
can be undoubtedly reduced by performing MRM detections on triple quadrupole 
analyzers. 
Fig. 75. Extraction of 200 pg/µL tetracycline hydrochloride from “synthetic blood 
hemolysate” sample (175 mg/mL hemoglobin spiked in serum). 
5-min extraction: column, Biotrap 500 MS, Chromtech, 13 x 4 mm i.d.; mobile phase, 
(A) 10 mmol/L ethanolamine; flow rate, 3.2 mL/min; room temperature; sample, 300 
µL of 200 pg/µL tetracycline hydrochloride spiked in “synthetic blood hemolysate” and 
diluted 1/3 with 10 mmol/L ethanolamine prior to injection. 
Back flush elution: column, Prontosil 300-5-C18-H 5 µm, Bischoff, 125 x 2.0 mm i.d.; 
mobile phase, (A) 0.05 % aqueous TFA, (B) 0.05 % TFA in ACN; linear gradient, 0-
50 % B in 7.5 min; 50-100 % B in 2.5 min, isocratic conditions at 100 % B for 2 min, 
flow rate, 0.3 mL/min; room temperature. Detection with Surveyor MSQ in selected 
ion monitoring mode targeted on m/z 445.2 ± 1.0. 
 
We intended to perform the same experiment with 5-methyltetrahydrofolate as an 
analyte. However, the analyte did not show any retention on the Biotrap 500 MS 
column because of the predominance of negative species at pH 10.7 (see Fig. 76). 
To circumvent the unability of Biotrap 500 MS to retain charged compounds (mostly 
negatively charged because of high pH values), the use of ion pair reagents such as 
butyldimethylammonium bicarbonate could be considered. 
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Fig. 76. Injection at pH 10.7 of 5-methyltetrahydrofolate over Biotrap 500 MS. 
Column, Biotrap 500 MS, Chromtech, 13 x 4 mm i.d.; mobile phases, (A) 10 mmol/L 
ethanolamine, (B) 10 mmol/L ethanolamine in ACN; gradient: isocratic conditions at 
100 % A for 5 min, then 0-100 % B in 10 min, followed by isocratic conditions at 100 
% B for 2 min; flow rate, 1.5 mL/min; room temperature; sample, 10 µg 5-
methyltetrahydrofolate and 10 µg ascorbic acid. 
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8 Quantitation of tetracycline hydrochloride in 
human whole blood hemolysates 
The extraction of tetracycline hydrochloride from “synthetic blood hemolysates” 
(serum spiked with hemoglobin) has already been achieved with Biotrap 500 MS at 
pH 10.7. However, the applicability of the developed method to real samples was not 
proven. This has been investigated on real hemolysates as follows. 
Whole blood hemolysate samples were injected over Biotrap 500 MS mounted in the 
two-dimensional HPLC-MS setup. After flowing through of hemoglobin, the analyte of 
interest was transferred to mass spectrometric detection by switching the 6-port 
valve. 
 
8.1 Limit of detection 
Thirty ng tetracycline hydrochloride were spiked in 3 mL whole blood hemolysate 
(150 µL blood + 1,350 µL 150 mmol/L NaCl + 1,500 µL 4 % lysis reagent). The 
resulting concentration of tetracycline hydrochloride corresponds to 200 pg/µL in 
whole blood. Then, 2.5 mL of the sample were injected over Biotrap 500 MS and 
washed with 10 mmol/L ethanolamine at 3.2 mL/min. After 18 min the 6-port valve 
was switched and elution occurred over the analytical column at 300 µL/min. (A: H2O 
+ 0.05 % TFA, B: ACN + 0.05 %, linear gradient 10-30 % B in 7.5 min followed by 30-
100 % B in 2.5 min and isocratic conditions for 2 min). Mass spectrometric detection 
was performed by monitoring m/z 445.2 ± 1.0. Single ion monitoring chromatograms 
corresponding to a blank run and to an injection of 200 pg/µL tetracycline 
hydrochloride are depicted in Fig. 77 and in Fig. 78. As observed, tetracycline was 
still well detected at 200 pg/µL in whole blood hemolysate. However, the neighboring 
elution of a compound with the same m/z does not permit to detect much less 
concentrated samples. 
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Fig. 77. Blank injection of whole blood hemolysate. 
18-min extraction: column, Biotrap 500 MS, 13 x 4 mm i.d.; mobile phase, (A) 10 
mmol/L ethanolamine; flow rate, 3.2 mL/min; room temperature; sample, 2.5 mL of a 
blood hemolysate obtained by mixing 150 µL whole blood, 1,350 µL 150 mmol/L 
NaCl and 1,500 µL 4 % lysis reagent. 
Back flush elution: column, Prontosil 300-5-C18-H 5 µm, 125 x 2.0 mm i.d.; mobile 
phase, (A) 0.05 % aqueous TFA, (B) 0.05 % TFA in ACN; linear gradient, 10-30 % B 
in 7.5 min; 30-100 % B in 2.5 min, isocratic conditions at 100 % B for 2 min, flow rate, 
0.3 mL/min; room temperature. Detection in SIM mode targeted on m/z 445.2 ± 1.0. 
 
 
Fig. 78. Extraction of tetracycline from whole blood hemolysate. 
Conditions as in Fig. 77; sample, 2.5 mL of a blood hemolysate obtained by mixing 
150 µL whole blood, 1,350 µL 150 mmol/L NaCl and 1,500 µL 4 % lysis reagent and 
spiked with 30 ng tetracycline. Tetracycline concentration in blood was 200 pg/µL. 
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8.2 Carry-over 
To check the carry-over of hemoglobin on biotrap 500 MS, 2.5 mL of a whole blood 
hemolysate were injected into the HPLC-MS system. The loading step on Biotrap 
500 MS was performed with 10 mmol/L ethanolamine at 3.2 mL/min for 18 min. The 
6-port valve was then switched and back flush elution was performed with a gradient 
of ACN + 0.05 % TFA (10-30 % B in 7.5 min, 30-100 % B in 2.5 min, 100 % B for 2.0 
min, and 0 % B for 7.9 min). During the back flush elution, the sample loop was 
washed by performing a gradient of ACN + 10 mmol/L ethanolamine (0 % B for 2 
min, 0-100 % B in 4 min, 100 % B for 6 min, and 0 % B for 7.9 min). 
The carry-over of hemoglobin on Biotrap 500 MS was checked by performing a blank 
chromatographic run (see Fig. 80) after such an injection of hemolysate (see Fig. 79). 
Detection was performed at 396 nm. 
No carry-over was observed. This result is similar to a blank chromatographic run 
performed after an injection of “synthetic blood hemolysate” (hemoglobin spiked in 
human serum) as described in section 7. The lysis of erythrocytes with the lysis 
reagent do not seem to influence the carry-over of hemoglobin on Biotrap 500 MS at 
pH 10.7. 
Fig. 79. Flowing-through of hemoglobin on Biotrap 500 MS. 
18-min extraction: column, Biotrap 500 MS, Chromtech, 13 x 4 mm i.d.; mobile 
phase, (A) 10 mmol/L ethanolamine; flow rate, 3.2 mL/min; room temperature; 
sample, 2.5 mL of a blood hemolysate obtained by mixing 150 µL whole blood, 1,350 
µL 150 mmol/L NaCl and 1,500 µL 4 % lysis reagent; detection at 396 nm. 
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Fig. 80. Blank chromatographic run on Biotrap 500 MS after an injection of 
hemolysate. 
18-min extraction: column, Biotrap 500 MS, Chromtech, 13 x 4 mm i.d.; mobile 
phase, (A) 10 mmol/L ethanolamine; flow rate, 3.2 mL/min; room temperature; 
previous sample, 2.5 mL of a blood hemolysate obtained by mixing 150 µL whole 
blood, 1,350 µL 150 mmol/L NaCl and 1,500 µL 4 % lysis reagent; detection at 396 
nm. 
 
 
8.3 Calibration curve 
Five samples consisting of tetracycline hydrochloride spiked in blood hemolysates 
were prepared. The concentrations of tetracycline hydrochloride in whole blood were 
200 pg/µL, 600 pg/µL, 1,000 pg/µL, 1,500 pg/µL, and 2,000 pg/µL. The 
corresponding concentrations in the hemolysate solutions to be injected were: 9.5 
pg/µL, 28.5 pg/µL, 47.5 pg/µL, 70.9 pg/µL, and 94.3 pg/µL. For each sample, 2.5 mL 
were injected and analyzed after an 8-min extraction. Peak areas corresponding to 
tetracycline were integrated. Values are only approximated because of difficulties of 
integration due to co-elution of tetracycline with another compound, and peak 
broadening at high concentrations. Example chromatograms are depicted in Fig. 81. 
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Fig. 81. Extraction of tetracycline from human whole blood hemolysates. 
8-min extraction: column, Biotrap 500 MS, Chromtech, 13 x 4 mm i.d.; mobile phase, 
(A) 10 mmol/L ethanolamine; flow rate, 3.2 mL/min; room temperature; samples, 2.5 
mL of blood hemolysates containing tetracycline at (a) 9.5 pg/µL, (b) 28.5 pg/µL, (c) 
47.5 pg/µL, and (d) 70.9 pg/µL. 
Back flush elution: column, Prontosil 300-5-C18-H 5 µm, Bischoff, 125 x 2.0 mm i.d.; 
mobile phase, (A) 0.05 % aqueous TFA, (B) 0.05 % TFA in ACN; linear gradient, 10-
30 % B in 7.5 min; 30-100 % B in 2.5 min, isocratic conditions at 100 % B for 2 min, 
flow rate, 0.3 mL/min; room temperature. Detection with Surveyor MSQ in selected 
ion monitoring mode targeted on m/z 445.2 ± 1.0. 
 
A calibration curve was computed and is plotted in Fig. 82. A linear correlation is 
observed (R2 = 0.945), proving the ability of Biotrap 500 MS to quantitatively extract 
antibiotics from whole blood hemolysates at physiologically meaningful 
concentrations (200 pg/µL in whole blood). Multiple reaction monitoring (MRM) 
detections on triple quadrupole analyzers should permit to avoid integration errors 
due to coelution of the analyte with other compounds. MRM detections should also 
permit to get lower limits of detection. 
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Fig. 82. Tetracycline recovery in human whole blood hemolysates. 
8-min extraction: column, Biotrap 500 MS, Chromtech, 13 x 4 mm i.d.; mobile phase, 
(A) 10 mmol/L ethanolamine; flow rate, 3.2 mL/min; room temperature; samples, 2.5 
mL of blood hemolysates containing tetracycline at 9.5 pg/µL, 28.5 pg/µL, 47.5 pg/µL, 
70.9 pg/µL, and 94.3 pg/µL. 
Back flush elution: column, Prontosil 300-5-C18-H 5 µm, Bischoff, 125 x 2.0 mm i.d.; 
mobile phase, (A) 0.05 % aqueous TFA, (B) 0.05 % TFA in ACN; linear gradient, 10-
30 % B in 7.5 min; 30-100 % B in 2.5 min, isocratic conditions at 100 % B for 2 min, 
flow rate, 0.3 mL/min; room temperature. Detection with Surveyor MSQ in selected 
ion monitoring mode targeted on m/z 445.2 ± 1.0. 
A linear correlation is observed but peak integration was rather difficult because of 
co-elution of tetracycline with another compound. 
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9 Conclusions 
Six different restricted access materials have been evaluated with respect to their 
ability to remove hemoglobin from hemolysates. In general, all six columns showed 
similar behavior: at pH 2.1, RAM materials showed significant adsorption and 
memory effects for hemoglobin. 
Derivatization of LiChrospher ADS material with aminodextran did not decrease the 
adsorption of proteins. Derivatizations with polyethyleneimines and polylysine 
generally increased the adsorption of proteins on the LiChrospher ADS material. 
However, no correlation between properties of proteins (e.g. molecular weight, pI) 
and adsorption was observed. 
Experiments at different pH (2.1-10.7) revealed that the retention of hemoglobin can 
be suppressed at alkaline pH (10 mmol/L ethanolamine, pH 10.7). A small amount of 
hemoglobin was still retained; however, carry-over between different injections was 
completely eliminated. Because of better chemical stability at elevated pH, the 
polymeric Biotrap 500 MS RAM column was optimized for the analysis of 
hemolysates. 
Tetracycline spiked into real hemolysates could be extracted with Biotrap 500 MS at 
alkaline pH, and detected down to 200 pg/µL concentrations using a linear 
quadrupole mass spectrometer operated in selected ion monitoring mode. The ability 
of the developed setup to quantitatively extract antibiotics from whole blood 
hemolysates at biologically relevant concentrations [128,129], and without carry-over of 
hemoglobin was proven. Better detection limits and less interference with matrix 
compounds should be achievable using selected reaction monitoring tandem mass 
spectrometry. 
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V. Development and evaluation of 
multidimensional HPLC-MS systems for 
proteome analysis 
In the field of proteomics, the detection of all the components present in a sample 
may be required. For instance, differential analysis of two cell states is performed by 
checking in two cell extracts the presence (or the absence) of all the presumably 
expressed proteins. Such a holistic strategy (holistic, greek holos, “whole”) requires 
analytical methods able to separate and identify a huge set of proteins and peptides. 
In this framework, two multidimensional setups for the separation of complex 
mixtures of peptides were developed and evaluated with tryptic digests of protein cell 
extracts of Corynebacterium glutamicum. 
Corynebacterium glutamicum is a gram positive soil bacterium used for the industrial 
production [136] of L-glutamate and L-lysine (1,500,000 to/a, and 700,000 to/a, 
respectively). Aside this evident industrial interest, C. glutamicum was chosen as a 
model organism for various reasons. Although related to pathogenic bacteria such as 
Corynebacterium diphtheriae or Mycobacterium tuberculosis, C. glutamicum is itself 
not pathogenic and did not require any special security equipment in the lab. 
Metabolic pathways of C. glutamicum are known [137] and the genome was available 
in database [138-140]. The annotation of around 3,000 proteins permitted us to perform 
peptide and protein identification with tandem mass spectrometry and database 
search. 
The first investigated scheme of separation followed a classical off-line strong cation 
exchange (SCX) separation, followed with ion-pair reversed-phase high-performance 
liquid chromatography (IP-RP-HPLC) at pH 2.1. The second separation scheme was 
a very new approach based on a peptide separation with RP-HPLC at pH 10.0, a 
fraction collection, and a separation with IP-RP-HPLC at pH 2.1. Peptide 
identification was achieved in both setups with electrospray ionization tandem mass 
spectrometry (ESI-MS/MS). 
In the following chapter, both approaches are described and evaluated. The new RP 
x IP-RP separation scheme is compared to the classical SCX x IP-RP approach in 
terms of peptide separation, proteome coverage, dimension repeatability, dimension 
orthogonality, and method complementarity. 
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1 Materials and methods 
1.1 Chemicals 
Deionized water (18.2 MΩ cm) was prepared with a Purelab Ultra Genetic system 
(Elga, Griesheim, Germany). Acetonitrile (E Chromasolv) and 2-mercaptoethanol (> 
98 %) were purchased from Sigma-Aldrich (Steinheim, Germany). Analytical reagent 
grade sodiumdihydrogen-phosphate-1-hydrate, acetic acid (100 %), and 
triethylamine (> 99 %) were obtained from Merck KGaA (Darmstadt, Germany). 
Sodium chloride was supplied by Grüssing GmbH (Filsum, Germany). Urea (≥ 99.5 
%), ortho-phosphoric acid (85 %), ammonium hydrogencarbonate (≥ 99.5 %), 
ammonium formate (> 97 %), iodacetic acid (≥ 99.5 %), formic acid (88-91 %), 
heptafluorobutyric acid (≥ 99.0 %), and trifluoroacetic acid (≥ 99.5 %) were purchased 
from Fluka (Buchs, Switzerland). Sequencing grade modified trypsin was supplied by 
Promega (Madison, WI, USA) and Slide-A-Lyzer dialysis cassettes by Perbio 
Science (Bonn, Germany). 
 
1.2 Preparation of tryptic digests 
Protein cell extracts of Corynebacterium glutamicum (wild type) were kindly obtained 
from the workgroup of Prof. E. Heinzle (Biochemical Engineering, Saarland 
University, Saarbrücken, Germany). Protein concentrations were evaluated by 
Bradford tests [141]. Proteins were denaturated by addition of 120 µL 8 mol/L urea, 
500 mmol/L ammonium hydrogencarbonate to 200 µL of cell lysate. The sample was 
incubated for one hour at 37°C under gentle agitation (600 rpm). The disulfide 
bridges were then reduced by addition of 12 µL 300 mmol/L dithiothreitol, sample 
degazing under argon, and incubation for 2 hours at 37°C at 600 rpm. After sample 
cooling, 8 µL 2 mol/L iodacetic acid were added for carboxymethylation and the 
sample was incubated for 30 minutes at room temperature under light protection. 
Excess of iodacetic adic was eliminated with 16 µL 1 mol/L 2-mercaptoethanol and 
incubation for 20 minutes at room temperature. Finally the sample was dialyzed for 
16 hours against 1 L distillated water in a dialysis cassette (3,500 MW cut-off 
membranes). Trypsin (1 µg for 50 µg protein) was activated for 30 minutes at 30°C in 
50 mmol/L acetic acid and incubated in the protein solution for a 24-hour digestion. 
Finally, the digestion was quenched by addition of trifluoroacetic acid (1.0 % (v/v) end 
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concentration). The protein digest was centrifuged for 5 minutes at 13,000 rpm. The 
supernatant was collected and split into aliquots. 
 
1.3 Analytical setups for the first separation steps 
A first chromatographic setup designed for flow rates of 1 mL/min consisted of an 
Agilent 1050 series HPLC system (Waldbronn, Germany), and a Rheodyne injection 
system (Rohnert Park, CA, USA) with a 400 µL external loop. UV detection was 
monitored at 214 nm with a Spectromonitor 3100 from Milton Roy (Ivyland, PA, 
USA). The flow cell had an optical pathway of 10 mm (volume: 14 µL). Eluents were 
degassed with helium. This setup was used to run a 250 x 4.0 mm ProPacTM SCX-10 
column preceded by a 100 x 4.0 mm guard column from Dionex (Idstein, Germany). 
A second chromatographic setup adapted for flow rates of 200-250 µL/min consisted 
of a low-pressure Rheos 2000 HPLC system (Flux Instruments, Basel, Switzerland), 
a degasser from Knauer GmbH (Berlin, Germany), and an injection system from 
Rheodyne (Model 7725, Rohnert Park, CA, USA) with a 400 µL external loop. UV 
detection was monitored at 214 nm with a capillary detector 433 purchased from 
Kontron AG (Zuerich, Switzerland). The flow cell had an optical pathway of 5 mm 
(volume: 1 µL). This setup was used to run a 250 x 2.0 mm ProPacTM SCX-10 
column preceded by a 50 x 2.0 mm guard column from Dionex (Idstein, Germany), a 
200 x 2.1 mm PolySULFOETHYL column from PolyLC (Southboro, MA, USA) 
preceded by a 10 x 2.1 mm guard column, and a 150 x 2.0 mm 3 µm C18 Gemini 
column from Phenomenex (Aschaffenburg, Germany). 
After collection, the fractions were evaporated with a vacuum concentrator (model 
5301) supplied by Eppendorf AG (Hamburg, Germany). 
 
1.4 Second separation step and data acquisition 
The second separation setup consisted of a 2D capillary/nano system from 
LCPackings (Amsterdam, The Netherlands), equipped with an Ultimate low-pressure 
gradient micro-pump (model Ultimate), a Switchos micro-column 10-port switching 
unit with loading pump (model Switchos), and a micro-injector (model Famos). Trap- 
(10 x 0.2 mm) and analytical columns (60 x 0.1 mm) were poly-
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styrene/divinylbenzene (PS-DVB) monoliths prepared according to the already 
published procedure [120]. Eluents were degassed with helium. 
An ion-trap mass spectrometer (model esquire HCT) from Bruker Daltonics (Bremen, 
Germany) with a modified ESI-ion source (spray capillary: fused silica capillary, 0.090 
mm o.d., 0.020 mm i.d.) was utilized as detector. The instrument was operated in 
data-dependent mode. MS/MS spectra were recorded in positive ion mode with an 
electrospray voltage of 3,500 V and fragmentation amplitude ramped from 0.5 to 3.0 
V. The heated capillary temperature was set to 300°C. The following mass 
spectrometric parameters were applied for automated peptide identifications by data-
dependent tandem mass spectrometry: mass range mode, ultra scan 50 – 3,000 m/z; 
scan speed, 26,000 m/z per s; full scan, 450 – 1,500 m/z; ion polarity, positive; trap 
drive, 93.2; octapole RF amplitude, 88.5 Vpp; lens 2, -36.1 V; capillary exit, 253.8 V; 
nebulizer gas, 20 psi; dry gas, 4 L/min; end-plate high-voltage offset, -500 V; ICC 
target, 70,000; maximum accumulation time, 200 ms; precursor ions auto MS(n), 3; 
MS averages, 5 spectra; MS/MS scan range, 200 – 2,000 m/z; active exclusion, after 
2 spectra for 0.50 min; MS/MS fragmentation amplitude, 1.5 V; smart fragmentation, 
on (30 – 200 %); absolute threshold MS/MS, 4,500. 
 
1.5 Data processing and evaluation 
Mass spectra processing was performed with Data Analysis 3.3 from Bruker 
Daltonics (Bremen, Germany). Database searches were performed against an in-
house database containing the sequenced proteins of Corynebacterium glutamicum 
ATCC 13032 Kitasato. The database (2,993 entries) was downloaded from the 
Institute for Genomic Research (TIGR) under http://cmr.tigr.org/tigr-
scripts/CMR/CmrHomePage.cgi. The engine software was Mascot 2.1 based on the 
MOWSE algorithm (Matrix Science, London, UK) [6;7]. The following search 
parameters were applied: taxonomy, all entries; fixed modification, cysteine 
carboxymethylation; variable modification, methionine oxidation; enzyme, trypsin; 
peptide tolerance, ± 1.3 Da; MS/MS tolerance, ± 0.3 Da; maximum number of missed 
cleavages, 1. 
A protein was positively identified with a significance threshold of 0.05, meaning that 
random hits (so called false positives) occurred with a frequency lower than 5 %. The 
95 % significance level corresponded to a MOWSE score of 23. The ion score cut-off 
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was set at 23. This value was already over the identification threshold for some 
peptides, leading to loss of peptides by the identification process. However, this 
strong cut-off value was utilized to ensure protein identifications based on very 
reliable peptide hits. 
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2 Experimental 
2.1 A classical 2D-HPLC-MS setup: SCX x IP-RP-HPLC 
The first separation scheme utilized for the analysis of C. glutamicum consisted of a 
strong cation exchange separation hyphenated to an ion-pair reversed-phase 
separation at pH 2.1. A schematic representation of the setup is depicted in Fig. 83.  
 
Fig. 83. Instrumental setup for off-line, two-dimensional peptide separations by SCX-
HPLC x IP-RP-HPLC-ESI-MS [20]. 
(a) Pumping system for SCX separation; (b) strong cation exchange column; (c) UV 
detector for monitoring the first dimension; (d) fraction collector; (e) pumping system 
for IP-RP separation; (f) autosampler; (g) 10 x 0.20 mm i.d. monolithic trap column; 
(h) 10-port switching valve; (i) pump for loading and washing; (j) 60 x 0.10 mm i.d. 
monolithic separation column; (k) UV detector for monitoring the second dimension; 
(l) electrospray-ion trap mass spectrometer. 
 
 
e-
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j) (k)
1st dimension:
cation-exchange HPLC
2nd dimension:
ion-pair reversed-phase
HPLC-ESI-MS, 
pH 2.1
(l)
Chapter V: 2D-HPLC-MS systems for proteome analysis  
   
146   
The detection was performed by electrospray ionization tandem mass spectrometry. 
The hyphenation of both methods of separation was achieved following an off-line 
approach: fractions were collected after the first separation step and injected after 
partial evaporation in the second chromatographic system. The use of a small trap 
column permitted the injection of large volumes of fractions without leading to peak 
broadening in the second dimension of separation. The trap column was also used to 
desalt the fractions before injection into the mass spectrometer. This consequently 
avoided salt contamination in the ion source of the mass spectrometer. Different 
cation exchangers were implemented in the setup and several peptide separations 
were performed in order to avoid data misinterpretation. 
 
2.1.1 Proteome analysis of C. glutamicum with SCX x IP-RP-HPLC 
Approximately 280 µg of a tryptic digest of C. glutamicum protein cell extract were 
injected over a 250 x 4.0 mm ProPacTM SCX-10 column. Sample loading was 
performed at 1 mL/min with (A) 5 mmol/L NaH2PO4, pH 3.0, 20 % ACN and elution 
with (B) 5 mmol/L NaH2PO4, pH 3.0, 20 % ACN, 500 mmol/L NaCl. The gradient was 
0 - 3 % B in 9 min, 3 - 10 % B in 8 min, and 10 - 100 % B in 4 min. The very shallow 
salt gradient was combined with increasing fraction volumes to get higher 
homogeneity, in terms of peptide amount, between the collected fractions. Fractions 
were collected as follows: 250-µL fractions till 7.25 min, 500-µL fractions between 
7.25 and 13.25 min, and 1,000-µL fractions until the end of the chromatographic 
separation. The fractions were evaporated to a final volume of 100 µL (2.5-, 5- and 
10-fold concentration for the 250-, 500- and 1,000-µL fractions, respectively). 
The second separation step was performed by loading and washing for 4 min 10 µL 
of the evaporated fractions on the 10 x 0.2 mm PS-DVB trap column with H2O + 0.10 
% heptafluorobutyric acid at 10 µL/min. The switching valve was then commuted and 
a back flush elution over the 60 x 0.1 mm PS-DVB analytical column was performed 
at 0.75 µL/min. Mobile phases consisted of (A) 0.05 % trifluoroacetic acid in water 
(pH 2.1) and (B) 0.05 % trifluoroacetic acid in acetonitrile. Peptides were separated 
at room temperature by using a gradient from 0 to 20 % B in 60 min, followed by 
isocratic conditions at 100 % B for 3 min. A total of 44 fractions collected between 
1.25 min and 21.25 min were analyzed in triplicate, leading to 132 HPLC-MS/MS 
runs. 
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2.1.2 Fractionation repeatability after peptide separation with SCX 
Approximately 90 µg of a tryptic digest of C. glutamicum protein cell extract were 
injected in triplicate over a 50 + 250 x 2.0 mm ProPacTM SCX-10 column. The flow 
rate was set to 250 µL/min. Mobile phases were (A) 5 mmol/L NaH2PO4, pH 3.0, 20 
% ACN and (B) 5 mmol/L NaH2PO4, pH 3.0, 20 % ACN, 500 mmol/L NaCl. The 
gradient was 0 - 100 % B in 30 min, followed by isocratic conditions at 100 % B for 5 
min. 250-µL fractions were collected per hand every minute and evaporated to 100 
µL (2.5-fold concentration). Five consecutive fractions were selected and analyzed by 
injecting 10 µL of each in the IP-RP-HPLC-ESI-MS/MS system. Each fraction was 
analyzed in quintuplicate to avoid data misinterpretation due to potential bad 
repeatability of the second separation and/or detection step (e.g. ion suppression in 
the electrospray source). 
Fractionation repeatability was also evaluated with a 10 + 200 x 2.1 mm 
PolySULFOETHYL column. The flow rate was set to 250 µL/min and 90 µg of C. 
glutamicum peptides were injected in triplicate. Sample loading was performed for 10 
min with (A) 10 mmol/L ammonium formate, pH 3.0, 25 % acetonitrile. Elution 
occurred under a gradient of (B) 500 mmol/L ammonium formate, pH 6.8, 25 % 
acetonitrile: 0 – 50 % B in 40 min, 50 – 100 % B in 10 min, followed by isocratic 
conditions at 100 % B for 10 min. 250-µL fractions were collected per hand every 
minute, evaporated to 100 µL (2.5-fold concentration), and 5 consecutive fractions 
were selected and analyzed such as the fractions collected after the ProPacTM SCX-
10 column. 
 
2.2 A new 2D-HPLC-MS setup: RP-HPLC x IP-RP-HPLC 
The second separation scheme utilized for the analysis of C. glutamicum consisted of 
a reversed-phase separation at pH 10.0 hyphenated to an ion-pair reversed-phase 
separation at pH 2.1. As in the classical SCX x IP-RP-HPLC approach, the 
hyphenation of both methods of separation was achieved off-line, and the detection 
was performed by electrospray ionization tandem mass spectrometry. Fractions were 
also collected after the first separation step and injected after partial evaporation in 
the second chromatographic system. Although sample desalting was not required 
because of the absence of salt in the eluents of the first dimension of separation 
(elution with acetonitrile), a small trap column was used to quickly inject large 
volumes of fractions in the second dimension of separation. 
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The feasibility of a two-dimensional separation of peptides with different pH in first 
and second separation dimensions was already proven on small set of peptides [142-
144] but no literature was found for large scale separations of peptides. In both 
dimensions, hydrophobic interactions between stationary phase and peptides occur. 
However, the separation of peptides at high and low pH is achievable because of the 
amphiphile structure of peptides. Since peptides are charged molecules comprised of 
ionizable basic and acidic functional groups, the change of mobile phase pH has a 
pronounced effect on their retention behavior. At high pH, most of the basic sites are 
neutral and the acidic groups are negatively charged. On the contrary, under low pH 
conditions, the basic sites are positively charged and the acidic groups are neutral. 
These differences in terms of charges can be combined with different retention 
mechanisms (e.g. RP and IP-RP) and stationary phases (e.g. C18 and PS-DVB) to 
obtain separation systems with high peak capacity. A schematic representation of 
such a chromatographic system is depicted in Fig. 84. Silica-based stationary phases 
are usually only stable up to pH 8 in aqueous solutions. Consequently, polymer-
based stationary phases are often used for the separation of peptides at high pH. 
However, silica-based stationary phases stable up to pH 12 have been developed in 
the last years [145] and are now commercially available (e.g. Waters, Phenomenex). 
Such a column was used at pH 10.0 to separate the peptides in the first 
chromatographic step. 
Fig. 84. Separation of peptides by (a) reversed-phase- under alkaline conditions and 
(b) ion-pair reversed-phase chromatography under acidic conditions.  
(a) RP-HPLC of peptides at pH 10.0 (b) IP-RP-HPLC of peptides at pH 2.1
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2.2.1 Proteome analysis of C. glutamicum with RP x IP-RP 
Approximately 280 µg peptides from C. glutamicum were injected over a 150 x 2.0 
mm Gemini C18 column. Sample loading was performed at 200 µL/min with (A) 72 
mmol/L triethylamine titrated to pH 10.0 with acetic acid. Elution was performed with 
(B) 72 mmol/L triethylamine, 52 mmol/L acetic acid in acetonitrile. Triethylamine is 
known to act as ion-pair reagent [146;147]; however under these conditions reversed-
phase mechanism predominates over ion-pair reversed-phase mechanism (see 
3.2.2). The gradient was 0 - 55 % B in 55 min, followed by isocratic conditions at 100 
% B for 2 min. 200-µL fractions were collected every minute. Acetonitrile was 
eliminated by evaporating the fractions to a final volume of 20 µL (10-fold 
concentration). Fractions were finally taken up with 105 µL of 0.10 % aqueous 
heptafluorobutyric acid. 
Thirty-one fractions collected between 14 min and 45 min were analyzed in triplicate 
(total of 93 HPLC-MS runs). Columns, mobile phase solvents, flow rates and 
gradients were identical to the one used for the SCX fraction analysis (see 2.1.1). 
Because the fractions did not contain salts, the switching valve was commuted 
directly after sample transfer (2.5 min). 
 
2.2.2 Fractionation repeatability after peptide separation with RP-
HPLC at pH 10.0 
Approximately 90 µg of C. glutamicum peptides were injected in triplicate over the 
150 x 2.0 mm Gemini C18 column. Sample loading was performed at 200 µL/min 
with (A) 72 mmol/L triethylamine titrated to pH 10.0 with acetic acid. Elution was 
performed with (B) 72 mmol/L triethylamine, 52 mmol/L acetic acid in acetonitrile. 
The gradient was 0 - 60 % B in 35 min, 60 – 100 % B in 10 min, followed by isocratic 
conditions at 100 % B for 2 min. 400-µL fractions were collected per hand every two 
minutes and evaporated to 20 µL to eliminate acetonitrile (20-fold concentration). 
Five consecutive fractions were taken up with 95 µL 0.10 % aqueous 
heptafluorobutyric acid and analyzed in quintuplicate with the IP-RP-HPLC-ESI-
MS/MS system previously described (see 2.1.1).  
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3 Results and discussion 
3.1 Peptide separation 
In the following section, peptide separations in the first chromatographic dimensions 
(SCX and RP-HPLC at pH 10.0) and in the second chromatographic dimension (IP-
RP-HPLC at pH 2.1) are investigated. 
 
3.1.1 Peptide separation with SCX 
The chromatogram of the peptide separation performed with SCX in order to analyze 
the proteome of C. glutamicum is depicted in Fig. 85. 
Fig. 85. Strong cation exchange fractionation of a digested C. glutamicum lysate (first 
chromatographic dimension). 
Column, 100 + 250 x 4 mm i.d. ProPacTM SCX-10; mobile phase, (A) 5 mM 
NaH2PO4, pH 3.0, 20 % acetonitrile, (B) 0.50 mol/L NaCl in eluent (A); gradient, 0-3 
% B in 9.0 min, 3-10 % B in 8 min, 10-100 % B in 4 min; flow rate, 1 mL/min; 
temperature, 25°C; detection, UV at 214 nm; sample, 280 µg tryptic digest of a C. 
glutamicum protein cell extract; fractions, 24 x 0.25 min, 12 x 0.50 min, 8 x 1.00 min. 
 
As observed, the strong cation exchanger does not show a high peak capacity and 
most of the peptides are eluting within a narrow gradient strength window (0 - 50 
mmol/L NaCl). This is partially explained by the fact that separations in SCX are 
generally based on the charge of the analytes. Practically, peptides are not 
individually separated but sets of peptides with similar charges (1+, 2+, 3+, and 4+) 
are separated. Although the salt gradient was very shallow, most of the peptides 
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were eluting in two sets (fractions 1-12, and fractions 19-34). To get a higher 
homogeneity in terms of peptide amount between the collected fractions, fractions at 
the very beginning of the chromatographic process were collected every 0.25 min, 
whereas fractions with less peptides were collected only every 1.00 min. 
 
3.1.2 Peptide separation with RP-HPLC at pH 10.0 
The same amount of peptides was injected into the RP-HPLC system at pH 10.0. 
The obtained chromatogram is depicted in Fig. 86. Peaks are observed over a broad 
separation window (over 45 min), highlighting a good peptide separation with a linear 
gradient of acetonitrile. Previous experiments showed an absence of peptides during 
the first 15 min of the separation and consequently fractions were not collected at the 
beginning of the separation. Peaks observed in this time window may be partly 
attributed to chemicals used during the extraction and/or the digestion of the proteins. 
Because peptides appeared to be continuously eluted from the column, fractions 
were collected with the same periodicity (1.00 min fractions). 
Fig. 86. Reversed-phase fractionation at pH 10.0 of a digested C. glutamicum lysate 
(first chromatographic dimension). 
Column, 150 x 2.0 mm i.d. 3 µm Gemini C18; mobile phase, (A) 72 mmol/L 
triethylamine titrated to pH 10.0 with acetic acid, (B) 72 mmol/L triethylamine and 52 
mmol/L acetic acid in acetonitrile; gradient, 0-55 % B in 55.0 min; flow rate, 200 
µL/min; temperature, 25°C; detection, UV at 280 nm; sample, 280 µg tryptic digest of 
a C. glutamicum protein cell extract; fractions, 31 x 1.00 min. 
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3.1.3 Peptide separation with IP-RP-HPLC at pH 2.1 
All fractions collected after separation with strong cation-exchange- and reversed-
phase HPLC at pH 10.0 were analyzed with IP-RP-HPLC at pH 2.1 and detected with 
ESI tandem mass spectrometry. Typical reconstructed total ion current 
chromatograms are depicted for three consecutive fractions in Fig. 87. A mass 
spectrum (see Fig. 88a) corresponds to each point of such chromatograms. For each 
mass spectrum, most intensive ions are selected and submitted to fragmentation 
(collision-induced dissociations). Fragments are obtained (see Fig. 88b) and finally 
compared to a database for peptide identification. The principle of peptide 
identification with Peptide Fragment Fingerprinting (PFF) is outlined in chapter II, 
section 3.13. 
Fig. 87. Ion-pair reversed-phase separation at pH 2.1 of three consecutive cation-
exchange fractions of C. glutamicum. 
Columns, 10 mm × 0.20 mm i.d. monolithic PS-DVB preconcentration column, and 
60 mm × 0.20 mm i.d. monolithic PS-DVB separation column; loading solvent, 0.10 
% aqueous heptafluorobutyric acid; trapping time, 4.0 min; loading flow rate, 10 
μL/min; mobile phase: (A) 0.050 % aqueous trifluoroacetic acid, (B) 0.050 % 
trifluoroacetic acid in acetonitrile; gradient, 0–20 % B in 60 min; flow rate, 0.750 
μL/min; temperature of preconcentration- and separation column, 25 °C; detection, 
ESI-MS/MS; sample, 10 μL tryptic peptides of C. glutamicum, fraction 27, 28, and 29 
from strong cation-exchange chromatography, 10 µL injected. 
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Fig. 88. (a) MS spectrum of cation exchange fraction # 29 at 35.9 min and (b) 
MS/MS spectrum of m/z 857.4. Chromatographic conditions as in Fig. 87 and MS 
parameters as described in section 1421.4. 
 
 
3.2 Peptide distribution 
In the following section, the peptide distributions obtained after separation with SCX 
and RP-HPLC at pH 10.0 are discussed. 
 
3.2.1 Peptide distribution with SCX 
The 44 fractions, collected after the strong cation exchanger, were injected in 
triplicate into the second separation dimension. For each HPLC-MS/MS run, a 
database search was performed, leading to 132 different identification reports. For 
the three replicates of each fraction, the three identification reports were compared 
and a nonredundant list of identified peptides was established. Then the number of 
unique identified peptides as a function of the fraction number was plotted. The 
obtained distribution is depicted in Fig. 89a. Peptides are identified all over the 44 
fractions. As expected, the peptide hits are not continuously distributed and most of 
the peptides are identified in two distinguished time windows (bimodal distribution). 
The bimodal distribution shows maxima in fractions 1 and 25, and minima in fractions 
16 and 44. The same data interpretation was performed at the protein level and a 
similar profile was obtained (see Fig. 89b). Maxima were observed for fractions 7 and 
27 and minima for fractions 18 and 44. 
 
 
 
1.0
0
2.0
3.0
4.0
500 1,000
si
gn
al
in
te
ns
ity
.
10
- 4
[ c
ou
nt
s]
m/z
600 700 800 900 200 1,700
0
1.0
2.0
si
gn
al
in
te
ns
ity
.
10
-3
[c
ou
nt
s
]
m/z
500 800 1,100 1,400
0.5
1.5
2.5
(a) MS spectrum of fraction # 29 at 35.9 min (b) MS/MS spectrum of m/z 857.4
X
857.4
b15
y9
y10y8
y5
y3
b15++y9++
Chapter V: 2D-HPLC-MS systems for proteome analysis  
   
154   
Fig. 89. (a) Peptide hit and (b) protein hit distribution over SCX fractions. Data 
correspond to three replicate injections in the second chromatographic dimension. 
Redundant hits within replicates have been eliminated but redundant hits between 
fractions are present. 
 
As already discussed, the bimodal distribution is attributed to the charge states of the 
tryptic peptides [20;148]. Doubly charged peptides are eluting at the very beginning of 
the separation, whereas peptides carrying three or more charges are retained on the 
column and are eluted at higher salt concentrations. In order to verify this hypothesis, 
for each identified peptide of each fraction (Σ 6,254), the number of positively 
charged residues was computed. Because the separation was performed at pH 3.0, 
positive residues were the N-terminus of the peptide (pKa 9-11) and the three basic 
amino acids: arginine (pKa 12.5), lysine (pKa 10.5), and histidine (pKa 6.0). At pH 3.0, 
no residue is negatively charged. Consequently, retention of peptides on the cation 
exchanger is mostly determined by the number of positive charges in the amino-acid 
sequence and no correlation should be obtained in a plot representing pI as a 
function of the fraction number. As observed in Fig. 90, a slight tendency of 
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increasing pI values with increasing fraction numbers appears. However, no real 
correlation is observed.  
Fig. 90. Plot representing the average pI value of the identified peptide as a function 
of the fraction number. The pI values were computed with the compute pI/Mw tool 
on-line available under www.expasy.org, and arithmetically averaged. 
 
On the other hand, if we assume that the positive charges carried by the peptides are 
mainly responsible for the peptide distribution, low charged peptides should elute at 
the beginning of the separation, whereas peptides carrying more charges should 
elute latter. In Fig. 91, elution profiles for peptide charged 1+ to 6+ are depicted. The 
elution of doubly charged peptides at the very beginning of the separation process is 
confirmed. The elution of the triply charged peptides occurs later (from fraction # 19). 
The elution of some three-time charged peptides in the first two fractions may be 
explained by a column overloading. Very few peptides with only one single positive 
charge were detected. They correspond to C-terminus fragments of proteins which 
do not contain any basic residues. 
Acetonitrile was utilized in the eluents during the SCX separation in order to diminish 
hydrophobic interactions (secondary interactions) between peptides and the 
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of GRAVY values were computed for each fraction and plotted in Fig. 92. Despite a 
slight tendency of decrease, no correlation was observed. This reveals the negligible 
role of hydrophobic interactions occurring in the separation process. 
Fig. 91. Dependence between the number of positive charges carried by a peptide 
and the retention time of the peptide in a strong cation-exchange separation. 
 
Fig. 92. Plot representing the average GRAVY value of the identified peptides as 
function of the fraction number. 
It results from these different computations that the most important parameter, 
influencing the retention of the peptides in the cation exchanger, is the number of 
positive charges carried by the peptides. Negative charges and hydrophobic 
properties play a minor role. 
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3.2.2 Peptide distribution with RP-HPLC at pH 10.0 
The 31 fractions collected after the reversed-phase separation at pH 10.0 were 
injected in triplicate into the second separation dimension. As for the SCX fractions, 
for each HPLC-MS/MS run a database search was performed. 93 identification 
reports were obtained. Redundant hits within replicates were filtered out and for each 
fraction a list of non redundant identified peptides was established. The peptide hit 
distribution is plotted in Fig. 93a. 
 
Fig. 93. (a) Peptide hit and (b) protein hit distribution over RP fractions. Data 
correspond to three replicate injections in the second chromatographic dimension. 
Redundant hits within replicates have been eliminated but redundant hits between 
fractions are occurring. 
 
Peptides are identified all over the 31 fractions. The peptide hit distribution is quite 
similar to a Gauss curve with a truncated maximum. After an increase over 6 
fractions, the number of peptide hits is stable over 18 fractions, and finally decreases 
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over 7 fractions. The same data interpretation was performed at the protein level and 
a very similar profile was obtained (see Fig. 93b). 
In order to check the influence of the charge state of the peptides on retention, the 
number of negative charges was computed for each peptide. Because the first 
dimension of separation was performed at pH 10.0, peptides were carrying negative 
charges at C-terminus (pKa 1.8-2.4), and at aspartic acid (pKa 3.9) and glutamic acid 
(pKa 4.3) residues. For each charge state (1- to 7-), the average retention time of the 
peptides (expressed as an average fraction of elution) in the first dimension was 
computed. It was then possible to plot a diagram representing the mean elution time 
as a function of the charge state of the peptides. As depicted in Fig. 94, a very good 
correlation was observed. 
Fig. 94. Plot representing the average fraction of elution for negative charged 
peptides. 
 
The more charged the peptides, the shorter the elution. This leads to the assumption 
that the reversed-phase mechanism predominated over the ion-pair reversed-phase 
mechanism during the separation. Under such conditions, peptides carrying many 
charges are presenting much more affinity to the mobile phase than low-charged 
peptides. Consequently, peptides carrying many charges are eluting first and 
peptides with few charges are eluting later. 
R  = 0.9898
8
10
12
14
16
18
20
0 1 2 3 4 5 6 7 8
2
peptide negative charge
av
er
ag
e 
fr
ac
tio
n 
of
 e
lu
tio
n
                                              Chapter V: 2D-HPLC-MS systems for proteome analysis 
   
  159 
In order to check this hypothesis, the GRAVY index of each identified peptide was 
computed. Then, for each fraction, the arithmetic average of the GRAVY values of all 
the detected peptides was calculated. Finally, these average GRAVY values were 
plotted as a function of the fraction number (see Fig. 95). 
Fig. 95. Plot representing the average GRAVY value of the identified peptides as a 
function of the fraction of elution. 
 
A linear correlation was observed (R2 = 0.9843). The plot reveals that less 
hydrophobic peptides were eluted at low acetonitrile content, whereas more 
hydrophobic peptides were eluted at higher concentration of acetonitrile. This 
signifies that the retention of the peptides was strongly influenced by solvophobic 
interactions and it confirms the predominant role of the reversed-phase mechanism. 
Triethylamine was not concentrated enough to deal as an ion-pair reagent. 
 
3.3 Proteome coverage 
The proteome analysis of C. glutamicum with the SCX x IP-RP-HPLC setup (132 
HPLC-ESI-MS runs) led to 6,254 peptide hits. After removal of redundant peptide hits 
between the fractions, a total of 2,398 unique peptides were identified. With the RP x 
IP-RP-HPLC setup (93 HPLC-ESI-MS runs), 3,124 peptide hits were obtained and 
after removal of redundancies, 2,708 unique peptides were identified. Thus, in 
comparison with the SCX approach, ca. 13 % more unique peptides were identified 
(2,708 vs. 2,398) with ca. 50 % less peptide hits (3,124 vs. 6,254) in the RP x IP-RP-
HPLC approach. The significant decrease in redundancies with the RP x IP-RP-
HPLC approach (1.15 hits per unique peptide) in comparison with the SCX x IP-RP-
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HPLC approach (2.61 hits per unique peptide) is partially explained by the analysis of 
less (31 vs. 44) but bigger (1.00-min vs. 0.25-, 0.50-, and 1.00-min) fractions in the 
RP x IP-RP approach. However, the weak retention of low charged peptides (1+ and 
2+) on the cation exchanger requires such a fractionation to avoid the collection of 
too complex fractions, which can be hardly analyzed because of strong ion 
suppression in ESI. The flowing-through of some peptides during the SCX separation 
is illustrated by the fact that more than 45 % of the unique identified peptides are 
already detected in the first 5 min of the separation. To sum up, the new RP x IP-RP-
HPLC approach permits to significantly increase the number of identified peptides in 
a significantly shorter time of analysis (124 vs. 176 hours).  
At the protein level, the SCX x IP-RP-HPLC setup led to 4,544 protein hits. After 
removal of redundant protein hits between the fractions, a total of 695 unique 
proteins were identified. The RP x IP-RP-HPLC approach led to the identification of 
745 unique proteins, which corresponds to 7 % more identifications than with the 
classical SCX x IP-RP method. 
The proteome coverage can be defined as the ratio between the number of detected 
proteins and the number of potentially expressed proteins. The number of potentially 
expressed proteins corresponds to the number of proteins annotated for a given 
genome, but not necessarily present in the protein cell lysate. In the case of the 
present study on C. glutamicum, the number of potentially expressed proteins 
corresponds to the number of entries in the database (2,993). Both analytical 
methods gave relevant proteome coverage: 23.2 % with the classical SCX x IP-RP-
HPLC setup and 24.9 % with the RP X IP-RP-HPLC setup. Considering that many 
proteins were not expressed in the cells and that proteins were lost during sample 
preparation (extraction, dialysis), these values are very promising for further 
biologically relevant applications. 
 
3.4 Identification confidence 
No set of identified peptides in a Peptide Fragment Fingerprinting approach is free of 
false-positive hits. The presence of false-positive identifications is intrinsic to the 
method of identification and mostly results from the algorithms utilized to identify the 
peptides. Algorithms compare experimental MS/MS spectra with theoretical 
fragmentation patterns and return the best peptide match for each MS/MS spectrum 
within the database. Because best matches are not necessarily perfect matches, a 
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portion of the identifications are incorrect peptide sequence assignments due to 
coincidental similarities in MS/MS fragmentation patterns. In the present study, the 
identification confidence threshold was set to 95 % by applying a MOWSE score 
cutoff of 23. However, the algorithm may always return random hits and the validity of 
the identifications has to be a posteriori checked. To address this issue, all the 
experimental mass lists were tested against nonsense protein sequences obtained 
by reversing the protein sequences of C. glutamicum (reverse sequence database 
strategy [95] ). 
The peak lists generated in the SCX x IP-RP-HPLC approach returned 2,398 peptide 
hits and 695 protein hits after a search in the forward database, whereas 38 peptide 
hits and 38 protein hits were randomly obtained from a search in the reverse 
database. At the peptide level, a false-positive identification rate of 1.6 % was 
computed, while a false-positive identification rate of 5.5 % was obtained at the 
protein level. With the RP x IP-RP-HPLC strategy, very similar results were obtained: 
40 peptides and 40 proteins were randomly identified in the reverse database. The 
corresponding false-positive identification rates were 1.5 % for peptides and 5.4 % 
for proteins. These values are in agreement with the 95 % identification confidence 
threshold set during the MASCOT searches and reveals that no systematic error 
occurred during the identification process. The imposing difference between false-
positive identification rates at peptide and protein levels are explained by the fact that 
more peptides may identify a single protein. Such peptides are very usual for true 
identifications in a forward database, but false protein identification in a reverse 
database is rarely achieved with more than one peptide. 
Nowadays a generally accepted rule only validates protein identifications which are 
based on the detection of more than one peptide of the protein sequence [149;150]. In 
the SCX x IP-RP-HPLC approach, 414 proteins fulfilled this criterion. With the RP x 
IP-RP-HPLC setup, 468 proteins were identified with more than one peptide, 
meaning that the new separation approach permitted to identify 13 % more proteins 
than the classical approach under such a criterion of data validation. 
Another criterion which influences the identification of peptides and proteins is the 
peptide tolerance used to perform the database search. For all the identifications 
performed in this work, a peptide tolerance of ± 1.3 Da was applied. This value is 
rather high but the aim of the present work was not to identify proteins at the highest 
confidence level but to develop and evaluate multidimensional HPLC-ESI-MS/MS 
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methods. Moreover, if some protein misidentifications occur, they should statistically 
happen at comparable levels in both HPLC-ESI-MS/MS approaches. This was 
checked by reducing the peptide tolerance from ± 1.3 Da down to ± 0.3 Da and by 
maintaining the identification confidence threshold at 95 % with a MOWSE score 
cutoff of 17. In this case, 679 proteins were identified with the SCX x IP-RP-HPLC 
setup and 718 proteins with the RP x IP-RP-HPLC system. The protein identification 
decreases at similar levels: 2.3 % and 3.6 % respectively. 
 
3.5 Repeatability of the dimensions of separation 
3.5.1 Repeatability of peptide separation and identification with IP-
RP-HPLC-ESI-MS/MS at pH 2.1 
In order to check the repeatability of the second dimension of both HPLC-ESI-MS/MS 
setups, samples consisting of tryptic peptides of C. glutamicum were injected in 
quintuplicate into the IP-RP-HPLC-ESI-MS/MS system. For each replicate analysis 
an identification search was performed with Mascot. For each sample, the five 
identification reports were compared with each other at the peptide level. Some 
peptides were identified five times, whereas others were only once detected. Finally, 
frequencies of peptide identification were computed for each sample. In order to get 
statistically meaningful data, such analyses were pursued for 15 different samples 
and arithmetic averages were calculated. The data is schematically represented in a 
pie-chart in Fig. 96. A quite good repeatability of the HPLC-ESI-MS/MS analyses is 
observed: 30.6 % of the peptides were detected in all five replicate analyses. 
However, 28.7 % of the peptides were detected only once. Still too complex samples 
leading to peptide co-elution and ion suppression in the ESI source may partially 
explain these results. The peptide distribution in two major groups (54.0 % of the 
peptides are identified three or more times, whereas 28.7 % of the peptides are 
detected only once) is also due to the dynamic range in concentration of the 
peptides. Proteins, and as a matter of fact peptides, are not concentrated at the 
same level in the sample. Consequently some peptides are highly abundant and 
present at concentrations far above the limit of detection of the mass spectrometer, 
whereas the concentrations of low abundant peptides are ranging around the limit of 
detection of the mass spectrometer. As a result, high abundant peptides are quasi 
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always detected, whereas peptides at concentrations ranging around the limit of 
detection of the mass spectrometer are very rarely identified. 
Fig. 96. Pie-chart representing the repeatability of peptide identification with IP-RP-
HPLC-ESI-MS/MS of five replicate analyses of C. glutamicum tryptic digests. The 
values are arithmetic averages computed for 15 different samples. 
 
The computed data also prove that repetitive analyses help to significantly increase 
the number of identified peptides. In order to estimate a meaningful number of 
replicates one should perform, the cumulative amount of identified peptides as a 
function of the replicate number was computed for quintuplicate analyses. The 
results are depicted in Fig. 97.  
Fig. 97. Percent of identified peptides as function of the number of replicates for 
quintuplicate IP-RP-HPLC-ESI-MS/MS analyses at pH 2.1. 
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the gain is inferior to 10 % per injection. No absolute rules should be set and the 
operator should determine for each sample and analytical aim how much time can be 
invested to perform replicate injections. However, the analysis of a sample in 
triplicate appears to be a good compromise in terms of peptide identification and time 
consumption. This value was the one chosen for the identification study (see 3.3 
Proteome coverage), whereas five replicate measurements were performed in order 
to determine the repeatability of the first dimension of both two-dimensional HPLC 
setups (see next sections). 
 
3.5.2 Separation and fractionation repeatability with SCX 
The repeatability of the first dimension of the classical SCX x IP-RP-HPLC setup was 
investigated. Three injections of a same tryptic digest of C. glutamicum proteins were 
performed on a cation exchanger and fractions were collected in triplicate. Each 
collected fraction was injected in quintuplicate into the second separation dimension. 
The MS/MS data of the five replicates were merged together and for each fraction 
collected in the first separation step, one single peptide identification analysis was 
performed. These multiple injections in the IP-RP-HPLC-ESI-MS/MS system 
permitted to diminish data misinterpretation due to insufficient repeatability of the 
second dimension. 
Consecutive fractions containing between 90 and 200 peptides were collected after 
the cation exchanger and analyzed with IP-RP-HPLC-ESI-MS/MS. Because the SCX 
separation was performed in triplicate, it was possible to compute for each fraction 
the number of peptides identified in three, in two, or in one of the replicates. An 
arithmetic average of the identification redundancies was computed for five fractions. 
In order to check that the results were not dependent on the cation exchanger, the 
same experiment was performed on two different cation exchangers (ProPacTM SCX, 
and PolySULFOETHYL). The results are depicted in Fig. 98 and in Fig. 99. With both 
columns very similar results were obtained. Most of the peptides (41 – 45 %) were 
identified in all three replicates, showing a quite good repeatability of the separation 
and fractionation setup. The amount of peptides only once detected was rather high 
(37 – 39 %) and peptides twice detected were the less numerous (22 – 16 %). 
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Fig. 98. Repeatability of the separation and fractionation step with the ProPacTM 
SCX-10 column. Each pie-chart corresponds to one fraction collected in triplicate 
after the cation exchanger and analyzed in quintuplicate with IP-RP-HPLC-ESI-
MS/MS. The percentages correspond to the amount of peptides once, twice or three 
times identified. 
 
Because quintuplicate analyses should have permitted to identify most of the 
peptides present in a fraction, the identification distribution is mostly attributed to the 
first dimension of the setup. Factors leading to a limited repeatability are various. 
First, peptides may not be eluted from the cation exchanger in a repeatable manner. 
Such differences are explained by numerous factors: e.g. limited repeatability of 
gradient formation, small variations in column temperature, or equilibration of the 
column. Errors may also occur during the collection of the fractions. This is of 
particular importance for small fractions and for fractionations performed per hand. 
Finally, fractions are partially evaporated in polypropylene vials before injection in the 
second separation dimension and adsorption phenomena can take place [151]. 
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Fig. 99. Repeatability of the separation and fractionation step with the 
PolySULFOETHYL column. Each pie-chart corresponds to one fraction collected in 
triplicate after the cation exchanger and analyzed in quintuplicate with IP-RP-HPLC-
ESI-MS/MS. The percentages correspond to the amount of peptides once, twice or 
three times identified. 
 
It is not possible to accurately determine the importance of each source of 
imprecision but the influence of small differences in terms of retention time and 
fraction collection was evaluated. Delay in the elution results in the collection of 
peptides in later fractions. The five fractions collected after the cation-exchanger 
were consecutive fractions. Consequently, by merging the identification results of the 
five fractions, one gets a set of identified peptides independent of variations in 
retention/collection time. For each replicate injection in the first dimension of 
separation, such a data examination was performed. Finally, the three peptide sets 
were compared and the amounts of peptides once, twice, or three times identified 
were computed. A schematic representation of the computing process permitting to 
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determine the influence of the separation and fractionation step is depicted in Fig. 
100. The results are depicted for the ProPacTM SCX-10 column in Fig. 101a, and for 
the PolySULFOETHYL column in Fig. 101b. 
 
1st D, run # A
1st D, run # C
1st D, run # B
fraction number
# 1 # 2 # 3 # 4 # 5 merge of fractions # 1 to # 5
repeatability of 5 merged fractionsrepeatability fractions # 1 to # 5
repeatability average of 5 fractions
influence of retention and fractionation
inaccuracies on the repeatability  
Fig. 100. Determination of the influence of retention and fractionation inaccuracies on 
the repeatability of peptide identification. 
 
Fig. 101. Repeatability of the separation and fractionation step with (a) the ProPacTM 
SCX-10 and (b) the PolySULFOETHYL column. Pie-charts on the left side represent 
the average repeatability observed for five fractions. Pie-charts on the right side 
correspond to the repeatability obtained after a merge of the same five fractions. 
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For both columns, higher repeatability with merged fractions was observed as 
compared with averages of isolated fractions. In case of the ProPacTM SCX-10 
column, three times identified peptides represent 42 % of the identified peptides in 
isolated fractions whereas they are 46 % in merged fractions. With the 
PolySULFOETHYL column, the amount of twice or three times identified peptides is 
increased from 61 % to 65 % by merging the fractions. These results show that small 
changes in terms of peptide retention or fractionation have a real incidence on the 
repeatability of the first separation step of the classical SCX x IP-RP-HPLC-MS/MS 
setup. Similar repeatabilities were computed for two different columns (operated 
under different conditions), allowing the generalization of the observed results to 
setups based on other cation exchangers. 
 
3.5.3 Separation and fractionation repeatability with IP-RP-HPLC at 
pH 10.0 
As performed in the previous section with cation-exchangers, the repeatability of the 
first dimension of separation and of the fractionation step was determined with the 
column used to separate the peptides with RP-HPLC at pH 10.0. Thus, three 
replicate injections of the same tryptic peptide mixture of C. glutamicum were 
performed. Moreover, five fractions were collected in the same retention time window 
for each replicate. The fractions were analyzed in quintuplicate with the IP-RP-HPLC-
ESI-MS/MS system. The results are depicted in Fig. 102. Most of the peptides were 
detected three times (42 %). Peptides once identified represent 34 %, and peptides 
twice identified represent 24 % of all identified peptides. These percentages are very 
similar to those obtained with cation exchangers (41 – 45 %, 16 - 22 %, 37 - 39 % for 
once, twice, and three times identified peptides, respectively). Thus, the newly 
established setup presents the same performances than classical SCX setups in 
terms of repeatability of peptide identification. 
In order to check the influence of the fractionation itself, identification reports were 
merged for the five consecutive fractions as described in the previous section (see 
3.5.2). Finally, the percentages of peptides identified once, twice, and three times 
were computed. The results are depicted in pie-charts in Fig. 103.  
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Fig. 102. Repeatability of separation and fractionation with the Gemini column. Each 
pie-chart corresponds to one fraction collected in triplicate after the C18 column, and 
analyzed in quintuplicate with IP-RP-HPLC-ESI-MS/MS. The percentages 
correspond to the amount of peptides identified once, twice, or three times. 
 
 
Fig. 103. Repeatability of the separation and fractionation step with the C18 Gemini 
column. Pie-chart on the left side represents the average repeatability observed for 
five fractions. Pie-chart on the right side corresponds to the repeatability obtained 
after a merge of the same five fractions. 
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By merging the identification reports, 4 % more peptides (46 % instead of 42 %) were 
identified in all three replicates. This result is very similar to those obtained with 
cation exchangers (46 % instead of 42 % with ProPacTM SCX-10, and 48 % instead 
of 45 % with PolySULFOETHYL). It permits to conclude the inaccuracies, that occur 
during the separation and fractionation step with the new RP x IP-RP-HCLC setup, 
are equivalent to those made with classical SCX x IP-RP-HPLC setups. 
 
3.6 Dimension orthogonality 
For both setups, the orthogonality between the two dimensions of separation was 
evaluated. This can be relatively easily represented in a plot by depicting each 
peptide hit as a function of its retention time in both chromatographic dimensions 
[142;143]. In such a plot, the x-axis represents the retention time of the first dimension of 
separation, and the y-axis represents the retention time of the second dimension of 
separation. Because fractions were collected at relatively small intervals (0.25 – 1.00 
min), the retention time of a peptide in the first dimension of separation approximately 
corresponds to the middle point of the collection time window of the fraction in which 
the peptide was identified. Such plots were computed for the classical SCX x IP-RP-
HPLC and the new RP x IP-RP-HPLC approaches. They are depicted in Fig. 104 and 
in Fig. 105.  
The data used to plot the maps are presented in sections 3.2 and 3.3. The sample 
was a tryptic digest of a protein cell extract of C. glutamicum. Redundancies within a 
fraction are not depicted, but peptides identified in different fractions are taken into 
account. In case of redundant identifications for peptides within a fraction, the 
retention time retained to plot the map corresponds to the retention time of the 
peptide with the best identification (highest MOWSE score). To identify peptides, 
peaks were integrated in the chromatogram of the second dimension of separation 
(IP-RP-HPLC at pH 2.1, y-axis) until the peak corresponding to the wash peak and 
regeneration of the column. It explains the clear-cut peptide distribution at 65 min and 
72 min in Fig. 104 and in Fig. 105, respectively. 
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Fig. 104. Orthogonality map obtained for the SCX x IP-RP-HPLC approach. Each 
peptide hit is represented as a cross. The 6,254 peptide hits used to plot the map are 
presented in sections 3.2 and 3.3. 
 
Fig. 105. Orthogonality map obtained for the alkaline RP-HPLC x acidic IP-RP-HPLC 
approach. Each peptide hit is represented as a cross. The 3,124 peptide hits used to 
plot the map are presented in sections 3.2 and 3.3. 
 
In the case of the SCX x IP-RP-HPLC approach, a very good orthogonality is 
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density of the peptide distribution in the first 7 min of the SCX separation in 
comparison with the following 6 min and the last 8 min is explained by the collection 
of fractions at increasing periods (24 x 0.25 min, 12 x 0.50 min, and 8 x 1.00 min). A 
small zone for fractions collected between minutes 3 and 6 does not contain any hits. 
During this period of time, a steep decrease in the number of identified peptides is 
observed. It corresponds to a salt concentration at which 2+ peptides have already 
been eluted and 3+ peptides are still retained on the cation exchanger (see Fig. 91). 
In the RP-HPLC separation scheme under basic and acid conditions, peptide hits are 
also well dispersed over the diagram map. However, a clear trend is observed. The 
later the elution in the first dimension, the later the elution in the second dimension. It 
reveals that despite the use of different pH (10.0 vs. 2.1) and different stationary 
phases (silica-based C18 vs. PS-DVB), both dimensions of separation are not truly 
orthogonal. This result has been expected: the elution was performed for both 
separations by performing a linear gradient of acetonitrile. The orthogonality of the 
two RP dimensions should be increased by combining basic and acidic conditions 
with different eluents (acetonitrile vs. methanol). 
Despite a lower orthogonality, the RP x IP-RP-HPLC setup permitted to identify 
significantly more peptides than the classical SCX x IP-RP-HPLC approach (see 3.3 
Proteome coverage). The fact that both RP dimensions are not truly orthogonal does 
not seem to be a critical factor. The increase in terms of fraction homogeneity and 
sample decomplexification appears to be much more relevant than dimension 
orthogonality to better identify peptides. 
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3.7 Complementarity of SCX x IP-RP-HPLC and RP x IP-RP-
HPLC methods 
Peptide identification reports obtained with both 2D-HPLC-MS/MS setups were 
compared (see section 3.3 Proteome coverage). A nonredundant list of identified 
peptides was extracted from these two identification reports and Σ 3,659 unique 
peptides were identified. Peptides were finally classified into three categories: 
peptides only identified with the SCX x IP-RP-HPLC setup (Σ 951 peptides), peptides 
only identified with the RP x IP-RP-HPLC system (Σ 1,262 peptides), and peptides 
identified with both setups (Σ 1,447 peptides). The results are depicted in Fig. 106.  
Fig. 106. Intersection diagram of peptides of C. glutamicum identified with a classical 
SCX x IP-RP-HPLC setup and a new RP x IP-RP-HPLC setup. 
 
Peptides detected with only one single setup are representing 60.5 % of the identified 
peptides (SCX \ RP: 26.0 %, and RP \ SCX: 34.5 %). Only 39.5 % of the peptides 
were detected with both setups and at first sight both methods are complementary. 
Thus performing an analysis of C. glutamicum with RP x IP-RP-HPLC in addition to a 
classical SCX x IP-RP-HPLC analysis permits an increase of 52.6 % in terms of 
unique identified peptides (3,659 vs. 2,398). However, the identification of Σ 3,659 
peptides was performed with six analyses in the second separation step, and no 
longer with three replicates. The supplementary identifications are due to additional 
injections in the IP-RP-HPLC-ESI-MS/MS system but also to the complementarity of 
both methods of separation. In order to check the percentage of additional 
identifications just obtained by increasing the number of analyses, an extrapolation of 
Fig. 97 was computed. By three from a total of five replicates, 87 % of the peptides 
are identified with the IP-RP-HPLC-ESI-MS/MS setup. By three from a total of six 
new RP
approach
1,262951
SCX  \  RP-HPLC: 26.0 %
RP-HPLC  \  SCX: 34.5 %
SCX     RP-HPLC: 39.5 %U
classical SCX
approach
identification of 
3,659 unique 
peptides
1,447
Chapter V: 2D-HPLC-MS systems for proteome analysis  
   
174   
replicates, a rigorous estimation is that 80 % of the peptides are identified. With this 
approximation, the 2,398 peptides identified by means of three replicates represent 
approximately 80 % of the peptides possibly identified by performing six replicate 
injections in the classical SCX x IP-RP-HPLC setup. It is then possible to compute 
the theoretical number of peptides identified by performing six replicate injections in 
the classical SCX x IP-RP-HPLC setup (~ 2,998). The percent of peptides 
additionally identified for reason of the complementarity of both setups is obtained by 
computing: 
100
16
163 ⋅−
setupinreplicateswithtionsidentifica
setupinreplicateswithtionsidentificasetupeachininjectionswithtionsidentifica  
The gain in terms of peptide identification due to the complementarity of both setups 
was evaluated to 22 %. This signifies that the analysis in triplicate of one sample with 
two different setups is more advantageous than the analysis in sextuplicate with one 
setup. 
 
Identification reports at the protein level were also compared and the numbers of 
proteins identified with one setup or with both setups were computed. The results are 
depicted in Fig. 107. By combining both setups 871 unique proteins were identified 
(the list is available as appendix). This value corresponds to 29.1 % of the possibly 
expressed proteins in C. glutamicum (see 3.3 Proteome coverage). The combination 
of the new RP x IP-RP-HPLC setup with the classical SCX x IP-RP-HPLC setup 
permitted to increase the amount of unique identified proteins by 25 % (695 vs. 871). 
126 proteins were just identified with SCX x IP-RP-HPLC and 176 proteins were just 
identified with RP x IP-RP-HPLC. The amount of proteins identified with both setups 
is rather high (65.3 %) in comparison with the amount of peptides identified with both 
setups (39.5 %). This is explained by the fact that different peptides may lead to the 
identification of one single protein. Consequently, the number of proteins identified 
with more than one peptide increases by combining both setups. A commonly 
accepted criterion for the identification of a protein is the necessity to detect more 
than one single peptide from the protein sequence [149;150]. 414 proteins fulfill this 
criterion in the SCX x IP-RP-HPLC approach and 468 proteins with the RP x IP-RP-
HPLC setup (see 3.4 Identification confidence). By combining both methods, 585 
proteins are identified by at least two peptides, which corresponds to a gain of 41 % 
as compared with a single analysis based with the SCX x IP-RPHPLC setup. To sum 
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up, the combination of both methods of analysis does not only increase the amount 
of identified proteins but also leads to significantly more confident identifications. 
Fig. 107. Intersection diagram of proteins of C. glutamicum identified with a classical 
SCX x IP-RP-HPLC setup and a new RP x IP-RP-HPLC setup. 
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3.8 Ability of 2D-HPLC setups to analyze proteomes 
The aim of this work was to develop and evaluate multi-dimensional HPLC-MS 
systems and not to compare them with other systems of separation such as two-
dimensional gel electrophoresis. However, in order to illustrate that the 2D-HPLC 
systems developed in this work are not discriminating against proteins of particular pI 
or molecular mass, the proteins identified with both 2D-HPLC setups were plotted in 
a MW = f(pI) diagram (see Fig. 108a). A similar diagram was also plotted for the 
whole proteins potentially expressed in C. glutamicum (see Fig. 108b).  
 
Fig. 108. MW=f(pI) plots representing the (a) identified proteins with both 2D-HPLC 
setups and (b) the potentially expressed proteins of C. glutamicum. 
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A similar pattern was obtained for both cases, proving that the 2D-HPLC-ESI-MS/MS 
methods can be used to analyze complete proteomes and not only sets of proteins of 
particular properties. Finally the amount of enzymes detected by combining both two-
dimensional HPLC setups was computed. Enzymes are proteins of particular 
interest. Their expression or absence in a protein cell extract gives indeed useful 
data to understand the metabolic or biosynthetic pathways taking place in the 
production of analytes of interest (e.g. L-glutamate and L-lysine for C. glutamicum) 
[152;153]. 334 enzymes were identified. It corresponds to 56.7 % of the whole possibly 
expressed enzymes in C. glutamicum, proving the ability of the 2D-HPLC-ESI-
MS/MS setups to analyze whole proteomes in the frame of biologically relevant 
challenges. The detection of enzymes studied in an already published work about the 
production of L-lysine [153] with C. glutamicum ATCC 13287 (mutant) was checked. 
Enzymes involved in central carbon metabolism, energy metabolism, and respiratory 
chain were detected (see Tab. 13). 
Tab. 13. Biologically relevant enzymes of C. glutamicum detected by 2D-HPLC-ESI-
MS-MS. 
locus enzyme description
NCgl2553 phosphotransferase system IIC component [2.7.1.69]
NCgl0817 glucose-6-phosphate isomerase [5.3.1.9]
NCgl1202 6-phosphofructokinase [2.7.1.11]
NCgl2673 fructose-bisphosphate aldolase [4.1.2.13]
NCgl1524 triosephosphate isomerase [5.3.1.1]
NCgl1526 glyceraldehyde-3-phosphate dehydrogenase [1.2.1.12]
NCgl0630 citrate synthase [4.1.3.7]
NCgl1482 aconitase A [4.2.1.3]
NCgl0634 monomeric isocitrate dehydrogenase (NADP+) [1.1.1.42]
NCgl1084 2-oxoglutarate dehydrogenases, E1 component [1.2.4.2]
NCgl2477 succinyl-CoA synthetase beta subunit [6.2.1.5]
NCgl0967 fumarase [4.2.1.2]
NCgl2297 malate/lactate dehydrogenase [1.1.1.37]
NCgl1514 glucose-6-phosphate 1-dehydrogenase [1.1.1.49]
NCgl1516 6-phosphogluconolactonase [3.1.1.31]
NCgl1396 6-phosphogluconate dehydrogenase, family 1 [1.1.1.44]
NCgl1513 transaldolase [2.2.1.2]
NCgl1512 transketolase [2.2.1.1]
NCgl0659 pyruvate carboxylase [6.4.1.1]
NCgl1523 phosphoenolpyruvate carboxylase [4.1.1.31]
NCgl2765 phosphoenolpyruvate carboxykinase (GTP) [4.1.132]
NCgl2904 malic enzyme [1.1.1.40]
NCgl2247 malate synthase [4.1.3.2]
NCgl1162 F0F1-type ATP synthase delta subunit [3.6.1.34]
NCgl2437 heme/copper-type cytochrome/quinol oxidase, subunit 1 [1.9.3.1]
anaplerosis
ATP formation
respiratory chain
phosphotransferase uptake
glycolysis
Krebs cycle
pentose phosphate pathway
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4 Conclusions 
A classical SCX x IP-RP-HPLC setup was established in order to analyze very 
complex mixtures of peptides. Fractions were collected after the cation exchanger 
and peptides were separated with IP-RP-HPLC at pH 2.1 in the second dimension. 
The number of positive charges carried by the peptides appears to be the crucial 
parameter for the retention of peptides on the cation exchanger. The addition of 
acetonitrile in the eluents permits to suppress secondary interactions (hydrophobic 
interactions) between the peptides and the cation exchanger. A quite good 
repeatability in terms of peptide identification was obtained (by quintuplicate 
injections 54.0 % of the peptides are identified three or more times). Triplicate 
analyses appear to be a good compromise in terms of peptide identification and time 
consumption. A new two-dimensional HPLC-ESI-MS/MS setup was developed for 
proteome analysis. It consisted of a peptide separation by RP-HPLC under basic 
conditions (pH 10.0) followed by IP-RP-HPLC under acidic conditions (pH 2.1). 
Although triethylamine was used to set the alkaline pH, ion-pair mechanism is not 
taking place during the separation and solvophobic interactions are determining the 
peptide retention (insufficient triethylamine concentration for ion-pair mechanism). 
Because the second separation step was identical in both setups, it was possible to 
compare the first dimension of both methods (SCX vs. RP-HPLC at pH 10.0) with 
each other. The repeatability of the separations is similar with both setups. The 
orthogonality between methods of separation is higher in the SCX x IP-RP-HPLC 
approach than in the RP x IP-RP-HPLC scheme. However, the better peptide 
distribution and the better separation efficiency achieved with the RP x IP-RP-HPLC 
setup permitted to identify significantly more peptides than with the classical SCX x 
IP-RP-HPLC setup. Both approaches are complementary and consequently a 
combination of both setups permits to identify more peptides than replicate injections 
performed with a single setup. Both setups are not discriminating against pI and 
molecular weight of the proteins. Finally, the computation of the number of identified 
enzymes reveals the ability of the 2D-HPLC-ESI-MS/MS setups to analyze whole 
proteomes in the frame of biologically relevant challenges. 
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1 NCgl0245 isopropylmalate/homocitrate/citramalate synthase [4.1.3.12] 68,435 54,752 
2 NCgl1094 methionine synthase II [2.1.1.14] 81,611 44,876 
3 NCgl0480 elongation factor Tu 43,998 30,315 
4 NCgl1235 phosphoglycerate dehydrogenase [1.1.1.95] 55,384 20,050 
5 NCgl1304 ribosomal protein S1 53,998 16,733 
6 NCgl0935 enolase [4.2.1.11] 44,979 15,515 
7 NCgl1255 glucan phosphorylase [2.4.1.1] 90,728 14,740 
8 NCgl0802 fatty-acid synthase [2.3.1.85] 315,398 13,985 
9 NCgl0478 elongation factor G 78,075 12,933 
10 NCgl2167 pyruvate dehydrogenase, decarboxylase component [1.2.4.1] 102,820 10,644 
11 NCgl1950 ribosomal protein S2 30,158 10,256 
12 NCgl0460 ribosomal protein L1 25,031 10,120 
13 NCgl0472 DNA-directed RNA polymerase beta subunit/160 kD subunit [2.7.7.6] 147,899 9,584 
14 NCgl2673 fructose-bisphosphate aldolase [4.1.2.13] 37,365 9,527 
15 NCgl0490 ribosomal protein L2 31,164 9,116 
16 NCgl1165 F0F1-type ATP synthase beta subunit [3.6.1.34] 52,621 8,439 
17 NCgl0488 ribosomal protein L4 23,594 7,854 
18 NCgl2375 ABC-type transporter, periplasmic component 49,475 7,609 
19 NCgl0520 ribosomal protein L15 15,417 7,387 
20 NCgl1084 2-oxoglutarate dehydrogenases, E1 component [1.2.4.2] 138,844 7,151 
21 NCgl0954 glycine hydroxymethyltransferase [2.1.2.1] 46,570 7,110 
22 NCgl2702 70 kDa heat shock chaperonin protein 66,247 7,062 
23 NCgl0541 ribosomal protein L17 17,507 6,920 
24 NCgl0659 pyruvate carboxylase [6.4.1.1] 123,433 6,787 
25 NCgl2826 superoxide dismutase [1.15.1.1] 22,088 6,430 
26 NCgl0670 acyl-CoA carboxylase [6.3.4.14] 63,554 6,372 
27 NCgl2621 chaperonin GroEL 57,319 6,036 
28 NCgl0795 citrate synthase [4.1.3.7] 48,956 6,021 
29 NCgl2894 myo-inositol-1-phosphate synthase 39,373 5,938 
30 NCgl1163 F0F1-type ATP synthase alpha subunit [3.6.1.34] 60,149 5,726 
31 NCgl1409 NADH dehydrogenase, FAD-containing subunit [1.6.99.3] 51,042 5,708 
32 NCgl1999 glutamate dehydrogenase/leucine dehydrogenase [1.4.1.4] 49,363 5,701 
33 NCgl0725 ribosome-associated protein Y 24,558 5,481 
34 NCgl0754 pyridoxine biosynthesis enzyme 33,635 5,405 
35 NCgl1512 transketolase [2.2.1.1] 75,222 5,231 
36 NCgl0539 ribosomal protein S4 23,314 5,157 
37 NCgl1482 aconitase A [4.2.1.3] 102,510 5,126 
38 NCgl1346 argininosuccinate synthase [6.3.4.5] 44,223 5,060 
39 NCgl0491 ribosomal protein S19 10,454 4,944 
40 NCgl0634 monomeric isocitrate dehydrogenase (NADP+) [1.1.1.42] 80,148 4,770 
41 NCgl2409 3-oxoacyl-(acyl-carrier-protein) synthase [2.3.1.85] 316,847 4,739 
42 NCgl1524 triosephosphate isomerase [5.3.1.1] 27,360 4,598 
43 NCgl0540 DNA-directed RNA polymerase alpha subunit/40 kD subunit [2.7.7.6] 36,706 4,482 
44 NCgl1976 ribosomal protein S16 17,826 4,448 
45 NCgl0556 ribosomal protein L13 16,328 4,430 
46 NCgl0572 co-chaperonin GroES 10,763 4,290 
47 NCgl0487 ribosomal protein L3 23,203 4,247 
48 NCgl2133 glutamine synthase [6.3.1.2] 53,383 4,075 
49 NCgl0286 cAMP-binding domain containing protein 25,030 4,014 
50 NCgl0355 dihydrolipoamide dehydrogenase/glutathione oxidoreductase-like protein [1.8.1.4] 50,852 3,951 
51 NCgl0827 phosphoribosylaminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase [2.1.2.3] 56,015 3,942 
52 NCgl2008 pyruvate kinase [2.7.1.40] 51,671 3,825 
53 NCgl2480 acetyl-CoA hydrolase [2.8.3.-] 54,541 3,686 
54 NCgl2377 ABC-type transporter, ATPase component 40,348 3,624 
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55 NCgl1525 3-phosphoglycerate kinase [2.7.2.3] 42,787 3,623 
56 NCgl0471 DNA-directed RNA polymerase beta subunit/140 kD subunit [2.7.7.6] 128,199 3,509 
57 NCgl0537 ribosomal protein S13 13,884 3,372 
58 NCgl2473 cysteine synthase [4.2.99.8] 33,449 3,361 
59 NCgl1949 translation elongation factor Ts 29,320 3,271 
60 NCgl0837 ribosomal protein L31 10,003 3,173 
61 NCgl0469 ribosomal protein L7/L12 13,293 3,138 
62 NCgl1858 phosphoenolpyruvate-protein kinase [2.7.3.9] 59,977 3,082 
63 NCgl2198 class II glycyl-tRNA synthetase [6.1.1.14] 53,243 3,069 
64 NCgl2217 4-alpha-glucanotransferase [2.4.1.25] 78,881 3,019 
65 NCgl1513 transaldolase [2.2.1.2] 38,363 3,017 
66 NCgl0493 ribosomal protein S3 28,150 3,007 
67 NCgl0967 fumarase [4.2.1.2] 49,849 2,943 
68 NCgl0494 ribosomal protein L16/L10E 15,777 2,921 
69 NCgl0496 ribosomal protein S17 10,574 2,876 
70 NCgl2126 dihydrolipoamide acyltransferase [2.3.1.61] 70,862 2,870 
71 NCgl0390 phosphoglycerate mutase 1 [5.4.2.1] 27,287 2,844 
72 NCgl1224 ketol-acid reductoisomerase [1.1.1.86] 36,252 2,838 
73 NCgl0033 peptidyl-prolyl cis-trans isomerase (rotamase) [5.2.1.8] 20,111 2,837 
74 NCgl0492 ribosomal protein L22 12,962 2,831 
75 NCgl1136 homoserine dehydrogenase [1.1.1.3] 46,526 2,825 
76 NCgl2048 methionine synthase II [2.1.1.14] 44,042 2,768 
77 NCgl1385 FHA-domain-containing protein 15,393 2,735 
78 NCgl0303 cold shock protein 7,286 2,690 
79 NCgl2715 sulfate adenylate transferase subunit 1 46,901 2,659 
80 NCgl0794 phosphoserine aminotransferase [2.6.1.52] 40,137 2,617 
81 NCgl2340 aminopeptidase N [3.4.11.2] 96,326 2,603 
82 NCgl1523 phosphoenolpyruvate carboxylase [4.1.1.31] 103,308 2,491 
83 NCgl0579 putative inosine-5-monophosphate dehydrogenase 39,862 2,491 
84 NCgl0582 GMP synthase [6.3.5.2] 56,242 2,386 
85 NCgl0677 detergent sensitivity rescuer dtsR2 58,308 2,385 
86 NCgl2293 valyl-tRNA synthetase [6.1.1.9] 101,754 2,380 
87 NCgl0468 ribosomal protein L10 17,945 2,343 
88 NCgl0516 ribosomal protein L6 19,324 2,336 
89 NCgl2360 cystathionine gamma-synthase [4.2.99.9] 41,806 2,314 
90 NCgl0247 aspartokinase [2.7.2.4] 44,959 2,285 
91 NCgl1547 carbamoylphosphate synthase large subunit [6.3.5.5] 120,600 2,262 
92 NCgl1926 predicted dehydrogenase [1.1.99.16] 54,972 2,246 
93 NCgl0517 ribosomal protein L18 14,736 2,243 
94 NCgl2191 glucosamine 6-phosphate synthetase [2.6.1.16] 67,464 2,190 
95 NCgl2719 putative ferredoxin/ferredoxin-NADP reductase 50,157 2,161 
96 NCgl2329 FKBP-type peptidyl-prolyl cis-trans isomerase 49,726 2,151 
97 NCgl1222 thiamine pyrophosphate-requiring enzyme [4.1.3.18] 67,036 2,129 
98 NCgl2585 ATPase with chaperone activity, ATP-binding subunit 101,451 2,115 
99 NCgl0578 inosine monophosphate dehydrogenase [1.1.1.205] 53,559 2,113 
100 NCgl2494 phosphoribosylaminoimidazol (AIR) synthetase [6.3.3.1] 38,233 2,036 
101 NCgl0313 class III Zn-dependent alcohol dehydrogenase [1.2.1.-] 39,365 2,014 
102 NCgl0807 hypothetical protein 10,143 2,002 
103 NCgl0499 ribosomal protein L14 13,388 1,997 
104 NCgl2879 ribosomal protein L9 15,930 1,966 
105 NCgl2582 L-2.3-butanediol dehydrogenase 27,047 1,932 
106 NCgl0345 UDP-N-acetylglucosamine enolpyruvyl transferase [2.5.1.7] 47,255 1,912 
107 NCgl1041 peroxiredoxin [1.11.1.-] 17,970 1,912 
108 NCgl0248 aspartate-semialdehyde dehydrogenase [1.2.1.11] 36,306 1,911 
109 NCgl0237 aspartate transaminase [2.6.1.1] 46,605 1,901 
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110 NCgl2499 phosphoribosylformylglycinamidine (FGAM) synthase, synthetase domain [6.3.5.3] 81,430 1,883 
111 NCgl2915 leucyl-tRNA synthetase 106,886 1,882 
112 NCgl0477 ribosomal protein S7 17,528 1,866 
113 NCgl0501 ribosomal protein L5 21,775 1,814 
114 NCgl2165 hypothetical protein 15,476 1,799 
115 NCgl1557 translation elongation factor P 20,628 1,767 
116 NCgl2280 ribosomal protein L21 10,852 1,766 
117 NCgl0976 putative fructose-1,6-bisphosphatase/sedoheptulose 1,7-bisphosphatase 35,521 1,731 
118 NCgl1262 3-isopropylmalate dehydratase large subunit [4.2.1.33] 52,020 1,729 
119 NCgl0251 catalase [1.11.1.6] 58,731 1,716 
120 NCgl0719 S-adenosylhomocysteine hydrolase [3.3.1.1] 52,624 1,704 
121 NCgl2509 adenylosuccinate lyase [4.3.2.2] 52,319 1,693 
122 NCgl1871 hypothetical protein 50,498 1,690 
123 NCgl0625 O-acetylhomoserine sulfhydrylase [4.2.99.10] 46,724 1,684 
124 NCgl2765 phosphoenolpyruvate carboxykinase (GTP) [4.1.1.32] 67,238 1,660 
125 NCgl1573 aspartyl-tRNA synthetase [6.1.1.12] 67,201 1,627 
126 NCgl2287 nucleoside diphosphate kinase [2.7.4.6] 14,791 1,591 
127 NCgl1900 polyribonucleotide nucleotidyltransferase [2.7.7.8] 81,395 1,565 
128 NCgl2443 ribonucleotide reductase alpha subunit 81,433 1,557 
129 NCgl1396 6-phosphogluconate dehydrogenase, family 1 [1.1.1.44] 51,818 1,506 
130 NCgl0610 ABC-type transporter, periplasmic component 31,780 1,505 
131 NCgl0515 ribosomal protein S8 14,282 1,505 
132 NCgl2793 seryl-tRNA synthetase [6.1.1.11] 46,616 1,501 
133 NCgl1501 ABC-type transporter, ATPase component 27,623 1,475 
134 NCgl1910 translation initiation factor 2 103,523 1,455 
135 NCgl2669 adenylosuccinate synthase [6.3.4.4] 46,914 1,430 
136 NCgl0671 thiosulfate sulfurtransferase [2.8.1.1] 33,531 1,419 
137 NCgl1244 glutamyl- and glutaminyl-tRNA synthetases [6.1.1.17] 55,414 1,399 
138 NCgl2328 ATP-dependent Clp protease proteolytic subunit 1 [3.4.21.92] 21,253 1,394 
139 NCgl2500 phosphoribosylformylglycinamidine (FGAM) synthase, glutamine amidotransferase domain [6.3.5.3] 23,641 1,394 
140 NCgl2579 carbonic anhydrase [4.2.1.1] 22,331 1,387 
141 NCgl1886 phage shock protein A (IM30) 30,411 1,380 
142 NCgl2747 PLP-dependent aminotransferase [2.6.1.1] 48,899 1,380 
143 NCgl0533 adenylate kinase [2.7.4.3] 19,415 1,376 
144 NCgl1219 dihydroxyacid dehydratase/phosphogluconate dehydratase 65,213 1,373 
145 NCgl1607 threonyl-tRNA synthetase [6.1.1.3] 76,933 1,363 
146 NCgl2521 thiamine pyrophosphate-requiring enzyme [1.2.2.2] 62,375 1,362 
147 NCgl1915 ABC-type transporter, periplasmic component 57,711 1,349 
148 NCgl0658 dihydrolipoamide dehydrogenase [1.8.1.4] 49,800 1,326 
149 NCgl1545 hypothetical protein 11,860 1,321 
150 NCgl1456 hypothetical protein 14,245 1,298 
151 NCgl0880 hypothetical protein 37,649 1,279 
152 NCgl0500 ribosomal protein L24 11,182 1,267 
153 NCgl0817 glucose-6-phosphate isomerase [5.3.1.9] 59,130 1,264 
154 NCgl1024 quinolinate synthase [1.4.3.-] 47,000 1,261 
155 NCgl1152 transcription termination factor 83,976 1,259 
156 NCgl2337 ribose 5-phosphate isomerase RpiB [5.3.1.26] 17,151 1,258 
157 NCgl1177 1,4-alpha-glucan branching enzyme [2.4.1.18] 82,715 1,254 
158 NCgl2530 predicted hydrolase of the HAD superfamily 29,633 1,252 
159 NCgl1053 predicted membrane GTPase involved in stress response 68,775 1,246 
160 NCgl2449 putative Zn-NADPH,quinone dehydrogenase [1.1.1.1] 35,877 1,245 
161 NCgl0558 phosphomannomutase 46,441 1,238 
162 NCgl2368 ABC-type transporter, duplicated ATPase component 62,336 1,232 
163 NCgl2297 malate/lactate dehydrogenase [1.1.1.37] 34,887 1,219 
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164 NCgl0573 chaperonin GroEL 56,711 1,200 
165 NCgl0486 ribosomal protein S10 11,463 1,189 
166 NCgl2261 ribosomal protein S20 9,547 1,189 
167 NCgl0905 phosphoribosylpyrophosphate synthetase [2.7.6.1] 35,818 1,185 
168 NCgl1164 F0F1-type ATP synthase gamma subunit [3.6.1.34] 35,718 1,185 
169 NCgl2586 inositol-monophosphate dehydrogenase 50,903 1,162 
170 NCgl2475 predicted acetyltransferase 10,681 1,158 
171 NCgl2068 isoleucyl-tRNA synthetase [6.1.1.5] 117,621 1,148 
172 NCgl0171 cold shock protein 7,283 1,147 
173 NCgl2810 L-lactate dehydrogenase [1.1.1.27] 34,500 1,142 
174 NCgl2098 3-Deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) synthase 51,587 1,142 
175 NCgl1570 alanyl-tRNA synthetase [6.1.1.7] 96,456 1,129 
176 NCgl1223 acetolactate synthase, small subunit [4.1.3.18] 18,737 1,123 
177 NCgl0776 ABC-type cobalamin/Fe3+-siderophore transport system, periplasmic component 35,726 1,118 
178 NCgl1202 6-phosphofructokinase [2.7.1.11] 37,614 1,117 
179 NCgl1947 ribosome recycling factor 20,736 1,102 
180 NCgl1336 phenylalanyl-tRNA synthetase beta subunit [6.1.1.20] 89,729 1,101 
181 NCgl0518 ribosomal protein S5 22,714 1,094 
182 NCgl1503 predicted iron-regulated ABC-type transporter SufB 53,633 1,091 
183 NCgl1561 chorismate synthase [4.6.1.4] 43,764 1,088 
184 NCgl2116 asparagine synthase 72,517 1,079 
185 NCgl0317 nucleoside-diphosphate-sugar epimerase 33,574 1,063 
186 NCgl1676 hypothetical protein 13,220 1,059 
187 NCgl0489 ribosomal protein L23 11,081 1,056 
188 NCgl0620 5,10-methylene-tetrahydrofolate dehydrogenase [1.5.1.5] 30,363 1,056 
189 NCgl2015 phosphoribosylformimino-5-aminoimidazole carboxamide ribonucleotide (ProFAR) isomerase [5.3.1.16] 26,651 1,046 
190 NCgl0134 hypothetical protein 62,509 1,041 
191 NCgl0388 acyl-CoA synthetase [6.2.1.3] 62,706 1,024 
192 NCgl0726 preprotein translocase subunit SecA 95,461 1,014 
193 NCgl1353 universal stress protein UspA 16,160 1,008 
194 NCgl2508 phosphoribosylaminoimidazolesuccinocarboxamide (SAICAR) synthase [6.3.2.6] 33,260 988 
195 NCgl2698 NAD-dependent aldehyde dehydrogenase [1.2.1.3] 55,246 987 
196 NCgl1960 ribosomal protein L19 12,867 985 
197 NCgl2682 ATPase with chaperone activity, ATP-binding subunit 93,174 973 
198 NCgl0226 hypothetical protein 7,072 969 
199 NCgl0005 DNA gyrase (topoisomerase II) B subunit [5.99.1.3] 76,082 964 
200 NCgl2718 putative nitrite reductase 63,302 956 
201 NCgl1320 hypothetical protein 33,325 955 
202 NCgl1472 methylmalonyl-CoA mutase, N-terminal domain/subunit [5.4.99.2] 65,566 949 
203 NCgl1352 tyrosyl-tRNA synthetase [6.1.1.1] 46,532 944 
204 NCgl0834 ribosomal protein L28 8,884 936 
205 NCgl1541 S-adenosylmethionine synthetase [2.5.1.6] 44,265 912 
206 NCgl2123 branched-chain amino acid aminotransferase [2.6.1.42] 40,454 912 
207 NCgl2773 putative polyketide synthase 172,491 908 
208 NCgl1343 PLP-dependent aminotransferase [2.6.1.11] 41,470 905 
209 NCgl2511 phosphoribosylamine-glycine ligase [6.3.4.13] 43,750 899 
210 NCgl2555 glucosamine-6-phosphate isomerase [5.3.1.10] 27,435 889 
211 NCgl0351 predicted UDP-glucose 6-dehydrogenase [1.1.1.22] 43,030 879 
212 NCgl0187 FAD/FMN-containing dehydrogenase 53,087 879 
213 NCgl1845 Mn-dependent transcriptional regulator 25,527 871 
214 NCgl2026 pullulanase 94,565 870 
215 NCgl0002 DNA polymerase III beta subunit [2.7.7.7] 42,557 867 
216 NCgl0012 DNA gyrase (topoisomerase II) A subunit [5.99.1.3] 94,918 859 
217 NCgl1211 Asp-tRNAAsn/Glu-tRNAGln amidotransferase B subunit 54,548 851 
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218 NCgl2365 predicted thioesterase 17,584 839 
219 NCgl0495 ribosomal protein L29 8,760 829 
220 NCgl2886 transcriptional regulator 17,958 829 
221 NCgl1263 3-isopropylmalate dehydratase small subunit [4.2.1.33] 22,185 829 
222 NCgl2077 UDP-N-acetylmuramate-alanine ligase [6.3.2.8] 51,135 824 
223 NCgl1335 phenylalanyl-tRNA synthetase alpha subunit [6.1.1.20] 38,508 801 
224 NCgl1996 hypothetical protein 29,569 795 
225 NCgl2774 putative acyl-CoA synthetase 67,873 785 
226 NCgl2628 hypothetical protein 131,909 777 
227 NCgl2620 hypotheical protein 36,079 775 
228 NCgl1305 phosphotransferase system IIC component, glucose/maltose/N-acetylglucosamine-specific 72,699 772 
229 NCgl0385 hypothetical protein 17,819 758 
230 NCgl1982 nitrogen regulatory protein PII 12,240 757 
231 NCgl2269 hypothetical protein 17,959 757 
232 NCgl1423 glycosyltransferase 30,115 754 
233 NCgl1132 arginyl-tRNA synthetase [6.1.1.19] 59,802 753 
234 NCgl1502 predicted iron-regulated ABC-type transporter SufB 42,370 752 
235 NCgl1585 histidyl-tRNA synthetase [6.1.1.21] 47,271 748 
236 NCgl1448 phosphoribosyl-ATP pyrophosphohydrolase [3.6.1.31] 9,816 740 
237 NCgl1073 ADP-glucose pyrophosphorylase [2.7.7.27] 43,949 728 
238 NCgl2737 putative membrane protease subunit 34,823 726 
239 NCgl1182 electron transfer flavoprotein beta-subunit 27,204 716 
240 NCgl2716 sulfate adenylyltransferase subunit 2 34,384 708 
241 NCgl1938 gcpE-like protein 41,815 704 
242 NCgl2984 thioredoxin reductase [1.6.4.5] 34,408 703 
243 NCgl0519 ribosomal protein L30/L7E 6,859 695 
244 NCgl2904 malic enzyme [1.1.1.40] 41,024 691 
245 NCgl0186 putative dehydrogenase 26,706 688 
246 NCgl1835 transcriptional regulator [2.7.1.63] 26,671 679 
247 NCgl2259 membrane GTPase LepA 68,911 676 
248 NCgl2806 hypothetical protein 31,744 676 
249 NCgl0857 methionyl-tRNA synthetase [6.1.1.10] 67,867 672 
250 NCgl2973 hydroxymethylpyrimidine/phosphomethylpyrimidine kinase 28,217 670 
251 NCgl0328 nitroreductase [1.6.99.3] 21,209 669 
252 NCgl1890 hypothetical protein 10,601 663 
253 NCgl2277 aldo/keto reductase [1.1.1.-] 31,038 656 
254 NCgl1153 protein chain release factor A 39,711 654 
255 NCgl1836 DNA-directed RNA polymerase sigma subunit SigA 54,738 653 
256 NCgl1901 ribosomal protein S15P/S13E 10,304 647 
257 NCgl0811 inositol monophosphatase family protein 27,555 646 
258 NCgl2528 D-2-hydroxyisocaproate dehydrogenase 35,351 630 
259 NCgl1347 argininosuccinate lyase [4.3.2.1] 51,126 627 
260 NCgl1162 F0F1-type ATP synthase delta subunit [3.6.1.34] 28,865 624 
261 NCgl2279 ribosomal protein L27 9,435 621 
262 NCgl2453 phosphoglucomutase [5.4.2.2] 59,229 610 
263 NCgl1321 hypothetical protein 21,953 609 
264 NCgl2327 ATP-dependent Clp protease proteolytic subunit 2 [3.4.21.92] 23,081 609 
265 NCgl1980 signal recognition particle GTPase 58,356 606 
266 NCgl2045 1,4-alpha-glucan branching enzyme 65,812 600 
267 NCgl1057 ferredoxin 3 11,946 597 
268 NCgl0032 hypothetical protein 29,405 584 
269 NCgl1123 hypothetical protein 19,283 583 
270 NCgl1371 16S rRNA uridine-516 pseudouridylate synthase [4.2.1.70] 35,783 572 
271 NCgl2216 long-chain acyl-CoA synthetase (AMP-forming) [6.2.1.3] 67,134 572 
272 NCgl2289 predicted acetyltransferase 12,646 566 
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273 NCgl2881 ribosomal protein S6 11,010 565 
274 NCgl0946 transcription elongation factor 18,803 560 
275 NCgl2656 acetate kinase [2.7.2.1] 43,123 556 
276 NCgl0562 hypothetical protein 30,143 551 
277 NCgl1895 predicted hydrolase of the metallo-beta-lactamase superfamily 77,786 548 
278 NCgl0988 predicted GTPase 39,047 545 
279 NCgl0902 ribosomal protein L25 21,749 544 
280 NCgl0371 formyltetrahydrofolate hydrolase [3.5.1.10] 34,466 542 
281 NCgl2272 gamma-glutamyl phosphate reductase [1.2.1.41] 45,870 541 
282 NCgl1087 shikimate 5-dehydrogenase [1.1.1.25] 28,969 538 
283 NCgl1183 electron transfer flavoprotein alpha-subunit 32,124 538 
284 NCgl2658 putative ferredoxin/ferredoxin-NADP reductase [1.18.1.2] 50,098 533 
285 NCgl0641 exonuclease III 34,123 528 
286 NCgl2594 lysyl-tRNA synthetase class II [6.1.1.6] 59,064 522 
287 NCgl2497 acyl-CoA hydrolase 37,788 515 
288 NCgl0878 hypothetical protein 12,720 514 
289 NCgl1170 lactoylglutathione lyase 16,905 504 
290 NCgl1548 carbamoylphosphate synthase small subunit [6.3.5.5] 42,224 500 
291 NCgl2930 indole-3-glycerol phosphate synthase [5.3.1.24] 50,736 496 
292 NCgl2075 cell division GTPase 47,244 492 
293 NCgl2021 histidinol dehydrogenase [1.1.1.23] 46,801 489 
294 NCgl2578 NAD-dependent aldehyde dehydrogenase [1.2.1.-] 51,111 487 
295 NCgl1572 hypothetical protein 44,453 482 
296 NCgl2072 hypotheical protein 16,969 480 
297 NCgl1199 putative Asp-tRNAAsn/Glu-tRNAGln amidotransferase A subunit [6.3.5.-] 52,735 479 
298 NCgl2534 hypothetical protein 12,045 479 
299 NCgl0799 Na+/proline, Na+/panthothenate symporter or related permease 57,348 467 
300 NCgl1966 predicted RNA binding protein 81,674 462 
301 NCgl0654 uracil phosphoribosyltransferase [2.4.2.9] 22,567 461 
302 NCgl2070 cell division initiation protein 38,662 461 
303 NCgl1447 ATP phosphoribosyltransferase [2.4.2.17] 30,269 457 
304 NCgl2422 metal-dependent hydrolase [3.1.6.1] 27,700 457 
305 NCgl2804 hypothetical protein 11,939 456 
306 NCgl0285 Zn-dependent hydrolase 31,088 451 
307 NCgl1919 prolyl-tRNA synthetase [6.1.1.15] 64,408 451 
308 NCgl0396 exopolyphosphatase 30,287 450 
309 NCgl2607 inorganic pyrophosphatase [3.6.1.1] 17,894 450 
310 NCgl2474 serine acetyltransferase [2.3.1.30] 19,538 450 
311 NCgl1516 6-phosphogluconolactonase [3.1.1.31] 24,463 449 
312 NCgl0145 lactoylglutathione lyase-like protein 31,212 447 
313 NCgl0714 phosphomannomutase [5.4.2.8] 49,016 434 
314 NCgl1880 RecA/RadA recombinase 40,261 433 
315 NCgl0933 hypothetical protein 13,327 433 
316 NCgl0738 hypothetical protein 7,952 432 
317 NCgl0324 Zn-dependent alcohol dehydrogenase [1.1.1.2] 37,783 430 
318 NCgl1471 methylmalonyl-CoA mutase, N-terminal domain/subunit [5.4.99.2] 80,061 429 
319 NCgl2139 threonine synthase [4.2.99.2] 53,014 424 
320 NCgl2431 nicotinic acid phosphoribosyltransferase 48,053 417 
321 NCgl0538 ribosomal protein S11 14,377 416 
322 NCgl2436 phosphoserine phosphatase [3.1.3.3] 46,475 415 
323 NCgl1344 ornithine carbamoyltransferase [2.1.3.3] 34,423 414 
324 NCgl1340 acetylglutamate semialdehyde dehydrogenase [1.2.1.38] 37,243 412 
325 NCgl2117 hypothetical protein 12,261 412 
326 NCgl1833 hypothetical protein 11,032 411 
327 NCgl2281 ribonuclease E [3.1.4.-] 113,294 410 
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328 NCgl0160 hypothetical protein 35,681 410 
329 NCgl2842 hypothetical protein 32,318 405 
330 NCgl0314 Zn-dependent hydrolase or glyoxylase 22,912 405 
331 NCgl2970 ABC-type transport systems, periplasmic component 36,677 402 
332 NCgl2663 phosphoribosylglycinamide formyltransferase 2 44,138 402 
333 NCgl2817 L-lactate dehydrogenase 45,686 401 
334 NCgl0557 ribosomal protein S9 19,711 399 
335 NCgl0459 ribosomal protein L11 15,378 399 
336 NCgl2602 GTP cyclohydrolase I [3.5.4.16] 22,132 396 
337 NCgl1141 nitrate reductase beta chain [1.7.99.4] 60,252 382 
338 NCgl1055 hypothetical protein 31,018 377 
339 NCgl0853 glycosidase [3.2.1.54] 43,352 376 
340 NCgl2336 hypothetical protein 30,491 376 
341 NCgl0697 ABC-type transporter, periplasmic component 45,223 375 
342 NCgl1109 putative helicase 80,542 374 
343 NCgl1373 predicted GTPase 60,531 373 
344 NCgl2246 hypothetical protein 30,557 371 
345 NCgl1825 hypothetical protein 22,167 368 
346 NCgl1072 predicted glycosyltransferase 45,194 368 
347 NCgl0748 hypothetical protein 51,603 367 
348 NCgl1913 hypotheical protein 19,444 365 
349 NCgl2874 thioredoxin 13,563 365 
350 NCgl0906 N-acetylglucosamine-1-phosphate uridyltransferase 50,485 364 
351 NCgl1430 Xaa-Pro aminopeptidase [3.4.13.9] 40,324 362 
352 NCgl0948 uncharacterized protein 32,842 362 
353 NCgl2415 RNase PH [2.7.7.56] 26,348 362 
354 NCgl2170 hypotheical protein 34,347 358 
355 NCgl2929 anthranilate phosphoribosyltransferase [2.4.2.18] 36,611 357 
356 NCgl1237 isocitrate/isopropylmalate dehydrogenase [1.1.1.85] 36,123 356 
357 NCgl1090 hypothetical protein 29,766 351 
358 NCgl2659 predicted acyltransferase 20,218 347 
359 NCgl2490 hypothetical protein 24,575 346 
360 NCgl2834 two-component system, response regulator 22,362 346 
361 NCgl1023 nicotinate-nucleotide pyrophosphorylase [2.4.2.19] 29,416 344 
362 NCgl2501 phosphoribosylformylglycinamidine (FGAM) synthase, PurS component 8,739 344 
363 NCgl1558 Xaa-Pro aminopeptidase 38,969 339 
364 NCgl0534 methionine aminopeptidase [3.4.11.18] 28,059 337 
365 NCgl0273 hypothetical protein 16,625 336 
366 NCgl2156 Zn-ribbon protein 26,347 335 
367 NCgl1526 glyceraldehyde-3-phosphate dehydrogenase [1.2.1.12] 36,197 334 
368 NCgl1559 3-dehydroquinate synthetase [4.6.1.3] 38,950 332 
369 NCgl0678 detergent sensitivity rescuer dtsR1 58,787 332 
370 NCgl0151 predicted metalloendopeptidase 71,356 326 
371 NCgl2657 phosphotransacetylase [2.3.1.8] 49,285 322 
372 NCgl0341 predicted pyridoxal phosphate-dependent enzyme 41,885 320 
373 NCgl2128 lipoate synthase 39,693 319 
374 NCgl2554 beta-fructosidase [3.2.1.26] 48,101 318 
375 NCgl2470 UDP-N-acetylglucosamine enolpyruvyl transferase [2.5.1.7] 44,518 318 
376 NCgl2537 trehalose-6-phosphatase [3.1.3.12] 28,088 316 
377 NCgl1529 predicted P-loop-containing kinase 34,863 315 
378 NCgl2790 glycerol kinase [2.7.1.30] 56,284 310 
379 NCgl2205 GTPase 33,399 310 
380 NCgl0937 hypothetical protein 20,236 309 
381 NCgl2676 orotate phosphoribosyltransferase [2.4.2.10] 19,433 309 
382 NCgl0626 carbon starvation protein, predicted membrane protein 81,212 299 
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383 NCgl0832 ribosomal protein S14 11,725 299 
384 NCgl0337 putative ATPase involved in chromosome partitioning 50,080 298 
385 NCgl1731 hypothetical protein 11,257 296 
386 NCgl1844 DNA-directed RNA polymerase sigma subunit SigB 37,533 293 
387 NCgl2135 hypothetical protein 14,515 292 
388 NCgl1142 anaerobic dehydrogenase [1.7.99.4] 139,511 289 
389 NCgl2083 UDP-N-acetylmuramyl tripeptide synthase [6.3.2.13] 54,274 288 
390 NCgl1446 aspartate ammonia-lyase [4.3.1.1] 57,881 288 
391 NCgl2813 predicted flavoprotein 20,219 285 
392 NCgl0865 FAD/FMN-containing dehydrogenase [1.1.1.28] 63,799 285 
393 NCgl2310 predicted hydrolase/acyltransferase [4.1.1.44] 26,748 284 
394 NCgl0833 ribosomal protein L33 6,459 280 
395 NCgl2120 NaMN,DMB phosphoribosyltransferase [2.4.2.21] 37,594 278 
396 NCgl2492 predicted aminomethyltransferase related to GcvT 40,104 276 
397 NCgl0327 dTDP-D-glucose 4,6-dehydratase [4.2.1.46] 38,251 275 
398 NCgl1241 2-keto-4-pentenoate hydratase/2-oxohepta-3-ene-1,7-dioic acid hydratase [5.3.3.-] 29,157 274 
399 NCgl1549 dihydroorotase [3.5.2.3] 48,145 274 
400 NCgl2349 hypothetical protein 45,125 269 
401 NCgl1299 DNA polymerase I [2.7.7.7] 96,769 269 
402 NCgl1909 ribosome-binding factor A 16,459 265 
403 NCgl1485 predicted nucleoside-diphosphate-sugar epimerase 23,806 265 
404 NCgl2943 hypothetical protein 22,790 264 
405 NCgl2709 Zn-dependent alcohol dehydrogenase [1.1.1.1] 37,195 263 
406 NCgl1362 CTP synthase [6.3.4.2] 61,000 262 
407 NCgl2210 molecular chaperone 41,101 261 
408 NCgl2150 hypothetical protein 67,983 258 
409 NCgl1450 Methionine synthase I, cobalamin-binding domain [2.1.1.13] 134,077 256 
410 NCgl1860 putative fructose-1-phosphate kinase [2.7.1.11] 34,043 256 
411 NCgl2053 dehydrogenase [1.-.-.-] 31,207 255 
412 NCgl2219 Zn-dependent oligopeptidase [3.4.15.5] 73,835 255 
413 NCgl1941 hypothetical membrane protein 16,357 255 
414 NCgl1898 dihydrodipicolinate reductase [1.3.1.26] 26,066 254 
415 NCgl2446 NAD synthase [6.3.5.1] 30,408 253 
416 NCgl0842 molybdopterin biosynthesis enzyme 20,146 253 
417 NCgl0049 NAD-dependent aldehyde dehydrogenase [1.2.1.16] 51,974 252 
418 NCgl1829 hypothetical protein 30,674 252 
419 NCgl0458 transcription antiterminator 34,743 250 
420 NCgl2145 hypothetical protein 17,471 249 
421 NCgl0710 nucleoside-diphosphate-sugar pyrophosphorylase [2.7.7.13] 38,785 248 
422 NCgl0916 gamma-glutamyltranspeptidase [2.3.2.2] 68,396 245 
423 NCgl1823 hypothetical protein 15,793 245 
424 NCgl2985 thioredoxin 11,934 242 
425 NCgl2831 hypothetical protein 23,847 242 
426 NCgl0709 predicted glycosyltransferase 31,539 241 
427 NCgl1932 methionine aminopeptidase [3.4.11.18] 33,082 241 
428 NCgl2274 glutamate 5-kinase [2.7.2.11] 38,602 241 
429 NCgl0366 hypothetical protein 14,889 238 
430 NCgl2091 5,10-methylenetetrahydrofolate reductase [1.7.99.5] 36,205 237 
431 NCgl2227 PLP-dependent aminotransferase [2.6.1.-] 41,053 237 
432 NCgl1553 hypothetical protein 17,817 236 
433 NCgl2403 bacterioferritin comigratory protein 17,352 231 
434 NCgl1166 F0F1-type ATP synthase epsilon subunit [3.6.1.34] 13,076 228 
435 NCgl1824 hypothetical protein 27,008 227 
436 NCgl0304 topoisomerase IA [5.99.1.2] 109,583 227 
437 NCgl2767 predicted S-adenosylmethionine-dependent methyltransferase 28,846 225 
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438 NCgl1074 hypothetical protein 22,769 225 
439 NCgl2772 acetyl-CoA carboxylase beta subunit [6.4.1.3] 56,010 224 
440 NCgl2847 hypothetical protein 52,326 224 
441 NCgl2932 tryptophan synthase alpha chain [4.2.1.20] 29,115 224 
442 NCgl1948 uridylate kinase [2.7.4.-] 26,398 222 
443 NCgl2518 two-component system, response regulator 26,334 222 
444 NCgl1855 SOS-response transcriptional repressor [3.4.21.88] 27,283 219 
445 NCgl0647 tryptophanyl-tRNA synthetase [6.1.1.2] 37,861 217 
446 NCgl1316 universal stress protein UspA 15,528 217 
447 NCgl1876 glutamate ABC-type transporter, periplasmic component 31,822 217 
448 NCgl1912 transcription terminator 35,884 216 
449 NCgl1442 aspartyl aminopeptidase 44,989 216 
450 NCgl1058 PLP-dependent aminotransferase [2.6.1.1] 39,740 216 
451 NCgl1355 predicted sugar phosphatase of the HAD superfamily 33,846 214 
452 NCgl2159 protein-tyrosine-phosphatase [3.1.3.48] 17,285 213 
453 NCgl0793 hypothetical protein 34,696 212 
454 NCgl2507 protease II 78,987 212 
455 NCgl1554 hypothetical protein 16,376 208 
456 NCgl0416 delta-aminolevulinic acid dehydratase-like protein [4.2.1.24] 36,944 206 
457 NCgl0242 predicted glutamine amidotransferase 26,531 206 
458 NCgl2178 beta-lactamase class C 29,897 205 
459 NCgl2414 xanthosine triphosphate pyrophosphatase 22,142 205 
460 NCgl1369 rhodanese-related sulfurtransferase 30,654 204 
461 NCgl0353 cell wall biogenesis glycosyltransferase 31,533 201 
462 NCgl2175 predicted sugar phosphatase of the HAD superfamily 29,620 200 
463 NCgl1318 predicted nucleoside-diphosphate-sugar epimerase 29,473 198 
464 NCgl1514 glucose-6-phosphate 1-dehydrogenase [1.1.1.49] 57,645 198 
465 NCgl1267 D-alanine-D-alanine ligase [6.3.2.4] 38,709 196 
466 NCgl0957 hypothetical protein 14,716 195 
467 NCgl2333 hypothetical protein 9,045 194 
468 NCgl2531 hypothetical protein 16,594 193 
469 NCgl0679 biotin-(acetyl-CoA carboxylase) ligase [6.3.4.15] 29,047 193 
470 NCgl2788 UDP-galactopyranose mutase [5.4.99.9] 46,152 190 
471 NCgl0698 ABC-type transporter, ATPase component 36,167 189 
472 NCgl1479 protoheme ferro-lyase [4.99.1.1] 40,844 189 
473 NCgl0276 hypothetical protein 6,163 189 
474 NCgl0403 porphobilinogen deaminase [4.3.1.8] 32,163 188 
475 NCgl1422 hypothetical protein 15,283 188 
476 NCgl0420 uroporphyrinogen-III decarboxylase [4.1.1.37] 40,563 188 
477 NCgl1354 TPR-repeat-containing protein 49,704 185 
478 NCgl2046 threonine dehydratase [4.2.1.16] 46,775 185 
479 NCgl2616 rhodanese-related sulfurtransferase 10,400 185 
480 NCgl0950 3-Deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) synthase [4.1.2.15] 39,281 183 
481 NCgl1995 hypothetical protein 19,304 183 
482 NCgl0092 hypothetical protein 103,422 183 
483 NCgl0630 citrate synthase [4.1.3.7] 42,626 178 
484 NCgl2439 ferritin-like protein 18,055 176 
485 NCgl0583 hypothetical protein 15,785 176 
486 NCgl2086 predicted S-adenosylmethionine-dependent methyltransferase 36,786 173 
487 NCgl2247 malate synthase [4.1.3.2] 82,485 169 
488 NCgl2840 transcriptional regulator 23,845 169 
489 NCgl2425 transcriptional regulator 18,634 169 
490 NCgl0536 translation initiation factor IF-1 8,369 169 
491 NCgl2553 phosphotransferase system IIC component [2.7.1.69] 69,336 169 
492 NCgl2975 putative copper chaperone 6,976 168 
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493 NCgl2124 leucyl aminopeptidase [3.4.11.1] 52,755 167 
494 NCgl2362 hemoglobin-like protein 15,147 167 
495 NCgl2880 single-stranded DNA-binding protein 23,287 166 
496 NCgl2402 hypothetical protein 10,149 162 
497 NCgl2020 histidinol-phosphate aminotransferase/tyrosine aminotransferase [2.6.1.9] 39,894 161 
498 NCgl1196 NAD-dependent DNA ligase [6.5.1.2] 74,892 161 
499 NCgl0188 hypothetical protein 8,763 161 
500 NCgl0900 glyceraldehyde-3-phosphate dehydrogenase/erythrose-4-phosphate dehydrogenase [1.2.1.12] 53,229 159 
501 NCgl1493 ABC-type transporter, duplicated ATPase component 59,062 158 
502 NCgl2016 glutamine amidotransferase [2.4.2.-] 23,390 157 
503 NCgl1155 putative translation factor (SUA5) 22,786 156 
504 NCgl2001 hypothetical protein 14,778 156 
505 NCgl2104 1-acyl-sn-glycerol-3-phosphate acyltransferase [2.3.1.51] 27,184 154 
506 NCgl2604 hypoxanthine-guanine phosphoribosyltransferase 22,766 153 
507 NCgl1322 excinuclease ATPase subunit 105,037 153 
508 NCgl0503 aldo/keto reductase [1.1.1.-] 30,028 152 
509 NCgl1500 selenocysteine lyase 45,946 152 
510 NCgl0422 glutamate-1-semialdehyde aminotransferase [5.4.3.8] 45,793 150 
511 NCgl2110 Rieske Fe-S protein 45,446 150 
512 NCgl1213 predicted oxidoreductases 39,694 150 
513 NCgl1515 hypotheical protein 34,833 150 
514 NCgl2437 heme/copper-type cytochrome/quinol oxidase, subunit 1 [1.9.3.1] 65,233 149 
515 NCgl1584 glycerol-3-phosphate dehydrogenase 62,940 149 
516 NCgl0765 archaeal fructose-1,6-bisphosphatase 27,934 149 
517 NCgl1466 phospholipid-binding protein 18,979 148 
518 NCgl1326 ribosomal protein L20 14,774 148 
519 NCgl0392 two-component system, response regulators 26,042 146 
520 NCgl0730 5-enolpyruvylshikimate-3-phosphate synthase 45,673 146 
521 NCgl2471 hypothetical protein 21,123 146 
522 NCgl2551 rRNA methylase [2.1.1.-] 33,723 146 
523 NCgl0624 homoserine O-acetyltransferase [2.3.1.11] 41,385 145 
524 NCgl1357 predicted rRNA methylase 29,700 145 
525 NCgl1827 deoxyxylulose-5-phosphate synthase 67,954 145 
526 NCgl1342 N-acetylglutamate kinase [2.7.2.8] 33,645 144 
527 NCgl0830 hypothetical protein 30,729 144 
528 NCgl1944 predicted Fe-S-cluster redox enzyme 40,355 144 
529 NCgl0846 UDP-glucose pyrophosphorylase [2.7.7.9] 33,763 143 
530 NCgl1544 guanylate kinase [2.7.4.8] 22,619 143 
531 NCgl1551 pyrimidine operon attenuation protein [2.4.2.9] 20,939 142 
532 NCgl0361 succinate dehydrogenase/fumarate reductase Fe-S protein 27,269 142 
533 NCgl1070 SAM-dependent methyltransferase 30,807 142 
534 NCgl2146 hypothetical protein 24,226 142 
535 NCgl2295 molecular chaperone 52,101 141 
536 NCgl1850 transcriptional regulator 35,269 140 
537 NCgl2148 glutamine synthase [6.3.1.2] 50,524 140 
538 NCgl2502 glutathione peroxidase [1.11.1.9] 17,752 140 
539 NCgl1510 NADPH,quinone reductase [1.6.5.5] 35,156 140 
540 NCgl0099 predicted oxidoreductase [1.1.1.91] 33,981 140 
541 NCgl2440 transcriptional regulator 27,264 139 
542 NCgl1133 diaminopimelate decarboxylase [4.1.1.20] 47,614 138 
543 NCgl1543 DNA-directed RNA polymerase subunit K/omega 10,328 135 
544 NCgl1591 adenine/guanine phosphoribosyltransferase [2.4.2.7] 19,609 135 
545 NCgl2082 UDP-N-acetylmuramyl pentapeptide synthase [6.3.2.15] 53,407 134 
546 NCgl0046 hypothetical FHA-domain-containing protein 31,356 134 
547 NCgl2355 PLP-dependent aminotransferase [2.6.1.11] 49,458 133 
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548 NCgl0651 hypothetical protein 45,325 133 
549 NCgl0808 hypothetical protein 8,827 132 
550 NCgl0333 serine protease [3.4.21.26] 73,824 132 
551 NCgl0120 transcriptional regulator 40,867 132 
552 NCgl0421 protoporphyrinogen oxidase [1.3.3.4] 45,730 131 
553 NCgl1443 RecB family exonuclease 32,508 131 
554 NCgl1896 dihydrodipicolinate synthase/N-acetylneuraminate lyase [4.2.1.52] 31,300 129 
555 NCgl0338 protein-tyrosine-phosphatase [3.1.3.48] 22,104 128 
556 NCgl2631 hypothetical protein 48,669 128 
557 NCgl0105 deoR family transcriptional regulator of sugar metabolism 28,076 127 
558 NCgl2931 tryptophan synthase beta chain [4.2.1.20] 45,001 126 
559 NCgl1351 hypothetical protein 6,790 125 
560 NCgl1587 peptidyl-prolyl cis-trans isomerase (rotamase) [5.2.1.8] 29,791 125 
561 NCgl1536 pentose-5-phosphate-3-epimerase [5.1.3.1] 23,913 124 
562 NCgl0831 ribosomal protein S18 9,749 122 
563 NCgl2979 putative polynucleotide polymerase 55,721 121 
564 NCgl0183 hypothetical protein 53,204 120 
565 NCgl1178 glycosidase [3.2.1.1] 75,629 120 
566 NCgl1868 diaminopimelate epimerase [5.1.1.7] 29,590 118 
567 NCgl2645 exonuclease III [3.1.11.2] 29,759 118 
568 NCgl1071 beta-fructosidase [3.2.1.26] 54,737 118 
569 NCgl2105 glucose kinase [2.7.1.2] 34,455 118 
570 NCgl1364 integrase 33,172 117 
571 NCgl0223 prephenate dehydrogenase 36,384 116 
572 NCgl0603 predicted nucleoside-diphosphate-sugar epimerase 60,606 115 
573 NCgl1439 hypothetical protein 56,869 115 
574 NCgl0707 SNF2 family helicase 106,877 115 
575 NCgl2263 ankyrin repeat containing protein 14,148 114 
576 NCgl2401 amidase 20,342 113 
577 NCgl2552 cysteinyl-tRNA synthetase [6.1.1.16] 51,189 112 
578 NCgl0448 peptidase E 22,975 109 
579 NCgl1233 hypothetical protein 67,439 109 
580 NCgl2037 maltooligosyl trehalose synthase 90,572 109 
581 NCgl1861 phosphotransferase system, fructose-specific IIC component [2.7.1.69] 70,631 109 
582 NCgl1528 hypothetical protein 36,164 109 
583 NCgl0450 2-succinyl-6-hydroxy-2, 4-cyclohexadiene-1-carboxylate synthase [4.1.1.71] 57,484 107 
584 NCgl0930 hypothetical protein 7,503 107 
585 NCgl1588 hypothetical protein 19,082 106 
586 NCgl2292 folylpolyglutamate synthase 49,285 105 
587 NCgl2890 hypothetical protein 35,747 105 
588 NCgl0215 histidinol-phosphate aminotransferase/tyrosine aminotransferase [2.6.1.9] 36,659 105 
589 NCgl1532 riboflavin synthase beta-chain [2.5.1.9] 16,639 104 
590 NCgl2927 anthranilate synthase component I [4.1.3.27] 56,581 103 
591 NCgl2080 UDP-N-acetylmuramoylalanine-D-glutamate ligase [6.3.2.9] 49,330 103 
592 NCgl2013 imidazoleglycerol-phosphate synthase and cyclase hisF 27,344 103 
593 NCgl0702 hypothetical protein 23,505 102 
594 NCgl0293 hypothetical membrane protein 19,420 101 
595 NCgl1874 2-methylthioadenine synthetase 58,013 101 
596 NCgl2099 hypothetical protein 19,256 101 
597 NCgl0727 hypothetical protein 14,507 100 
598 NCgl2701 molecular chaperone GrpE 23,666 100 
599 NCgl2988 putative cell division protein ParB 40,611 99 
600 NCgl1200 siderophore-interacting protein 31,269 99 
601 NCgl1049 arsenate reductase 12,996 98 
602 NCgl2584 hypothetical protein 11,037 98 
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603 NCgl1078 ATPase 39,147 97 
604 NCgl1022 cysteine sulfinate desulfinase 37,996 97 
605 NCgl1533 GTP cyclohydrolase II [3.5.4.25] 46,144 95 
606 NCgl1703 site-specific DNA methylase or 40,070 95 
607 NCgl0843 large-conductance mechanosensitive channel 14,526 95 
608 NCgl2493 hypothetical protein 8,203 95 
609 NCgl1274 N6-adenine-specific methylase 21,126 94 
610 NCgl0779 ABC-type cobalamin/Fe3+-siderophore transport system, ATPase component 27,988 93 
611 NCgl0706 type II restriction enzyme, methylase subunits 171,795 93 
612 NCgl0112 panthothenate synthetase [6.3.2.1] 29,928 93 
613 NCgl0875 ABC-type transporter 67,218 92 
614 NCgl0797 acetyl-CoA carboxylase beta subunit [6.4.1.2] 51,375 92 
615 NCgl2495 glutamine phosphoribosylpyrophosphate amidotransferase 55,411 92 
616 NCgl0982 penicillin tolerance protein 35,812 91 
617 NCgl0118 predicted hydrolase of the HAD superfamily 22,701 91 
618 NCgl2595 panthothenate synthetase [6.3.2.1] 28,047 90 
619 NCgl2777 putative esterase 70,746 90 
620 NCgl1117 putative helicase 115,849 90 
621 NCgl0229 queuine/archaeosine tRNA-ribosyltransferase [2.4.2.29] 46,602 89 
622 NCgl0873 dimethyladenosine transferase [2.1.1.-] 31,754 89 
623 NCgl1441 predicted SAM-dependent methyltransferase involved in tRNA-Met maturation [2.1.1.77] 31,316 89 
624 NCgl2358 oxidoreductase [1.1.1.36] 25,330 88 
625 NCgl0622 flotillin-like protein 49,718 88 
626 NCgl2186 hypothetical protein 69,595 88 
627 NCgl2989 putative cell division protein ParA 33,340 87 
628 NCgl2472 regulatory-like protein 30,937 86 
629 NCgl0513 hypothetical protein 40,843 86 
630 NCgl1940 1-deoxy-D-xylulose 5-phosphate reductoisomerase [1.1.1.-] 40,990 85 
631 NCgl1597 Holliday junction resolvasome DNA-binding subunit 21,579 84 
632 NCgl0980 exonuclease VII small subunit [3.1.11.6] 9,014 84 
633 NCgl1956 hypothetical protein 12,197 83 
634 NCgl2359 transcriptional regulator 27,655 83 
635 NCgl2796 hypothetical protein 13,157 83 
636 NCgl1303 SAM-dependent methyltransferase 29,263 83 
637 NCgl0085 urea amidohydrolase (urease) alpha subunit [3.5.1.5] 61,471 82 
638 NCgl1239 predicted signal-transduction protein 69,294 82 
639 NCgl2344 hypothetical protein 6,022 81 
640 NCgl0672 hypothetical protein 39,705 81 
641 NCgl0767 protein chain release factor B 41,169 80 
642 NCgl2118 hypothetical membrane protein 29,860 80 
643 NCgl2934 hypothetical protein 29,015 80 
644 NCgl2897 starvation-inducible DNA-binding protein 18,344 80 
645 NCgl0618 ABC-type Fe3+-siderophores transport system, periplasmic component 35,113 80 
646 NCgl1846 UDP-glucose 4-epimerase [5.1.3.2] 35,300 79 
647 NCgl1586 putative Zn-dependent hydrolase 23,352 78 
648 NCgl0616 SIR2 family NAD-dependent protein deacetylase 28,842 78 
649 NCgl0336 hypothetical esterase 39,597 78 
650 NCgl0657 metal-dependent amidase/aminoacylase/carboxypeptidase 42,346 77 
651 NCgl1650 transcriptional regulator 26,925 76 
652 NCgl0721 two-component system response regulator 24,985 75 
653 NCgl0716 phosphomannose isomerase [5.3.1.8] 42,924 75 
654 NCgl0766 archaeal fructose-1,6-bisphosphatase 31,109 75 
655 NCgl0098 proline dehydrogenase [1.5.1.12] 126,476 75 
656 NCgl1106 putative mutT-like protein 14,747 74 
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657 NCgl2354 hypothetical protein 70,099 74 
658 NCgl0737 putative helicase 46,128 74 
659 NCgl2571 transcriptional regulator 22,245 74 
660 NCgl1015 putative PEP phosphonomutase [2.7.8.23] 26,570 73 
661 NCgl1599 hypothetical protein 27,105 73 
662 NCgl1325 ribosomal protein L35 7,250 73 
663 NCgl1461 dihydroorotate dehydrogenase [1.3.3.1] 39,537 72 
664 NCgl0315 dehydrogenase [1.1.1.100] 22,549 72 
665 NCgl2782 membrane-associated phospholipid phosphatase 17,610 72 
666 NCgl2787 predicted flavoprotein involved in K+ transport 67,005 71 
667 NCgl0703 hypothetical protein 94,038 70 
668 NCgl1568 predicted periplasmic solute-binding protein 41,934 70 
669 NCgl0326 dTDP-4-dehydrorhamnose 3,5-epimerase or related enzyme 49,123 70 
670 NCgl2195 chromosome segregation ATPase 72,306 69 
671 NCgl0239 DNA polymerase III, gamma/tau subunits 82,519 68 
672 NCgl1484 GMP synthase [6.3.5.2] 27,965 68 
673 NCgl1475 membrane protease subunit 47,287 67 
674 NCgl0576 hypothetical protein 35,206 67 
675 NCgl2273 putative phosphoglycerate dehydrogenase 33,032 67 
676 NCgl2730 putative peptidase 47,859 66 
677 NCgl0952 hypothetical protein 19,108 66 
678 NCgl1994 dsRNA-specific ribonuclease [3.1.26.3] 27,464 65 
679 NCgl0414 uroporphyrinogen-III synthase/methylase [2.1.1.107] 64,458 65 
680 NCgl0751 hypothetical protein 18,570 64 
681 NCgl2755 hypothetical protein 16,026 64 
682 NCgl0743 predicted NAD-binding component of Kef-type K+ transport system 38,197 64 
683 NCgl1606 diadenosine tetraphosphate (Ap4A) hydrolase 19,504 61 
684 NCgl2980 hypothetical protein 36,633 61 
685 NCgl0064 ATPase related to phosphate starvation-inducible protein PhoH 50,226 61 
686 NCgl2275 predicted GTPase 53,646 61 
687 NCgl2889 hypothetical protein 11,388 60 
688 NCgl0180 PAS/PAC domain containing protein [2.7.3.-] 16,294 60 
689 NCgl2376 hypothetical protein 46,596 60 
690 NCgl0507 putative formate dehydrogenase [1.2.1.2] 79,130 60 
691 NCgl0575 DNA-directed RNA polymerase specialized sigma subunit 20,712 58 
692 NCgl0431 hypothetical protein 11,668 58 
693 NCgl1025 ADP-ribose pyrophosphatase 23,999 58 
694 NCgl2875 copper chaperone 7,099 57 
695 NCgl0157 NAD-dependent aldehyde dehydrogenase [1.2.1.27] 53,726 56 
696 NCgl2304 ATP-dependent protease Clp, ATPase subunit 47,202 56 
697 NCgl0148 hypothetical protein 32,574 56 
698 NCgl2624 hypothetical protein 35,217 56 
699 NCgl0570 hypothetical protein 59,991 56 
700 NCgl2319 protocatechuate 3,4-dioxygenase beta subunit [1.13.11.1] 32,465 56 
701 NCgl2794 transcriptional regulator 29,524 56 
702 NCgl2809 pyruvate kinase-like protein 67,820 55 
703 NCgl2687 alkanal monooxygenase 37,859 55 
704 NCgl0628 uncharacterized protein 31,225 55 
705 NCgl0372 deoxyribose-phosphate aldolase [4.1.2.4] 22,810 55 
706 NCgl0070 hypothetical protein 14,552 54 
707 NCgl1902 inosine-uridine nucleoside N-ribohydrolase 33,301 54 
708 NCgl0094 nucleoside phosphorylase [3.2.2.4] 53,016 54 
709 NCgl1012 Mg-chelatase subunit ChlI 50,050 54 
710 NCgl0604 deoxyribodipyrimidine photolyase 55,259 54 
711 NCgl1738 hypothetical protein 20,271 54 
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712 NCgl1159 F0F1-type ATP synthase a subunit [3.6.1.34] 30,361 54 
713 NCgl0399 hypothetical protein 7,117 54 
714 NCgl2798 putative phosphoglycerate mutase 24,823 54 
715 NCgl0415 hypothetical protein 16,200 53 
716 NCgl0347 cell wall biogenesis glycosyltransferase 38,980 53 
717 NCgl1387 hypothetical protein 23,482 52 
718 NCgl1324 translation initiation factor IF3 21,763 52 
719 NCgl0784 hypothetical protein 7,011 52 
720 NCgl2896 hypothetical protein 55,380 50 
721 NCgl1539 N-formylmethionyl-tRNA deformylase [3.5.1.31] 18,647 50 
722 NCgl2990 glucose-inhibited division protein B 24,204 49 
723 NCgl1894 hypothetical protein 23,266 49 
724 NCgl1315 helicase subunit of the DNA excision repair complex 81,231 49 
725 NCgl2035 DNA polymerase III epsilon subunit [2.7.7.7] 41,713 48 
726 NCgl1384 preprotein translocase subunit SecA 83,566 47 
727 NCgl1974 RimM protein 18,606 47 
728 NCgl2477 succinyl-CoA synthetase beta subunit [6.2.1.5] 41,855 47 
729 NCgl1906 hypothetical protein 31,118 46 
730 NCgl0938 exopolyphosphatase [3.6.1.11] 34,974 46 
731 NCgl0673 hypothetical protein 15,169 46 
732 NCgl1277 ABC-type transporter, permease component 34,564 46 
733 NCgl2385 short-chain dehydrogenase 28,629 46 
734 NCgl2251 choline-glycine betaine transporter 68,335 45 
735 NCgl1609 hypotheical protein 18,696 45 
736 NCgl1748 periplasmic serine protease 35,266 44 
737 NCgl0523 NAD-dependent aldehyde dehydrogenase 52,581 44 
738 NCgl1391 hypothetical protein 34,478 44 
739 NCgl2242 2-5 RNA ligase 20,685 43 
740 NCgl0882 enoyl-CoA hydratase/carnithine racemase [4.2.1.17] 36,565 43 
741 NCgl1137 homoserine kinase [2.7.1.39] 32,658 43 
742 NCgl0720 thymidylate kinase [2.7.4.9] 22,364 42 
743 NCgl2278 hypothetical protein 23,007 41 
744 NCgl1161 F0F1-type ATP synthase b subunit [3.6.1.34] 21,082 41 
745 NCgl1552 predicted SulA family nucleoside-diphosphate sugar epimerase 42,380 41 
746 NCgl0476 ribosomal protein S12 13,479 41 
747 NCgl1184 cysteine sulfinate desulfinase 39,122 40 
748 NCgl0731 hypothetical protein 23,535 40 
749 NCgl1732 hypothetical protein 8,316 40 
750 NCgl0243 UDP-N-acetylmuramyl tripeptide synthase 45,223 39 
751 NCgl1527 hypotheical protein 35,712 39 
752 NCgl1341 Ornithine acetyltransferase [2.3.1.35] 40,037 38 
753 NCgl1670 hypothetical protein 140,349 38 
754 NCgl2438 ribonucleotide reductase beta subunit 38,032 38 
755 NCgl0684 phosphoribosylaminoimidazole carboxylase [4.1.1.21] 16,981 38 
756 NCgl2640 hypotheical protein 42,702 38 
757 NCgl2268 phosphoglycerate mutase 26,304 38 
758 NCgl2783 hypothetical protein 73,798 37 
759 NCgl0820 hypothetical helicase [3.6.1.-] 85,353 37 
760 NCgl2919 2-hydroxyhepta-2,4-diene-1,7-dioatesomerase 30,597 37 
761 NCgl2324 DNA-binding HTH domain containing protein 97,714 37 
762 NCgl1368 acetyltransferase 21,497 37 
763 NCgl0446 dihydroxynaphthoic acid synthase [4.1.3.36] 35,634 36 
764 NCgl1834 archaeal fructose-1,6-bisphosphatase 29,964 36 
765 NCgl0565 putative membrane protein 55,688 36 
766 NCgl2465 ABC-type transporter, ATPase component 30,811 36 
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767 NCgl0358 predicted transcriptional regulator 53,574 35 
768 NCgl1197 hypothetical protein 23,647 35 
769 NCgl1542 phosphopantothenoylcysteine synthetase/decarboxylase 44,061 35 
770 NCgl1830 dUTPase [3.6.1.23] 15,911 35 
771 NCgl0892 peptide chain release factor 3 60,502 34 
772 NCgl0632 transcriptional regulator 26,830 34 
773 NCgl0755 predicted glutamine amidotransferase 21,317 34 
774 NCgl1275 phosphopantetheine adenylyltransferase 17,680 34 
775 NCgl1734 hypothetical protein 19,833 34 
776 NCgl2208 phosphate starvation-inducible protein PhoH 38,800 34 
777 NCgl2487 histone acetyltransferase HPA2-like protein 32,115 34 
778 NCgl1011 hypothetical protein 72,022 33 
779 NCgl1618 hypothetical protein 67,824 33 
780 NCgl1240 DNA polymerase III epsilon subunit 24,328 33 
781 NCgl2152 galactokinase [2.7.1.6] 46,537 33 
782 NCgl2872 hypothetical protein 8,062 32 
783 NCgl2151 hypothetical protein 6,802 32 
784 NCgl2200 Fe2+/Zn2+ uptake regulation protein 16,029 32 
785 NCgl2751 deoxycytidine deaminase [3.5.4.13] 20,676 32 
786 NCgl0194 hypothetical protein 23,322 32 
787 NCgl2986 N-acetylmuramoyl-L-alanine amidase [3.5.1.28] 45,935 31 
788 NCgl2147 glutamine synthetase adenylyltransferase [2.7.7.42] 116,554 31 
789 NCgl0343 predicted glycosyltransferase 32,326 31 
790 NCgl0456 geranylgeranyl pyrophosphate synthase [2.5.1.30] 37,799 31 
791 NCgl0700 helicase family member 180,670 31 
792 NCgl0823 predicted transcriptional regulator 19,120 31 
793 NCgl1839 hypothetical protein 63,046 31 
794 NCgl1474 hypothetical protein 21,441 31 
795 NCgl1270 uracil DNA glycosylase [3.2.2.-] 26,928 31 
796 NCgl1924 hypothetical protein 51,737 30 
797 NCgl1488 cation transport ATPase [3.6.1.-] 95,418 30 
798 NCgl0074 permease 50,244 30 
799 NCgl1051 hypothetical protein 20,177 30 
800 NCgl0031 ABC-type transporter, ATPase component 27,477 30 
801 NCgl0340 predicted nucleoside-diphosphate sugar epimerase 64,410 30 
802 NCgl1150 molybdenum cofactor biosynthesis enzyme 41,660 30 
803 NCgl1181 hypothetical protein 42,076 30 
804 NCgl2766 hypothetical membrane protein 36,271 30 
805 NCgl2801 hypothetical membrane protein 24,063 30 
806 NCgl2510 PLP-dependent aminotransferase [2.6.1.1] 42,638 30 
807 NCgl0924 transcription-repair coupling factor - superfamily II helicase 133,782 29 
808 NCgl1460 hypothetical protein 35,146 29 
809 NCgl0838 hypothetical protein 6,616 29 
810 NCgl1061 tetrahydrodipicolinate N-succinyltransferase [2.3.1.117] 31,383 29 
811 NCgl0770 tmRNA-binding protein 18,993 29 
812 NCgl2040 hypothetical protein 39,482 29 
813 NCgl2606 D-alanyl-D-alanine carboxypeptidase [3.4.16.4] 44,717 29 
814 NCgl1189 spermidine synthase 34,634 29 
815 NCgl2129 hypothetical membrane protein 28,482 28 
816 NCgl0398 pyrroline-5-carboxylate reductase [1.5.1.2] 28,629 28 
817 NCgl2350 ABC-type transporter, duplicated ATPase component 59,194 28 
818 NCgl1209 ABC-type transport system, periplasmic component 35,908 28 
819 NCgl1309 inosine-uridine nucleoside N-ribohydrolase [3.2.2.1] 34,075 28 
820 NCgl0455 oxidoreductase 46,016 28 
821 NCgl0354 acetyltransferase 22,482 28 
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822 NCgl1085 ABC-type transporter, duplicated ATPase component 135,573 28 
823 NCgl1550 aspartate carbamoyltransferase, catalytic chain [2.1.3.2] 33,931 27 
824 NCgl0810 thymidylate synthase [2.1.1.45] 30,385 27 
825 NCgl0272 predicted phosphohydrolase [3.1.-.-] 33,262 27 
826 NCgl2909 D-amino acid dehydrogenase subunit 44,736 27 
827 NCgl2482 phosphate uptake regulator 28,286 27 
828 NCgl2928 anthranilate synthase component II [4.1.3.27] 22,267 27 
829 NCgl0364 hypothetical protein 35,537 27 
830 NCgl0128 ankyrin repeat protein 40,042 27 
831 NCgl0740 hypothetical protein 27,740 27 
832 NCgl0155 sugar kinases, ribokinase family [2.7.1.4] 34,957 27 
833 NCgl1865 GTPase 52,861 27 
834 NCgl2812 predicted hydrolase of the HAD superfamily 23,505 27 
835 NCgl0394 ABC-type transport system permease component 89,883 27 
836 NCgl1904 pseudouridine synthase [4.2.1.70] 31,825 27 
837 NCgl2692 hypothetical protein 42,276 27 
838 NCgl1715 hypothetical protein 91,924 26 
839 NCgl2649 predicted epimerase 29,873 26 
840 NCgl1706 hypothetical protein 57,266 26 
841 NCgl0305 hypothetical protein 24,388 26 
842 NCgl1412 predicted phosphoribosyltransferase 17,821 26 
843 NCgl2243 sugar kinase [2.7.1.15] 30,204 26 
844 NCgl0199 selenocysteine lyase 43,289 26 
845 NCgl2448 hypothetical protein 15,761 26 
846 NCgl2221 putative trehalose synthase 69,639 25 
847 NCgl0158 hypothetical protein 32,543 25 
848 NCgl1272 RecG-like helicase [3.6.1.-] 77,789 25 
849 NCgl2176 hypothetical protein 38,229 25 
850 NCgl0159 thiamine pyrophosphate-requiring enzyme 68,665 25 
851 NCgl2153 exoribonucleases 52,712 25 
852 NCgl2188 bacterial type DNA primase [2.7.7.-] 71,344 25 
853 NCgl0061 4-oxalocrotonate tautomerase-like protein 17,275 25 
854 NCgl1875 glutamate ABC-type transporter, ATPase component 27,512 24 
855 NCgl1334 rRNA methylase [2.1.1.34] 20,847 24 
856 NCgl0041 serine/threonine protein kinase [2.7.1.-] 50,401 24 
857 NCgl2309 acetyl-CoA acetyltransferase 42,738 24 
858 NCgl0234 hypothetical dioxygenase protein 34,751 24 
859 NCgl0257 predicted transcriptional regulator 12,794 24 
860 NCgl1066 putative dihydropteroate synthase [2.5.1.15] 29,812 24 
861 NCgl2717 phosphoadenosine phosphosulfate reductase 25,636 24 
862 NCgl2655 serine/threonine protein kinase 91,248 24 
863 NCgl0839 two-component system, response regulator 26,087 24 
864 NCgl2893 efflux system protein 63,883 24 
865 NCgl2158 predicted phosphatase [3.1.3.18] 24,867 24 
866 NCgl2079 bacterial cell division membrane protein 59,225 24 
867 NCgl2308 transcriptional regulator 27,697 24 
868 NCgl1806 integrase 44,101 23 
869 NCgl1506 ABC-type transporter, ATPase component 36,912 23 
870 NCgl2276 xanthine/uracil permease 70,314 23 
871 NCgl2057 23S RNA-specific pseudouridylate synthase [4.2.1.70] 33,427 23 
 
